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SUMMARY
The aims of the studies were to examine blood rheology, haemostatic factors and 
peripheral blood flow in diabetes mellitus in relation to treatment and the presence of 
vascular damage. First, studies of the specificity of positive pressure filtration of 
dilute erythrocyte suspensions as a measure of erythrocyte deformability were made. 
Second, the effects of improved blood glucose control (achieved by outpatient 
management) on whole blood viscosity, haemostatic factors, peripheral blood flow and 
peripheral nerve function was examined. Third, a double-blind crossover study of the 
effects of treatment with biosynthetic human insulin (BHI) and purified porcine insulin 
(PPI) on blood rheology, haemostatic factors and peripheral blood flow was carried out.
The subjects studied included, i) newly diagnosed Type I diabetics ii) longstanding 
Type I and Type II diabetic patients with diabetic retinopathy and, iii) a normal 
control group. The effects of improved diabetic control were examined in both newly 
diagnosed Type I and established Type I and Type II diabetics. In the established Type 
I diabetics, this period formed the run-in to the BHI and PPI study. Each study 
insulin was administered for 90 days.
1) Ervthrocvte Deformability '
The number of residual leucocytes contaminating the erythrocyte suspensions was a 
major determinant of suspension filterability in diabetic patients, p<0.0001. It was 
concluded that the filtration of dilute erythrocyte suspensions is not a specific measure 
of erythrocyte deformability. Diabetic control was not related to suspension 
filterability.
2) The Effects of Improving Diabetic Control
Improvement of diabetic control was confirmed by significant fall in HbA^C^o.
i) Whole Blood Viscosity
Whole blood viscosity was largely determined by haematocrit. At comparable 
haematocrits, whole blood viscosity was approximately 9% higher in diabetic patients 
(p=0.0029). Improvement of diabetic control had no effect on viscosity measurements. 
Newly diagnosed patients were not examined.
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ii) Haemostatic Factors
a) Fibrinogen
Levels were 41% higher in diabetic patients compared with normals (p=0.0005). 
Independent predictors of high fibrinogen levels were poor diabetic control, high blood 
pressure, the presence of deteriorating retinopathy, and treatment with oral anti­
diabetic agents. Improved diabetic control did not result in any change in fibrinogen.
b) Factor VIIL coagulant activity (VIII:C)
VIII.C was not elevated overall in diabetic subjects compared with normals; but 
concentrations of VIII:C were 18% lower in patients on oral anti-diabetic agents (Type
II) compared with insulin-treated patients (Type I) (p=0.0198). Type I patients had 
higher HbA^C levels than Type II patients (p=0.0033). High HbA^^/o was an 
independent predictor of high levels of VIII:C, but other factors included long duration 
of diabetes mellitus, the presence of deteriorating diabetic retinopathy and treatment 
with insulin. Improvement in diabetic control had no significant effect.
c) Yon Willebrand Antigen (vWF:AG)
VWF:AG levels were not elevated overall in diabetic patients compared with normal 
subjects, but levels were 36% lower in Type II patients compared with Type I patients 
(p=0.0016). Independent predictors of vWF.'AG were the same as those of VIII:C. 
Improved diabetic control resulted in a 13% fall of vWF:AG% (p=0.0065).
d) Ristocetin Co-factor
Again overall ristocetin co-factor was not significantly different from normal, but 
levels were 33% lower in Type II patients compared Type I patients (p=0.0005). Levels 
were 32% elevated in Type I patients compared with normals (p=0.0398). High FBG 
(but not HbA^C) was an independent predictor of high ristocetin co-factor%. Other 
independent predictors were high diastolic blood pressure and treatment with insulin. 
Improved diabetic control had no effect.
e) Fibrinolytic Activity
Fibrinolytic activity was assessed by measuring ECLT. Diabetic patient ECLT’s were 
not significantly different from normal. Independent predictors of lesser fibrinolytic 
activity were poor diabetic control (high HbA^C) and high diastolic blood pressure. 
Improving diabetic control had no effect on ECLT’s.
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f) Fibrinopeptide A (FPA)
These were measured in established Type I and the normal volunteers. FPA was 
greatly influenced by venesection technique. Levels were not significantly different in 
diabetics. In diabetics, an association of higher FPA with higher subject blood 
pressure was noted, p<0.04.
iii) Peripheral Blood Flow
a) Calf and Forefoot
Resting calf (RCF) and forefoot (RFF) flow and reactive hyperaemia in the forefoot, 
following a 4 minute arterial occlusion, were measured by plethysmography. RCF and 
RFF were not significantly different from normal but vasodilation following ischaemic 
stress was 35% reduced in diabetes (p<0.0001). In newly diagnosed patients, an 
increase in peak flow (vasodilation) and a decrease in time to reach peak flow (TPF) 
was noted after commencing treatment. No effects of improving diabetic control were 
noted in established diabetic patients. In established Type I and Type II diabetics, 
nerve conduction times were studied, and an association of Common Peroneal "F" 
latency and TPF was noted.
b) Toe-pad
Toe-pad skin blood flow was measured using a Laser Doppler Flowmeter. There was a 
marked delay in TPF following arterial occlusion of the forefoot of diabetic patients, 
suggesting impairment of vasodilation of small vessels.
c) Peripheral Nerve Conduction Studies
Fourteen established diabetics who participated in the crossover study of BHI and PPI 
insulins were studied. Improved diabetic control resulted in shortening of "F" latency 
times and quickening of motor conduction times in the Ulnar and Common Peroneal 
nerves (p<0.05). There was no associated clinical improvement in nerve function.
3) Double-Blind Study of Treatment with BHI and PPI
Diabetic control showed a tendency to deteriorate on treatment with BHI, although 
HbA^C levels were not significantly different. No effects on whole blood viscosity, 
haemostatic function factors, peripheral blood flow or peripheral nerve conduction 
times were noted.
These studies suggest that whilst many of the factors associated with diabetes mellitus 
are related to diabetic control, minor improvements in blood glucose as can be achieved 
by closer patient supervision do not result in substantial changes. Treatment with BHI
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does not have any advantageous effects on blood rheology, haemostatic function or 
peripheral blood flow or peripheral nerve conduction. The relationship of the various 
factors studied to the development of diabetic vascular damage is discussed.
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ABBREVIATIONS
art debt arterial debt, calculated by multiplying the resting flow value by the time 
of arterial occlusion.
BHI Biosynthetic Human Insulin.
°C  Degrees Celsius, 
cp Centipoise.
C Chlorpropamide.
CV Coefficient of Variation.
ECLT Euglobulin clot lysis time.
EDTA Ethylene diamine tetra acetic acid.
F Female.
FBG Fasting blood glucose.
Fib Fibrinogen.
FPA Fibrinopeptide A.
G Glibenclamide.
HbA^C Glycosylated haemoglobin.
Hct Haematocrit.
Hg Mercury.
IDD Insulin dependent diabetes, Type I.
MCV Motor (nerve) Conduction Velocity.
N Number.
M Male. 
mPa milliPascal.
Me Metformin.
NA Not Available.
NIDD Non-Insulin Dependent diabetes, Type II.
NR Not Recordable.
NS Not Significant.
PF Peak Flow (millilitres per 100 millilitres of tissue).
PF-RF Peak post stimulus flow minus resting basal flow (milliltres per 100 mis 
of tissue).
PI ECLT Euglobulin clot lysis time measured on a blood sample taken 1 hour after 
subcutaneous injection of insulin.
PPI Purified porcine insulin.
PPSF Peak post stimulus flow (millilitres per 100 millilitres of tissue).
PPSF-RFF Peak post stimulus flow minus resting basal blood flow in the foot.
PV ECLT Euglobulin clot lysis time measured on a sample taken after venous 
occlusion at 90 mmHg for 10 minutes.
RBC Red Blood Cell.
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RCF Resting calf flow (millilitres per 100 millilitres of tissue).
RFF Resting foot flow (millilitres per 100 millilitres of tissue).
Rs Spearman’s coefficient of variation.
SCV Sensory (nerve) conduction velocity.
SD Standard deviation of the mean..
SE Standard error of the mean.
TPF Time to reach peak flow values following arterial occlusion expressed in 
seconds.
T50 The half life of reactive hyperaemia following arterial occulusion 
expressed in seconds.
VIII:C Factor VIII: coagulant activity.
VWF:Ag Von Willebrand related antigen, occasionally in literature referred to as 
factor VIII antigen, VIII:AG, or factor VIII related antigen, VIIIR:Ag.
WCC White cell count, 
x Mean.
(0-30%) The percentage of arterial debt (following arterial occlusion) paid back in 
the first 30 seconds of reactive hyperaemia.
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CHAPTER 1
INTRODUCTION
1-1 HISTORICAL PERSPECTIVES OF THE VASCULAR COMPLICATIONS OF 
DIABETES MELLITUS
1-1-1 General Background
Diabetes mellitus is perhaps best considered as a heterogeneous group of disorders 
resulting in hyperglycaemia. Since the introduction of insulin treatment in the early 
1920’s, comparatively few people now die from the acute effects of uncontrolled 
hyperglycaemia but the complex metabolic effects and the long-term sequelae of the 
diabetic state remain a major cause of morbidity and reduced life expectancy in Britain 
and other industrialized societies. Indeed, the development of vascular complications is 
so characteristic of long-term diabetes mellitus that it is virtually regarded as part of 
the disease and the diagnostic criteria of both the American Diabetes Association 
(National Diabetes Data Group, 1979) and the World Health Organization (WHO Expert 
Committee on Diabetes, Second Report, 1980) are based on blood glucose levels which 
in epidemiological studies have been associated with the development of this specific 
diabetic tissue damage.
1-1-2 Atherosclerosis and Diabetes Mellitus
The long-term neurological, renal, eye and vascular complications were recognized and 
well described by the end of the nineteenth century but attracted little attention until 
after the introduction of insulin, when death from these causes became more common 
than death from acute metabolic disturbance. The excess of cardiovascular mortality 
was observed by *Levine in 1922. In 1924, *Labbe and Lefantin noted that arterial 
calcification was a frequent finding in diabetes mellitus, although it was 1968 before 
*Neubauer reported on the distinctive features of this calcification which occurs 
particularly in the media of the arterial wall. Gangrene of the lower limb was found 
to be forty times more common in diabetic patients surviving from the 1920’s onwards 
(*Bell 1958) and diabetic patients with peripheral vascular disease were found to be 
more prone to the development of gangrene (*Hines and Barker, 1940). This 
atheromatous disease of diabetes was found to involve more distal arteries than is 
found in non-diabetic individuals (*Semple, 1953) with involvement extending to the 
metatarsal arteries (Ferrier, 1967). Diabetic atheromatous plaques were found to 
contain higher concentrations of mucopolysaccharides (*Randerath and Dietzel, 1959) 
ash, calcium and cholesterol (*Hevelke, 1955). Thus diabetic patients appear to be at 
risk of developing a more severe form of atheromatous disease than non-diabetics,
26
involving more distal arteries and with heavy calcification of the media and increased 
susceptibility to gangrene (*as reviewed by Christensen, 1972).
1-1-3 Diabetic Microangiopathv
Appreciation that there was also a degeneration of vessels smaller than arteries, the 
microvessels, came later. Changes in the microvessels of diabetics were described by 
Woltman and Wilder in 1929 but comprehensive studies of the microvasculature in 
diabetes mellitus did not begin until the late 1950’s. In diabetic microangiopathy two 
types of lesion tend to occur: i) accelerated thickening of the basement membrane with 
an assimilation of PAS positive material which in immunohistological studies 
corresponds to various plasma proteins (Dustin 1962) and ii) endothelial cell 
proliferation together with basement membrane thickening. The presence of increased 
vessel thickness and PAS stainability was described by Fagerberg in 1959, and the 
presence of increased basal membrane thickness by Aagenaes and Moe in 1961. 
Goldenberg and his colleagues drew attention to the enlargement of endothelial cells 
with cell proliferation in 1959. These vessel changes were noted first in intraneural 
vessels by Fagerberg and gave rise to the vascular hypothesis of diabetic neuropathy, 
which proposed that diabetic neuropathy was the result of impaired vascular supply to 
the affected nerves. However, descriptions of similar morphological changes in the 
capillaries of other tissues in diabetes proved the vessel damage to be a generalized 
problem whose functional importance depended on the response of the organ or tissue 
affected. In diabetes mellitus these microvessel lesions are most critical in the eye and 
kidney where they are responsible for the development of diabetic retinopathy and 
diabetic nephropathy. Death from cardiovascular diseases and diabetic nephropathy are 
the major causes of reduced life expectancy in diabetics of whom a considerable 
proportion will also suffer amputation of a limb and blindness before death. The 
prevention of these long term vascular complications is a major challenge for 
contemporary medicine
1-1-4 Current Perspectives
Clinical diabetic practice is now based on the generally accepted view, that the 
development of vascular complications is related in some way to the duration and 
degree of hyperglycaemia but there is little evidence that once complications have 
occurred that good diabetic control will reverse the situation (Tamborlane et al, 1982; 
Lauritzen et al, 1983; Viberti et al, 1983). In order to develop a rational treatment 
policy, a more thorough understanding of the changes that lead to the development of 
diabetic vascular disease and the relationship of these changes to diabetic control is 
necessary. Consideration needs also to be given to the cost, physiological, financial and 
emotional, of achieving good control against the benefits, which may vary between
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diabetic patients depending on their predisposition to, or the presence of diabetic 
complications
Little has been achieved in the past sixty years since the introduction of insulin in the 
1920’s in terms of the prevention of diabetic complications. During the 1970’s 
technical advances and the development of genetic engineering led to a second major 
development in the treatment of diabetes with the mass production of biosynthetic 
human insulin. The principal impact of biosynthetic human insulin appears to be that 
it represents a potentially limitless supply of insulin for the world’s diabetic population. 
However, each new therapeutic option has to be examined for its specific therapeutic 
advantages. In human diabetes, human insulin might be considered a more 
physiological choice of treatment but clear therapeutic advantages have yet to be 
shown. The work presented in this thesis concerns itself chiefly with the control 
dependency or otherwise of various haemostatic, haemorreological and blood flow 
factors, all of which are thought to be involved in the development of diabetic 
microangiopathy and examines the therapeutic effects of treatment with biosynthetic 
human insulin on these variables.
1-2 THE MORTALITY AND MORBIDITY OF DIABETES MELLITUS.
Diabetes mellitus is essentially a biochemical diagnosis. Broadly speaking diabetic 
patients fall into one of two main groups, Type 1) insulin dependent or, Type 11) non­
insulin dependent. In both groups there is a defect of glucose metabolism, in Type I 
due to absolute insulin deficiency and in Type II due to impairment of insulin action. 
Both insulin deficient Type I and hyperinsulinaemic Type II diabetics develop diabetic 
complications but in these two main groups the pattern of chronic tissue damage varies. 
Type I diabetes is associated with a mortality rate five times greater than the normal 
population. Before death one third of these patients will be registered blind in one eye 
largely due to retinopathy. Whilst some deaths are still the result of acute metabolic 
derangement, deaths from myocardial infarction and renal failure resulting from 
diabetic nephropathy are the most significant causes of death. When diagnosed before 
the age of 30 years the life expectancy for these patients is 29 years - only half will 
live to the age of 50 (Deckert et al 1978, [a]). Of the 10-15 percent of Type I 
diabetics who live more than 40 years, 10 percent will be blind, largely from 
retinopathy, another 10 percent will have proliferative retinopathy, but as a whole they 
are relatively free of serious morbidity. The mortality rates of non-insulin dependent 
Type II diabetes mellitus are harder to define as these patients may be asymptomatic 
for many years. Blindness in these patients is more often due to cataract and exudative 
retinopathy than proliferative retinopathy. Foot ulceration is commoner than in Type I 
diabetes but diabetic nephropathy is rarer. This different pattern of diabetic tissue 
damage may reflect the generally later age of onset of Type II diabetes and thus 
shorter duration of exposure to hyperglycaemia, or basic differences in susceptibility
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and treatment. The prognosis of non-insulin dependent diabetes mellitus is worse for 
those patients who develop the disease at a young age (Oxford Textbook of Medicine 
1983 [a])
1-3 THE RELATIONSHIP OF DIABETIC CONTROL TO THE DEVELOPMENT 
OF VASCULAR COMPLICATIONS.
1-3-1 Atherosclerosis and Diabetes Mellitus
It is becoming clear that susceptibility to large vessel atherosclerosis and to diabetic 
microangiopathy are not synonymous. Whilst the incidence of microvascular 
complications appears to be fairly uniform in diabetic patients in different cultures and 
ethnic group exposed to equal hyperglycaemia, rates of atherosclerosis vary, (Jarrett 
and Keen, 1976) suggesting that the effects on the vasculature of hyperglycaemia may 
be influenced by other factors. In populations with a high incidence of atherosclerosis, 
the presence of even abnormal glucose tolerance as well as diabetes mellitus is 
associated with a sharp increase in the incidence of atherosclerosis, but there is less 
evidence of a relationship between duration and severity of hyperglycaemia and 
increased susceptibility to atherosclerotic disease of arteries. Susceptibility to 
peripheral vascular and ischaemic heart disease appears to be increased by the presence 
of hypertension, obesity, hyperlipaemia (particularly hypercholesterolaemia) and 
cigarette smoking. However, the excess of atherosclerotic disease in diabetic patients 
appears to be greater than that which would be predicted by these factors. Whilst it is 
generally held that the incidence of diabetic complications in a population is related to 
both degree and duration of exposure to hyperglycaemia, it is also accepted that the 
susceptibility of the individual to the effects of hyperglycaemia varies widely (West,
1982).
1-3-2 The Early Studies of Diabetic Microangiopathv
From the 1950’s onwards, many studies have attempted to define the relative 
importance of genetic predisposition, diabetic control and environmental factors to the 
development of diabetic complications, particularly to diabetic microangiopathy. The 
pathogenesis of diabetic microangiopathy is undoubtedly multifactorial. Genetic 
susceptibility, (Barbosa and Saner, 1984) the male sex (Bodansky et al, 1982), social 
habits including heavy alcohol consumption (Young et al, 1984) and cigarette smoking 
(Christiansen, 1978) and the presence of hypertension (Kornerup, 1957; Knowler et al, 
1980; Hasslacker et al, 1985) have all been reported as risk factors but severity and 
duration of exposure to hyperglycaemia has been the only factor consistently linked 
with the development of microvascular damage. The first studies examining the 
relationship of diabetic control to the development of diabetic microangiopathy, 
reported in the 1950’s and 1960’s, were largely retrospective and the methods available
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for assessing diabetic control were less accurate than those at present. However, even 
in some of these early studies (*as reviewed by Tchobroutsky, 1978) many authors 
including * Jackson et al (1950), *Colwell, (1966) and *Caird et al (1969), concluded 
that good control of blood glucose was beneficial in diabetic patients as regards the 
development of chronic complications. However there were others who found no such 
certain association between control of blood glucose and complications, *Knowles 
(1964), *Bondy and Felig (1971), *Kaplan and Feinstein (1973) and *Raskin (1978).
1-3-3 The Recent Studies of Diabetic Microangiopathv
Interpretation of these largely retrospective studies was complicated by many factors, 
not least the unknown influence of the tendency for diabetic control to improve once 
diabetic complications are discovered. In more recent years, the results of several large 
retrospective (Deckert et al, 1978 (b)) and prospective studies of diabetic control and 
the development of diabetic complications have become available (Job et al, 1977;
Pirat, 1977; West et al, 1982; Howard-Williams et al, 1984, ). In these long-term 
studies hyperglycaemia has emerged as the major risk factor for the development of 
diabetic microangiopathy. Other evidence supporting the relationship of blood glucose 
and the occurrence of microangiopathy is derived from work with experimental animal 
models where the severity of diabetic complications is related to the severity of 
hyperglycaemia, (Rasch, 1979, [a, b, & c]) and it has been noted in man that lowering 
of blood glucose levels towards normal may result in reversal of many of the changes 
which accompany the diabetic state, such as slowing of nerve conduction times 
(Gregersen, 1968), hormonal disturbances, the presence of proteinuria, abnormally high 
glomerular filtration rates, abnormalities of lipid and amino acid metabolism 
(Tamborlane et al, 1979 [a & b]), all factors which may play a role in the development 
of complications. However, others argue that control of glucose levels is not the single 
cause of diabetic vascular damage, noting that even with poor control of glycaemia 
some patients remain well whilst others exposed to mild hyperglycaemia develop severe 
complications (as reviewed by West, 1982). Not all the recent studies of blood glucose 
control and the development of vascular complications show a positive relationship.
The University Group Diabetes Program, a long-term prospective trial of treatment of 
asymptomatic adult onset diabetes (Type 11) found that despite differences of glucose 
levels within different treatment groups, there were only minor differences in the 
occurrence of fatal or non-fatal events, (Knatterud et al, 1978). The results of this 
study have been criticized on the basis of the low incidence of diabetic retinopathy and 
often doubtful diagnosis of diabetes in the patients studied which may limit the scope 
of its conclusions.
In recent years, the relationship of blood glucose control to the development of 
complications has been more or less accepted and attention has focused on the 
therapeutic effects of improving diabetic control when microangiopathy has already
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occurred and on elucidating the pathogenetic mechanisms of microangiopathy. Whilst 
long-term maintenance of good diabetic control remains the best therapeutic option for 
the prevention of diabetic complications, the effects of improving diabetic control in 
patients with pre-existing diabetic vascular damage are less obviously beneficial, and 
there is evidence of worsening of microangiopathy on institution of strict control of 
blood glucose levels (Hooymans et al, 1982). Whilst after a certain stage microvascular 
damage may be irreversible, the possibility of adverse effects of reversal of 
hyperglycaemia or of the specific regimes used to achieve near normoglycaemia has 
also to be considered. Near normal blood glucose levels can be obtained by treatment 
with continuous subcutaneous insulin given by infusion pump but patients are at 
increased risk of both hyperglycaemia if the pump fails and probably also 
hypoglycaemia (Pickup et al, 1985). In addition, these devices are expensive and thus 
not widely available and patients require extensive management and access to 
immediate medical advice in case of technical failure or medical problems.
Considerable improvements in blood glucose control can also be achieved by more 
intensive management of diabetic patients with conventional multiple subcutaneous 
injection regimes but whether glucose levels are lowered sufficiently to achieve 
physiological benefit, without the same and with additional disadvantages to those of 
continuous insulin infusion devices has yet to be established.
Amongst the complex metabolic and hormonal changes resulting from the presence of 
hyperglycaemia, changes in the blood’s rheological properties and the haemostatic 
system have been suggested as contributing directly to the development of vascular 
damage by impairing blood flow in the microcirculation and by predisposing to 
thrombosis. These changes in blood rheology and the haemostatic system and their 
influence on blood flow in diabetes mellitus are the main subject of this thesis and will 
now be considered in detail.
1-4 WHOLE BLOOD VISCOSITY IN DIABETES MELLITUS 
1-4-1 Introduction
Rheology is the science of flow and deformation of matter. It is a term, which when 
applied to blood refers to its viscous properties and the deformability and interaction 
of its cellular elements, of which whole blood viscosity is an overall measure.
Skovborg and his colleagues reported in 1966 that whole blood viscosity was raised in 
diabetes mellitus and postulated that this increased viscosity might impair flow in the 
microcirculation, resulting in the intravascular erythrocyte aggregation and slowing of 
flow in small vessels in the retina reported earlier (as reviewed by Ditzel 1968). 
Skovborg suggested that deoxygenation subsequent to these disturbances of blood flow 
could promote the structural changes of microangiopathy and theories, that increased 
blood viscosity in association with hypercoagulability, might contribute to thrombus
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formation and a final occlusive event in the microvessels, are still accepted (in Joslin’s 
Diabetes Mellitus, 1985). Whilst there have now been many reports of abnormal blood 
rheology, including raised blood viscosity, decreased erythrocyte deformability and 
increased erythrocyte aggregability in diabetes mellitus, evidence that these abnormal 
rheological parameters contribute to either the development of macrovascular or 
microvascular disease still rests purely on clinical correlation. At extremes of blood 
hyperviscosity due to either an increase in plasma viscosity, caused by excess of large 
proteins, as in Waldenstrom’s macroglobulinaemia, or loss or deformability of the 
erythrocytes, as in sickle cell disease, blood flow in the microcirculation is impaired 
and examination of retinal blood vessels reveals vessel dilation, increased tortuosity, 
clumping of erythrocytes within the vessel leading to segmentation of dilated vessels 
and retinal haemorrhage (see the Oxford Textbook of Medicine 1983 [b]). Gross 
impairment of flow in the microcirculation also occurs in polycythaemia vera, where 
the cell volume is greatly increased but the effects of a much more modest elevation of 
blood viscosity, as reported in diabetes mellitus, are less obvious.
1-4-2 Theoretical Aspects of Whole Blood Viscosity and Blood FLow
The French physician Poisseuille is widely regarded as being the first to examine the 
dynamics of flow in capillary sized tubes. However, it was *Girad (1813-15) who 
defined the relationship of flow, pressure and tube length and *Hagen (1839) who 
noted that flow in fact varied with the 4th power of the radius. *Poiseuille (1840) 
modified the formulae by K, a constant relating to the viscosity of the fluid. Although 
correct in principle, Poisseuille’s equation was refined mathematically by *Wiedemann 
(1856) and *Hagenbach (1860), but remains known as the Hagen-Poisseuille formula:
Rate of Flow = tt/ 8  x  AP x  r4/L x N,
where AP= the pressure gradient, r= the radius of the vessel, L= the length of the 
vessel and N= viscosity. (*see Skalak and Chien 1981 and Usami 1982).
Thus viscosity is a major determinant of flow although it must immediately be stated 
that the experimental data on which this formula is based were obtained using water, 
alcohol and mercury and that the rigid capillary tubes were only comparable in size but 
not in other characteristics to the dynamic tapering endothelial lined vasculature. The 
Hagen-Poisseuille formulae describes steady laminar flow in a Newtonian fluid in a 
straight tube without turbulence. In the human body blood flow is pulsatile, the 
architecture of the blood vessels is complex, the vessel wall is distensible and blood is a 
non-Newtonian fluid whose viscosity varies inversely with flow rate. However it is 
still true that the relation between pressure gradient and blood flow is a function of 
vessel geometry and blood viscosity and these latter two factors are in fact related.
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1-4-3 Studies of Whole Blood Viscosity in Diabetes Mellitus
Skovborg’s original observation of increased blood viscosity in diabetes mellitus has 
been confirmed by many others including (Hoare et al, 1976, Barnes et al, 1977, Lowe 
et al, 1980, Paisey et al, 1980; Poon et al, 1982; Caimi, 1983). The increase in whole 
blood viscosity found in diabetes, although described at high shear rates, is more 
obvious when measurements are made at low shear rates (as reviewed by Caimi, 1983). 
Increased whole blood viscosity has been found to be more marked in diabetic patients 
with vascular complications (Isogai et al, 1976; Barnes et al, 1977; Lowe et al, 1980) 
and in patients with poor metabolic control (Skovborg & Nielsen, 1969; Schmid- 
Schonbein and Volger, 1976; Paisey et al, 1980), conditions associated with increases in 
plasma proteins such as fibrinogen. As serum viscosity is not increased in diabetes 
mellitus (Mosora et al 1972), the increase in whole blood viscosity in diabetes mellitus 
would appear to be due to changes in plasma proteins and their interaction with 
erythrocytes. Although the presence of increased viscosity in diabetes is supported by 
many reports its relevance to the development of diabetic complications is not yet 
established.
1-4-4 The Influence of Haematocrit and Fibrinogen Levels on Whole Blood Viscosity 
in relation to Diabetes Mellitus
Blood viscosity when transformed logarithmically, is linearly related to packed cell 
volume (Begg and Hearns, 1966). The haematocrit in diabetes mellitus is often 
increased during periods of poor control because of dehydration. Even when 
corrections are made for elevation of packed cell volume, viscosity is still relatively 
elevated in diabetes mellitus and this appears to correlate with the presence of 
hyperfibrinogenaemia (Skovborg et al, 1966; Hoare et al, 1976; Barnes et al, 1977;
Lowe et al, 1980; Poon et al, 1982). In studies of the effects of improved diabetic 
control on blood viscosity, an initial fall in viscosity occurs with rehydration and fall in 
haematocrit but the corrected viscosity remains elevated for some months until 
fibrinogen levels return to normal (Barnes, 1981). Thus the factors responsible for the 
increase in in vitro blood viscosity in diabetes mellitus appear to be increased 
haematocrit and raised levels of fibrinogen. Fibrinogen is an acute phase reactant 
protein and is elevated in a variety of disorders besides uncontrolled diabetes mellitus 
and the presence of vascular diabetic complications. Addition of fibrinogen has been 
shown to increase blood viscosity in vitro, but within the range of fibrinogen normally 
found in man and at the flow rates normally encountered, the effects on viscosity are 
theoretically likely to be small, (Weaver et al, 1969, Rampling and Challoner, 1983). It 
has been questioned whether the elevation of whole blood viscosity in diabetes mellitus 
due to hyperfibrinogenaemia, calculated as being equivalent in one study to a change in 
haematocrit of 1.7% (normal range of haematocrit 14%) is of any significance (Poon et 
al, 1982). Mild hyperfibrinogenaemia and hyperviscosity are not unique to diabetes
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mellitus and are found in a variety of conditions, not associated with the development 
of microangiopathy, including atherosclerosis, (Mayer, 1964, Dintenfass et al, 1966, 
Dormandy, 1970, Fuch et al, 1984), non-embolic cerebro-vascular disease (Marshall, 
1982 ), oral contraceptive use (Oski & Lubin 1972), cigarette smoking (Dintenfass, 
1975), alcohol intake (Galea and Davidson, 1983), and mild hypertension (Letcher et al, 
1981). In polycythaemia vera, the incidence of vascular occlusive episodes is increased 
even at modest elevations of blood haematocrit and correlates positively with the 
haematocrit (reviewed by Stuart and Kenny, 1980). Whilst elevated blood viscosity is 
commonly found in diabetic patients in whom atherosclerosis is the major cause of 
death, more work is required before high haematocrit is established as a risk factor for 
atherosclerosis in these patients.
The increase in blood viscosity in diabetes mellitus is of a much lesser magnitude of 
that seen in the hyperviscosity syndromes but it is marked at low shear rates at which 
erythrocyte aggregability and deformability contribute to the non-Newtonian behaviour 
of blood. Specific defects of erythrocyte deformability have also been reported in 
association with diabetes mellitus and it has been suggested that these effects may also 
impede flow. The various methods which have been applied to the study of 
erythrocyte deformability will now be discussed.
1-5 ERYTHROCYTE DEFORMABILITY IN DIABETES MELLITUS 
1-5-1 Definition of Ervthrocvte Deformability
The deformability of erythrocytes can be defined as the ability of these cells to change 
shape when subjected to fluid shear. The normal erythrocyte is an extremely 
deformable cell and it is this property which allows erythrocytes to enter the smaller 
nutritive capillaries which are only about half their diameter. In theory, impairment of 
erythrocyte deformability might result in failure of eryhtrocyte perfusion of the small 
capillaries leading to poor tissue nutrition and it has also been suggested that the higher 
pressures exerted on the vessel wall during passage of these hardened erythrocytes 
might contribute to microvascular degeneration of diabetes mellitus.
1-5-2 Studies of Ervthrocvte Deformability bv Filtration Methods in Diabetes Mellitus
Reduced erythrocyte deformability in association with diabetes mellitus was first 
reported by Schmid-Schonbein and Yolger in 1976. They measured deformability by 
examining the filterability of 10 percent erythrocyte suspension in autologous cell-free 
plasma comparing 45 control subjects with 77 ’early and mature’ diabetic subjects. The 
diabetic group had different duration of disease, variable metabolic status which was 
assessed by 24 hour urine glucose excretion and post-prandial blood glucose levels and 
various degrees of complications which were defined as either no retinopathy, 
background retinopathy or proliferative retinopathy by direct fundoscopy. Filterability
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was examined by determining the flow rate of the erythrocyte suspensions through 5 
micron Nucleopore sieves under a driving pressure of 5 cm of water compared with 
that of autologous plasma. The difference in flow rates of plasma and of erythrocytes 
suspended in plasma through the capillary sized channels of the Nucleopore filter was 
assumed to be a measure of the ability of the erythrocytes to deform, a pre-requisite 
for passage through the filter pores. Erythrocyte filterability was found to be reduced 
in all the diabetics, showed no correlation with duration of disease or presence of 
diabetic complications but did appear to correlate with the current metabolic control, in 
that of two groups of diabetic patients, one with high and one with low 24 hour 
glucose excretion and glucose levels, filterability was lower in the high 24 hour glucose 
excretion group and most of all in 6 patients who presented with diabetic coma. In 
vitro studies of the effects of lactate, acetoacetic and free fatty acid ketone bodies and 
lowering of pH were all found to harden erythrocytes from both normal and diabetic 
subjects. Further studies of erythrocyte filterability in diabetes mellitus were in 
essential agreement with Schmid-Schonbein and Volger’s original findings. Reduced 
whole blood filtration in diabetes mellitus was also reported by Barnes and his 
colleagues (1977) who examined whole blood filterability, under the effects of a 
negative pressure of 20 centimetres of water, a method introduced by Reid et al 
(1976[a]). Thirty-six diabetic subjects were examined and the lowest filterability was 
found in those diabetic patients with extensive microangiopathy. In their first study, 
Juhan and colleagues (1978) examined whole blood filtration, using a similar method 
but employing 5 micron millipore filters (which are now regarded as being 
unsatisfactory because of the non-uniformity of the pores). Forty diabetic in-patients, 
twelve arteriopaths from a vascular ward and fourteen control subjects were examined. 
Again the diabetic group were heterogeneous in terms of diabetic control, treatment 
and presence of diabetic complications, although details of individual patients were not 
supplied. Whole blood filterability was found to be reduced in the diabetic patients, 
particularly in diabetic patients with atheromatous disease and also in the non-diabetic 
group with vascular disease. There was no apparent difference of filterability in the 
insulin dependent and non-insulin dependent diabetics and no apparent difference in 
poorly and well controlled diabetics, although control was rather arbitrarily divided 
into two groups of ‘controlled’ and ‘non-controlled’ diabetes on the basis of fasting 
glucose levels. However, a tendency of increased filterability in the well-controlled 
insulin treated patients was noted. In subsequent studies, using essentially the same 
methods but employing the more reliable nucleopore filters and examining both whole 
blood and concentrated washed erythrocyte preparations Juhan et al (1981) and Drouin 
et al (1981) found that the abnormal deformability in insulin dependent diabetics was 
corrected by reversal of hyperglycaemia in vivo after treatment with insulin given 
using an artificial pancreas to control the blood glucose levels. Infusion of insulin also 
reduced the abnormality of erythrocyte filtration even when the hyperglycaemia was 
maintained by a feed back controlled infusion of glucose (Juhan et al 1981) and a
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further report by the same group suggested that the defect in erythrocyte deformability 
could also be corrected in vitro by incubation with insulin (Juhan et al 1982). 
Considerable interest was expressed in these findings and various different factors such 
as glycosylation of haemoglobin and alterations in other factors associated with 
impairment of erythrocyte deformability in vitro such as alterations of the membrane 
lipid composition (Cooper 1978), were suggested has being responsible for this apparent 
diminution of erythrocyte deformability in diabetes mellitus. However, later research 
into the techniques of erythrocyte filtration cast doubt on the validity of these 
filtration tests as a specific measure of erythrocyte deformability. It has been 
recognized that plasma factors such as hyperprotinaemia resulting in erythrocyte 
aggregation and the haematocrit of the sample, elevated leucocyte counts and platelet 
activation also exert an influence on erythrocyte filterability (as reviewed by Boisseau, 
1981). Thus in Schmid-Schonbein and Volger’s study using autologous plasma as the 
suspending medium, filterability may have been influenced by fibrinogen levels 
producing erythrocyte aggregation. In Barnes’s and Juhan’s early studies on whole 
blood, the sample haematocrit, plasma factors, leucocytes and platelets may well have 
influenced the sample filterability. Whilst whole blood filterability appears to be a 
more physiological test, the overall opinion of workers in the field is now that 
filtration tests ought to be carried out on suspensions of washed erythrocytes in order 
to avoid these artifactitious effects.
1-5-3 Studies of Ervthrocvte Deformability bv the Micropipeting of Ervthrocvtes in 
Diabetes Mellitus
A variety of other methods have been used to measure erythrocyte deformability in 
diabetes mellitus including the micropipetting of individual cells. Micropipetting of 
erythrocytes as a measure of membrane viscoelasticity was introduced by Rand and 
Burton (1964) who modified the technique used by Mitchison and Swann for the study 
of marine egg stiffness. Problems with the micropipette technique are that it is time- 
consuming and cumbersome. Micropipettes of uniform bore of around 3 micron bore 
have to be produced and only small numbers of cells can be examined at any one time. 
For comparison studies the same delicate glass micropipette has to be preserved and 
used. Rand and Burton (1964) examined the pressure required to partially aspirate 
erythrocytes into the bore of the micropipette. McMillan et al (1978) examined the 
flow properties of individual erythrocytes in glass pipettes of 4 micron diameter by 
measuring the pressure gradient required to establish a standard oscillatory movement 
over a 130 micron path by an erythrocyte wholly aspirated into the micropipette, and 
also by recording the time taken for cells ejected from the pipette to recover their 
normal discoid shape. Paired studies of control and experimental erythrocytes were 
performed using the same pipette and examining seven cells from each sample.
McMillan et al, (1978) found that the pressures required to oscillate diabetic
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erythrocytes within the micropipettes was elevated by approximately 50 percent in both 
a heterogeneous group of 9 diabetic patients and in diabetic rats as compared with 
matched controls. Erythrocytes from subjects with hereditary spherocytosis, in which 
erythrocyte deformability is reduced, offered less flow resistance than diabetic cells. 
The diabetic cells were also slower to restore their shape on discharge from the 
micropipette. These findings were strongly suggestive of an increase in either the 
membrane or intra erythrocyte viscosity and McMillan et al, (1978) postulated that the 
presence of increased amounts of haemoglobin AjC might increase intra erythrocyte 
viscosity. However, when McMillan and Gion (1981) examined the viscosity of normal 
and glycosylated haemoglobins in solution they found these to be identical, which 
suggested that the chemical changes in haemoglobin in diabetes did not contribute to 
reduced erythrocyte deformability.
1-5-4 Other Methods used to Assess Ervthrocvte Deformability in Diabetes Mellitus
The micropipette technique is not suitable for the study of large numbers of different 
samples. In an attempt to find a suitable method for the study of large patient 
numbers, McMillan and his co-workers then looked at the rate at which erythrocytes in 
dilute suspension form doublets after settling to the surface of a microscope slide 
(McMillan et al, 1981). The rate of doublet formation was reduced in 20 diabetic 
patients when compared with 20 normal subjects but there was no association of 
doublet formation with fasting blood glucose, type of diabetes or presence of 
complications. The formation of cell doublet consists of elevation and subsequent 
apposition of one cell over another, a process limited by the ability of each cell to 
deform and by intercellular attraction. Although this is a simple rapid technique it is 
not yet established how doublet formation compares with other tests of erythrocyte 
deformability.
Yet another approach in evaluating erythrocyte deformability in diabetes has been the 
examination of shear induced deformation of cells, either by photographing the shape 
taken up by erythrocytes in a shear field (induced in a highly viscous suspension fluid) 
or by assessing the elongation ability of the erythrocytes by analysis of diffraction 
patterns from a laser beam (Kiesvetter et al,1981 ). In both cases, an important 
determinant of deformability is the viscosity of the suspending media. Williamson et al 
(1981) first reported that shear induced deformation of erythrocytes was decreased in 
diabetes. The numbers in this study were small, only 5 control and 6 diabetic subjects 
and in a later study of 10 diabetic and 10 control subjects, this same group reported no 
significant differences between diabetic and normal subjects (Williamson et al, 1985).
Direct studies of erythrocyte membrane fluidity in diabetes, are also contradictory.
Using an eiectron spin resonance method with stearic acid probes, Kamada and Otsuji 
(1983) found membrane fluidity to be reduced in diabetes mellitus. They found no
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relation of impaired fluidity to diabetic control, blood glucose or duration of diabetes 
mellitus, but changes in erythrocyte membrane lipid classes were noted. The effect of 
insulin on human erythrocyte membrane fluidity was examined by Bryszewska and 
Leyko (1983) who found that addition of 10”^ mol/1 of porcine insulin significantly 
increased the membrane fluidity as measured by an optical method using the 
fluorescent label pyrene. No comment was made on differences in membrane fluidity 
between normal and diabetic erythrocytes as the small numbers, 13 diabetic patients 
and 6 normal control subjects probably precludes meaningful statistical analysis. In 
contrast to this study, Luly and colleagues (1981) reported that insulin at a similar
Q
concentration of 10 M, decreased membrane fluidity as measured by fluorescence 
labelling with 1,6 diphenyl 1,3,5- hexatriene. They suggested that the reaction of 
insulin with its receptor altered the erythrocyte membrane microenvironment 
decreasing (Na+ - K+) - Atp-ase and membrane fluidity.
Thus, rheological studies in diabetes mellitus have produced confusing results, largely 
because of methodological problems, with little agreement over the presence of specific 
rheological abnormalities and no hard evidence of the physiological significance of 
these putative defects in vivo.
1-6 HAEMOSTATIC FUNCTION IN DIABETES MELLITUS 
1-6-1 Introduction
Interest in the role of abnormalities of the haemostatic system in the development of 
both micro- and macro- vascular complications of diabetes mellitus has waxed and 
waned over the past 20 years. Haemostasis has been defined as "the spontaneous arrest 
of bleeding from a ruptured vessel" (MacFarlane, 1976) and is normally accomplished 
by a combination of three processes, i.e. the contraction of the vessels, the adhesion 
and aggregation of formed blood elements such as platelets and the process of blood 
coagulation. In man these vascular, cellular and biochemical haemostatic functions 
have evolved to a high degree of complexity and all are required for efficient 
haemostasis. Excessive clot formation may constitute as much a threat as catastrophic 
haemorrage and is prevented by various homeostatic control mechanisms. Once the 
function of the haemostatic barrier has been served, fibrin is removed by the 
fibrinolytic enzyme system and the leucocytes, a process which leads to recanalization 
of damaged vessels. In addition it would appear that the haemostatic system is also 
involved in various other physiological and pathological processes including the 
inflammatory process through the release of kinins and activation of the complement 
system.
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1-6-2 Evidence that an Excess of Haemostatic Factors is Thromboeenic
Most studies of the haemostatic mechanism have highlighted the effects of deficiency 
of any one of its components. From these studies it is obvious that deficiency of any 
one factor is generally still compatible with survival and that the various components 
are normally available in excess to that required for normal function. Little is known 
about the influence of relatively higher than normal circulating levels of haemostatic 
factors.
On the basis of evidence from various epidemiological studies in the general 
population, it has been suggested that high levels of blood haemostatic factors may 
predispose to the development of a hypercoagulable state which in turn predisposes to , 
vascular damage. Positive associations have also been reported between fibrinogen 
levels and risk of stroke (Wilhelmsen et al, 1984), but the commonly quoted study is 
the Whitehall survey, a long-term prospective epidemiological study of 1510 male civil 
servants, where higher levels of factor VIII, factor VII and fibrinogen were found in 
individuals at who later died from cardiovascular disease as compared with survivors 
recruited at the same time (Meade et al, 1980). In a later report of the same study 
(Meade et al, 1986), factor VII and fibrinogen levels were found to be particularly high 
in those subjects who went on to develop myocardial infarction within the next 5 
years. These results have been cited as evidence that thrombogenesis may play an 
important role in the development of coronary artery disease. However, although the 
mean follow-up period in Meade et al’s study was 10 years at the time of the 1986 
report, the development of coronary artery disease may take place over a longer period. 
It is possible that the high levels of various haemostatic factors simply mark out those 
individuals with pre-existing asymptomatic vascular damage.
As mentioned previously, the haemostatic system is also involved with the 
inflammatory process. A "haematological stress syndrome", (Annotation, 1979) is 
reported in association with surgery (Egeberg, 1962, Aronsen et al, 1972), trauma, 
acute infection, myocardial infarction and atheroslerosis (see Stuart et al 1981). The so 
called haematological stress syndrome consists of raised levels of blood platelets, 
leucocytes and various blood proteins including fibrinogen, antithrombin III, factor 
VIII and serum globulins, the latter hyperprotinaemia probably accounting for the 
hyperviscosity associated with atherosclerosis. Whilst, in surgery, trauma, acute 
infection and myocardial infarction, there is a predisposition to thrombosis, the 
thrombotic complications noted are chiefly those of venous thrombosis, pulmonary 
embolism and disseminated intravascular coagulation, conditions somewhat different 
from diabetic microangiopathy. However the different pattern of vascular problems 
may reflect on the interaction of disturbances of haemostatic function with other risk 
factors which determine the site of damage.
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Circumstantial evidence has also linked hypofibrinolysis with atherosclerosis, venous 
thrombotic disorders and other diverse conditions such as cutaneous vasculitis, Bechet’s 
disease, preclampsia, hyaline membrane disease (as reviewed by Davidson & Walker, 
1981). The fibrinolytic system is the major component of the fibrin clearing 
mechanism and evidence that hypofibrinolysis might be atherogenic was provided by 
Kadish et al (1979) who found that endothelial cells became disorganized when 
contacted by fibrin. Fibrinolytic activity in the veins of the arms has been found to be 
much greater than that of the leg (Pandolfi et al, 1968) and it is the relatively 
hypofibrinolytic leg which is predominantly affected by atheromatous and diabetic 
microvascular damage. However studies of large vein fibrinolytic activity may not be 
relevant to the arterial circulation and small vessels.
Some evidence for a thrombogenic role of haemostatic factors is provided by animal 
studies. It has been noted that pigs with von Willebrand’s disease are resistant to the 
development of atheroma and it has been postulated, that by promoting adherence of 
platelets to injured endothelial surfaces, von Willebrand factor might contribute to 
smooth muscle proliferation and the development of atheroma (as reviewed by 
Zimmerman & Meyer, 1981).
' ' ' /
1-6-3 Studies of Haemostatic Factors in Diabetic Patients
Following the first reports in the 1960’s, which suggested that blood clotting times were 
shorter in diabetic patients (Egeberg, 1963), the coagulation system has been 
extensively studied in diabetes mellitus. Large numbers of studies have examined 
platelet function in diabetes. Several abnormalities of diabetic platelets are reported 
including hyperaggregability, (*Kwaan et al, 1972), and reduced in vivo survival in 
diabetes mellitus, (Abramhamsen, 1968; Ferguson et al, 1975; Paton 1979). These 
abnormalities have been associated with the presence of hyperglycaemia (Gonzalez et 
al, 1980; Peterson et al, 1977), microvascular complications, (Szirtes, 1970; Mayne et al, 
1970; Heath et al, 1971), hyperlipidaemia (Betteridge et al, 1981) and the presence of 
higher levels of Factor VIII or Willebrand factor (Bensoussan et al, 1975).
Abnormalities of the prostaglandin pathway, with proportionally less production of the 
antiaggregatory prostacyclin and increased generation of the platelet aggregatory of 
thromboxane in diabetes have also been reported in diabetes mellitus, (Dollery et al,
1979 and Halushka et al, 1981). Insulin infusion has been reported as reversing platelet 
sensitivity to aggregation with ADP (Juhan et al, 1982 and Giugliano et al, 1982) but 
also conversely has increasing platelet hyperaggregability, (Jackson et al, 1984).
1-6-4 Fibrinogen in Diabetes Mellitus
Studies of the coagulation factors in diabetes mellitus generally agree on the presence 
of hyperfibrinogenaemia, noted by Mayne et al, (1970). Whilst it is generally agreed
41
that the highest levels of fibrinogen are to be found in those diabetic patients who 
have vascular disease (Little and Sacks, 1977; Cederholm- Williams et al, 1981; Fuller, 
1981), positive correlation of fibrinogen level with diabetic control as measured by 
HbAjC has also been reported (Coller et al, 1978) and treatment with insulin has been 
associated with higher levels than treatment with oral agents (Brooks et al, 1983).
1-6-5 Factor VIII in Diabetes Mellitus
Factor VIII has been the most extensively studied of the coagulation factors with many 
reports of raised levels of the coagulant and of both von Willebrand components, 
antigenic and ristocetin cofactor associated activity. As mentioned, studies of the 
factor VIII complex have been prolific in the field of atherosclerosis but interpretation 
of the results of factor VIII studies in vascular disease remains vexed. In diabetes 
mellitus studies of the factor VIII complex give conflicting results. Elevated factor 
VIIIC levels in diabetes mellitus are reported by Borkenstein & Muntean, 1982, Gensini 
et al, 1979, Bern et al, 1980, Vergani et al, 1981 and by Dornan et al, 1983). Raised 
levels of factor VIIIC have been reported in diabetic children apparently free of 
vascular disease (Borkenstein & Muntean, 1982) and in this group of 86 insulin- 
dependent diabetic children factor VIIIC was highest in a subdivision of these children 
who were designated as having poorly controlled diabetes mellitus on the basis of 
HbAjC levels and urinary glucose excretion. Duration of diabetes mellitus was not 
found to be of any significance as regards factor VIIIC levels. Further suggestions that 
factor VIIIC levels are related to diabetic control was suggested by Hughes et al,
(1983), who found that treatment of hyperglycaemia resulted in lowering of factor 
VIIIC levels in -36% of the group studied. Others have suggested that the highest VIIIC 
levels are fourid in diabetics with vascular complications (Dornan et al, 1983) and this 
has led to suggestions that high levels of VIIIC are related to the presence of 
vasculopathy. Other studies have been negative (Fuller et al, 1979; Cederholm- 
Williams et al, 1981 and Masperi et al, 1980). These discrepancies may in part be 
explained by the very wide range of normal factor VIIIC levels. Christe et al, (1984), 
found that the factor VIII complex as well as other coagulation parameters including 
fibrinogen levels and euglobulin clot lysis times showed a relationship with age in both 
normal subjects and diabetic patients without vascular disease. In the cases of diabetic 
patients with vascular disease the relationship of factor VIIIC and age and that of 
fibrinogen with age were obscure. Duration of diabetes does not appear to be an 
important factor but many of the variables discussed here i.e. age, duration of diabetes 
mellitus, increased incidence of vascular disease and poor diabetic control are related 
and without appropriate analysis an incomplete understanding will follow.
Studies of factor VIII von Willebrand factor in diabetes mellitus give similar mixed 
results. Cultured human umbilical endothelial cells respond to incubation with elevated 
glucose concentrations by increasing factor VIIIR:Ag levels, (Mordes et al, 1983) but
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there has been little other evidence to suggest that endothelial synthesis and/or release 
of factor VIIIR:Ag is related to hyperglycaemia rather than physical injury of the 
endothelium. Factor VIIIR:Ag (von Willebrand antigen) was also elevated in the 
diabetic children of Borkenstein & Muntean (1982), and raised levels are also reported 
by Gensini et al, (1979) and Dornan et al, (1983). Raised levels of factor VIII 
ristocetin cofactor activity were also reported by Gensini et al, (1979) and Lufkin et al, 
(1979). Lufkin et al, (1979) found that ristocetin cofact'or was higher in diabetic 
patients with vasculopathy whereas there was a smaller increase in factor VIIIR:Ag 
levels. Both factor VIII ristocetin cofactor and factor VIIIR:Ag are secreted in 
increased amounts in diabetics compared with normals after venous occlusion, 
suggesting that larger amounts of these proteins may be stored by the diabetic 
endothelium (Giustolisi et al, 1980). Diabetics with proliferative retinopathy are 
reported to have particularly high levels of factor VIII von Willebrand factor compared 
to those with lesser degrees of retinopathy (Coller et al, 1978). Similarly Christe et 
al,(1984), found diabetic patients with vasculopathy had both higher levels of factor 
VIII:C, VIIIR:Ag (von Willebrand antigen) and particularly ristocetin cofactor, although 
VIIIR:Ag levels were also high in non-diabetic patients with vascular disease. Whilst 
elevation of factor VIIIC appeared to be specific to the presence of diabetes mellitus 
rather than vascular disease, ristocetin cofactor levels in the diabetic patients as a 
whole were positively correlated with diabetic control as measured by HbAjC levels. 
Patients with poor diabetic control, however, also tended to be the ones with vascular 
complications. Insulin-induced hypoglycaemia in both juvenile diabetics and normal 
subjects results in increased levels of factor VIII related antigen (Dalsgaard-Nielsen et 
al 1982) and factor V I11 coagulant activity (Corrall et al 1980) though it is possible 
that the effects here are also mediated by concomitant hormonal changes such as 
adrenalin.
So far the evidence of a role of the factor VIII complex in the development of vascular 
disease lies solely on the basis of clinical correlations. However, it is noted that pigs 
with von Willebrand’s disease are resistant to the development of atheroma (Bowie et 
al, 1975) less information is available on the development of atheroma or diabetic 
complications in humans with von Willebrand’s disease.
1-6-6 Other Fluid Phase Coagulation Factors in Diabetes Mellitus
Other coagulation factors have been less extensively studied in diabetes mellitus but 
there are also reports of raised levels of factor V and factor VII (Fuller et al, 1979). 
Whilst there are some negative studies of coagulation factors in diabetes, reports of 
factors inhibiting the coagulation process are more conflicting. Antithrombin III levels 
are variously reported as being normal (Gandolfo et al, 1980), reduced (Banerjee et al, 
1974) and increased in diabetes (Grigiani et al, 1981). These discrepancies might be 
partly explained by different means of assessing antithrombin III levels as its biological
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activity and immunologic activity do not appear to be one and the same thing 
(Gandolfo et al, 1980).
1-6-7 Fibrinolytic Activity in Diabetes Mellitus
Studies of fibrinolytic capacity in diabetes mellitus are also hampered by 
methodological differences and inhomogeneity in the patients studied. Fibrinolytic 
activity can be measured directly by measuring the plasminogen activator activity of 
the vein wall (Pandolfi et al, 1968) or by measuring the fibrinolytic capacity of blood. 
In studies of blood, the presence of inhibitors of fibrinolysis which are not removed in 
some assays, must be taken into account (Kluft, 1979). Stimulation studies give a 
measure of the amount of plasminogen activator released from the vein on dynamic 
testing. The commonest of these is the venous occlusion test (Clarke et al, 1960, 
Robertson et al, 1972). Fibrinolytic capacity in diabetes mellitus is reported as being 
reduced (Fearnley et al, 1963; Aimer and Nilsson, 1975), normal (Mackay and Hume,. 
1964; Tanser, 1967) and increased (Bellet et al, 1961. Obesity and old age, common to 
many diabetics, are associated with reduced fibrinolytic capacity (Fearnley et al, 1963, 
Hamilton et al, 1974) and both hypo (Dalsgaard-Nielsen et al, 1982) as well as 
hyperglycaemia have been reported to result in shortening euglobulin clot lysis times. 
Interesting studies of plasminogen activator content of vein wall in diabetes have 
reported that diabetic patients with retinopathy have normal plasminogen activator 
content of the vessel wall but on stimulation by venous occlusion, low blood levels of 
fibrinolytic activity. The converse was found in diabetics free of retinopathy, who had 
low levels of vessel plasminogen activator but high levels of blood fibrinolytic activity 
on stimuation testing (Aimer and Pandolfi, 1976; Haitas et al,[a] 1984). These authors 
have speculated that the changes in patients with microvascular damage, might be due 
to faulty release of plasminogen activator from the vessel wall, which has predisposed 
them to vascular damage.
In addition to metabolic factors, fibrinolytic activity is also influenced by venous 
pressure. Fibrinolytic capacity is four times higher in the arm veins than in leg veins 
(Pandolfi et al 1968). Prolonged recumbency results in a rise in leg vein fibrinolytic 
capacity until it reaches values obtained in arm veins. It has been suggested, that the 
higher venous hydrostatic pressure associated with the upright position results in 
continuous plasminogen activator release and subsequent exhaustion of the leg vein wall 
content. Reduction of hydrostatic pressures allows restoration of the plasminogen 
activator content to arm vein levels (Karaca and Nilsson, 1971; Keber, 1983). Release 
of plasminogen activator in response to venous occlusion forms the basis of the 
commonly used venous occlusion test used for assessment of fibrinolytic potential 
(Robertson et al 1972). Prolonged venous occlusion results in exhaustion of 
plasminogen activator content which takes some 10 to 14 days to return to normal 
levels (Keber and Stegnar, 1982). Diabetic patients are commonly hypertensive (Drury,
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1983) and vasomotor regulation is thought to be disturbed (Tooke,1986). Whether these 
factors influence plasminogen activator release in addition to the many possible 
metabolic factor remains to be established.
1-6-8- Evidence of a Thromboeenic Tendency in Diabetes Mellitus
Thus in diabetes mellitus, investigations of haemostatic function have suggested that 
there are abnormalities of several aspects of the haemostatic process. Diabetic platelets 
are hyperaggregable, (*Kwann et al, 1972; Colwell et al, 1976 and many others), raised 
levels of various coagulation factors occur, (Mayne et al, 1970; Pandolfi et al, 1974; 
Fuller et al, 1979 and many others), abnormalities of the fibrinolytic mechanism are 
reported (Fearnley et al, 1963; Cash & McGill, 1969; Aimer et al, 1975 and others) and 
decreased levels of regulatory proteins such as antithrombin III are also reported, 
(Banerjee et al, 1974; Cerielo et al, 1983). However the heterogeneity of diabetic 
patients combined with a paucity of intra laboratory standardization of haemostatic 
function tests account for many conflicting reports in the literature, particularly the 
studies of fibrinolytic activity and of concentrations of coagulation inhibitors. 
Correlations of altered haemostatic factors and the presence of diabetes mellitus are not 
proof of a hypercoagulable state but some evidence of enhanced thrombogenesis might 
be provided by studies of fibrinogen turnover. If the coagulation process is activated, 
the turnover of fibrinogen - the end product should be increased and that there should 
be evidence of fibrin deposition. Fergusson et al, (1975) reported that mean fibrinogen 
survival in 11 diabetic subjects was 4 days compared with 6.9 days in 7 normal 
volunteers. These results were substantiated by reports from Banerjee et al, (1973) and 
by Jones and Peterson (1979) who found reduction of fibrinogen survival in 15 poorly 
controlled diabetic subjects, which was reversible with good control of blood glucose 
levels and also by infusion of heparin, suggesting that the action of thrombin was 
involved. Subsequently it was shown that the short fibrinogen survival was due to 
factors operative in the poorly controlled diabetic environment, as labelled fibrinogen 
obtained from poorly controlled diabetic patients had a normal turnover rate when 
infused into well controlled diabetic subjects (as reviewed by Jones and Petersen,
1981). Other studies have suggested that fibrinopeptide A levels are increased in 
diabetes indicating thrombin activation (Jones, 1985) but initial reports require 
confirmation. In diabetic nephropathy, increased excretion of fibrin degradation 
products in the urine has been reported (Chan et al, 1982), suggesting that 
intraglomerular thrombosis may contribute to renal damage.
Thus in diabetes there is some circumstantial but no conclusive evidence of an 
enhanced thrombogenic tendency with increased turnover of fibrinogen and deposition 
of fibrin. The interpretation of haemostatic function studies in diabetes mellitus is 
complex and the comparatively crude in vitro measurements of single factors probably 
bears little relationship to the intricate control of the haemostatic system in vivo but
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the changes described support the existence of a thrombogenic tendency in diabetes 
mellitus.
1-7 PERIPHERAL BLOOD FLOW IN DIABETES MELLITUS.
1-7-1 Introduction
Blood flow is under the control of neural and hormonal systems, intrinsic 
autoregulatory capacity and the rheological properties of blood, all of which may be 
altered by the diabetic state. Disturbances of blood flow occur early in diabetes, but 
whether these changes represent an appropriate response to the raised metabolic rate 
and need for heat dissipation, or are manifestations of the effects of autonomic nerve 
dysfunction, the direct effects of hyperglycaemia and accompanying hormonal 
disturbances, or are due to alterations in the vessels has yet to be determined. These 
flow disturbances are suspected of leading to the development of vessel damage. In 
addition, haemorheological abnormalities, blood hypercoagulability and activation of 
the haemostatic mechanism, with release of vasoconstrictor substances and alteration of 
prostaglandins, may all affect the blood vessels and consequently blood flow.
1-7-2 The Early Studies of Peripheral Blood Flow in Diabetes Mellitus
Peripheral blood flow has classically been studied by venous occlusion plethysmography 
(*as reviewed by. Christensen, 1972). Interesting early studies, using less accurate 
equipment and techniques than are currently available, identified the presence of 
disturbed blood flow control in diabetic patients. Amongst the first studies were those 
made by *Megibow and his colleagues in 1953, who used venous occlusion 
plethysmography to examine blood flow in the halluces of 47 diabetic patients. The 
response of halluceal blood flow to nitroglycerine and ganglionic blocking agents, 
which are both vasodilators, was examined. Vasodilation, to both agents, was impaired 
in diabetic patients and the authors thought that this represented occlusion of small 
vessels due to diabetic microangiopathy. However, although no patient in the Megibow 
study are reported as having evidence of peripheral vascular disease or pre-existing 
autonomic neuropathy, failure of vasodilation could also have been explained by the 
presence of either digital vascular disease or autonomic neuropathy. Methods for 
assessing the presence of mild neuropathy were not advanced in 1953. In the same 
year, a similar study with similar results and conclusions was reported by *Mendlowitz 
et al, (1953). Mendlowitz and his colleagues used a calorimetry method to examine the 
effects of indirect heating and administration of a ganglionic blocking agent on 
circulation in the big toe. Nine out of the 38 diabetic patients, examined by the 
Mendlowitz group, showed impaired vasodilation, which was again interpretated by the 
authors has being a sign of an organic vascular lesion.
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Soon afterwards evidence, of a possible neurogenic basis for the blood flow 
abnormalities described in diabetes mellitus, was provided by studies of skin 
temperature responses to indirect heating and cooling of the calf and thumb in diabetic 
patients (*Martin, 1953). Twenty diabetic patients with symptoms and signs of 
neuropathy were examined. Skin temperature of the leg was abnormal in the majority 
of diabetic patients, 9 of whom initially demonstrated higher skin temperature and 10 
lower skin temperature, than control subjects. The response of skin temperature to 
indirect cooling and heating was reported as being impaired. Patients with abnormally 
low foot skin temperatures were then given priscol, a drug which produces vasodilation 
whether the nerve supply is intact or not. A prompt rise of temperature in the patients 
occurred and was felt to demonstrate the presence of intact'microvessels and probable 
neurogenic basis of the blood flow abnormalities in diabetes mellitus.
Various other studies of impaired temperature regulation in the diabetic limb have also 
been interpreted as manifestations of diabetic autonomic neuropathy. *Sigroth, (1957) 
found that skin temperature changes of the fingers of diabetics to indirect heating was 
impaired in 53 out of 91 diabetic subjects and noted, that in some cases, these 
abnormalities were reversible with careful regulation of blood sugar levels. *Aagenaes 
& Moe,(1961) found impairment of temperature rise on indirect heating of the foot in 
association with the presence of vascular calcification and the presence of anhidrosis, 
findings both suggestive of autonomic neuropathy. (Calcification of vessels has 
recently been shown to be a feature of denervated limbs ,[Goedel & Fuessl, 1983]) .
* Weber and Wicht, (1962) examined the pulse volume changes in response to indirect 
heating in diabetics, without evidence of macrovascular arterial disease, and found that 
abnormal responders had more pronounced morphological changes in small vessels of 
the skin, suggesting that the state of the blood vessel was an important factor in 
determining blood flow.
9
Thus early evidence provided support for both the presence of abnormal neurogenic 
control mechanisms of blood flow and of an intrinsic vascular lesion in diabetes 
mellitus.
1-7-3 Evidence of Overperfusion in Diabetes Mellitus
At present, emphasis is being placed on the concept that high blood flow rates in 
diabetes mellitus might damage the vasculature. Increased resting blood flow in 
diabetic patients was noted by * Alexander et al in 1968 who studied flow in forearm 
muscle. This finding was confirmed by Christensen (1970), who also found high flow 
rates in diabetic patients, particularly in association with poor diabetic control. 
Gundersen (1974), found that these high blood flow rates returned to normal with 
reversal of hyperglycaemia. In addition, the renal hyperfiltration of uncontrolled 
newly diagnosed diabetes is thought to be a manifestation of increased renal plasma
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flow and, this too appears to be related to diabetic control (Parving et al, 1984). Also, 
increased retinal blood flow is a feature of diabetes, although with the development of 
severe retinopathy, flow rates diminish and ischaemia supervenes (Kohner et al, 1975). 
Thus, it is generally agreed that high blood flow rates occur in diabetic patients.
Blood flow to an organ or tissue is determined by the mean pressure gradient between 
the arteries and veins and by vascular resistance. During poor diabetic control, the 
arterial pressure is unchanged and venous pressure is low and constant. Thus the 
increased blood flow noted, often in combination with raised blood viscosity, suggests 
that vascular resistance is reduced and this could result in capillary overperfusion and 
in increased capillary hydrostatic pressure. This concept of overperfusion and capillary 
hypertension has been proposed as leading to enhanced leakage of plasma proteins and 
their deposition in the walls of arterioles and capillaries resulting in increased basement 
membrane thickness and alterations of the physical chemical properties (Parving et al, 
1983[b]). There is some direct evidence to support this theory. Glomerular capillary 
pressure appears to be higher in moderately hyperglycaemic streptozocin diabetic rats 
compared with controls, (Hostetter et al, 1981), but in man direct estimates of capillary 
pressure have only been possible in nailfold capillaries. Whilst capillary pressure in 
young type 1 diabetic was not significantly different in the hand at heart level (Tooke, 
1980), in the dependant foot capillary hypertension is demonstrable (Rayman et al, 
1986). Whether or not high flow rates in diabetic patients are an appropriate 
physiological response to hyperglycaemia, rather than due to an intrinsic failure of flow 
autoregulation or autonomic neuropathy, there is some theoretical reason to believe that 
high blood flow might be harmful.
1-7-4 The Development of Underperfusion
In the limbs, the development of atheroma may result in abnormally low resting 
peripheral flow rates and thus the pattern in diabetes mellitus may be one of initial 
"overperfusion" supervened by decreasing blood flow rates associated with long 
duration of diabetes mellitus and the development of vessel disease. The eventual 
development of iow flow in vessels has also been attributed to the development of 
microvascular sclerosis and inherent stiffness of small vessels. However, a functional 
defective response of vessels to normal vasodilatory stimuli cannot be excluded.
The vascular response after a period of ischaemia is considered to be a sensitive 
measure of the state of the vessels and their capacity to dilate. In diabetic patients 
various abnormalities of reactive hyperaemia following arterial occlusion have been 
reported. First, the time taken for blood flow to reach its maximum value, after 
release of an arterial tourniquet which has induced ischaemia, is delayed (Haitas et 
al,[b] 1984) Second, the maximum peak blood flow value attained after a period of 
ischaemia is reduced, particularly in patients with longstanding diabetes (Christensen,
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1969). Both these results suggest that vascular distensibility is decreased in diabetes 
but are apparently contradicted by Alexander et al, (1968) who reported that blood 
flow during reactive hyperaemia (in association with higher resting flow values) was 
greater in diabetic subjects than in normal subjects. However, Alexander and his 
colleagues found that the rise in integrated capillary pressure was lower and slower 
during reactive hyperaemia in diabetic subjects and suggested that a shunting of blood 
through arterio-venous anastomoses might be occurring at the expense of a decrease in 
nutritive blood flow.
1-7-5 Evidence of Arterio-venous Shunting
The proposal of abnormal distribution of blood flow and of arterio-venous shunting in 
diabetes was first raised by Popoff in 1934 and is currently receiving renewed 
attention. Studies with Doppler probes using the ultrasound principle have shown 
abnormalities of the blood velocity waveform. In cases of diabetic neuropathy, the 
normal biphasic waveform with a small diastolic back flow is replaced by continued, 
rapid and increased forward flow in the feet (Edmonds et al, 1981). In diabetic 
neuropathic feet, the veins over the back are turgid and distended in the recumbent 
position and the venous oxygen tension is high (Boulton et al, 1982), suggesting that 
oxygen consumption is decreased. Although plethysmographic studies of arterial inflow 
typically reveal increased flow in poorly controlled diabetes, flow in the corresponding 
nailbed capillaries is lower than normal, (Tooke, 1983). These findings of Edmonds, 
Boulton and Tooke provide evidence for the presence of arteriovenous shunting of 
blood with by-passing of smaller nutritive channels. The cause of this shunting occurs 
has yet to be established, although it does appear to be a feature of neuropathic limbs.
1-7-6 Autoregulation of Blood Flow in Diabetes Mellitus
Loss of appropriate autoregulation of capillary flow in response to changes in perfusion 
pressure has also been noted in diabetes. First, diabetic patients appear to be less able 
to maintain constancy of retinal blood flow in the face of changes of intraoccular 
pressure (Sinclair et al, 1982); second, in the kidney, glomerular filtration rates 
diminish with reduction of blood pressure (and hence perfusion pressure) in diabetic 
patients with diabetic nephropathy (Parving et al, 1984); and third elevation by tilting 
results in an inappropriate fall of blood flow in the arm in diabetics, (Faris et al, 1982) 
whilst in the dependant foot (in diabetic neuropathy) flow rates remain higher than 
normal (Rayman et al, 1986). Whether these abnormalities are functional or structural 
has yet to be established.
1-7-7 The Influence of Neural Control of Blood Flow
Blood vessels are richly supplied by sympathetic and parasympathetic nerve fibres.
Nerve conduction times of the sympathetic and parasympathetic nervous system cannot
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be tested directly but functional improvements of the autonomic nervous system 
reflexes occur with improvement of diabetic control (Hreidarsson, 1981). It has been 
postulated that reversible abnormalities of blood flow in diabetic patients might 
represent a transient autonomic nerve dysfunction associated with poorly controlled 
diabetes. Alternatively, delay of time to reach peak flow values and the reduction of 
maximal peak flow values could be explained by increased arterial rigidity.
1-7-8 Summary
The presence of abnormal blood flow patterns in diabetes mellitus is well established, 
but the underlying basis of these disturbances has yet to be clearly elucidated. The 
development of permanent vascular and neurological damage obviously influences blood 
flow but, it is not entirely clear from previous studies, which of the disturbances of 
flow are functional and which are due to permanent damage. Nor is it clear whether
early disturbances of blood flow are harmful or are, in fact, a necessary physiological
• .  •
adaptation to the diabetic state. High blood flow rates occur in diabetic patients but 
may be an appropriate response to the raised metabolic rate and need for heat 
dissipation. It is argued that high flow rates may result in capillary overperfusion and 
vascular damage; but paradoxically it has been suggested that much of this increased 
blood flow occurs through arteriovenous shunts, at the expense of nutritive blood flow, 
and that subsequent anoxia results in vascular damage and permanent hypoperfusion.
It seems feasible that reversible functional disturbances occur early in diabetic patients 
and that these result in loss of autoregulation of flow. Supervening structural and 
permanent vascular and neural damage will then further compound disturbances of 
blood flow. Disturbances of the neurovascular reflexes or metabolic effects acting 
locally on capillary sphincter tone remains a possible explanation of early alterations of 
blood flow. Alternatively, endothelial cell dysfunction secondary to the diabetic state, 
may affect the response of blood vessels to normal vasodilatory and vasoconstrictive 
stimuli. This may initially be reversible but lead to permanent damage. Also, a 
deterioration of the rheological properties of blood might contribute to impaired 
perfusion and preferential flow in larger channels of the small nutritive capillaries.
The resulting anoxia may then result in more permanent damage to the vessel and 
tissues leading to the classical manifestations of microarigiopathy and formation of new 
fragile vessels. Whilst this explanation is unlikely to be complete, it seems reasonable 
to assume that functional blood flow disturbances precede and contribute to the 
development of microangiopathy and that we do not yet know exactly how.
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1-8 BIOSYNTHETIC HUMAN INSULIN
1-8-1 The Development of Biosynthetic Human Insulin
Apart from maintaining the blood glucose as close as possible to the normal range, no 
other treatment has been shown to protect against the development of diabetic 
microangiopathy and the long-term complications of diabetes. Until recently diabetic 
patients, dependent on insulin, have been treated by injection of insulin derived from 
beef or pork pancreases. Human insulin (biosynthetic) became available in 1979 when 
Goeddel and his co- workers announced the successful production of human insulin A- 
and B-chains through recombinant DNA technology using Escherischia coli 
fermentation. Small quantities of human insulin had previously been available from a 
variety of different sources including human cadaver pancreases, the fluid used to 
maintain pancreatic islet cells in culture and from chemical synthesis; but the amount 
of insulin obtained by these methods was insufficient for any widescale testing or 
clinical use. Shortly after the first testing of biosynthetic human insulin of 
recombinant DNA origin in man in 1980 (Keen et al, 1980) semi-synthetic human 
insulin, a product manufactured from porcine pancreatic insulin by trypsin catalyzed 
removal of the B30 alanine and its replacement by threonine (Markussen et al, 1983) 
also became available.
1-8-2 Structure and Properties of Human Insulin
The amino acid sequence of human insulin differs from that of porcine insulin by just 
one residue at the B30 position where the human B chain contains threonine and pork 
insulin alanine. Beef insulin is more different, containing alanine at B30, and also 
valine at position 10 in the A chain and alanine at A8 instead of isoleucine and 
threonine respectively. The physical differences of human insulin from pork insulin 
are slight, and no great differences in the biological action of human and pork insulins 
were anticipated. The safety and biological efficiency of human insulin were soon 
confirmed and found as regards blood glucose lowering effects and plasma insulin 
pharmacokinetics to be virtually identical to that of purified porcine insulin (see Skyler 
& Raptis, editors of Symposium on Biosynthetic Human Insulin 1981, Skyler, 1982, 
Karam & Etzwiler, editors of International Symposium on Human Insulin, 1983). 
However, even the small differences between human and porcine insulin result in 
slightly different properties. Human insulin is more quickly absorbed from 
subcutaneous injection sites, (Botterman et al 1981; Owens et al, 1984) a factor thought 
to be due to the greater hydrogen bonding capacity of B30 threonine on human insulin 
making it more soluble, (Chawdhury et al 1983). In practice, this results in quicker 
onset of action but consequently in a shorter overall duration of both short acting and 
intermediate depot insulin preparations. In clinical trials comparing diabetic control 
patients on twice daily subcutaneous injections of human and pork purified soluble and
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isophane type insulins, overall glycaemic control has tended to be slightly worse on 
treatment with human insulin. In particular, fasting blood glucose concentrations have 
been higher on treatment with human insulin (Clarke et al, 1982 and as reviewed by 
Pickup, 1986). Manipulation of the timing of insulin injections or substitution of a 
longer acting insulin should allow comparable control to be achieved on human insulin 
and is of great practical importance.
1-8-3 Clinical Use of Biosynthetic Human Insulin
The major therapeutic advantage of human insulin appears to be that it is less 
immunogenic than purified porcine insulin which in turn is less immunogenic than 
beef insulin. In patients not previously treated with insulin, the production of 
circulating anti-insulin antibodies is less after treatment with biosynthetic human 
insulin than purified porcine insulin (Fineberg et al, 1983; Heding et al, 1984). The 
clinical importance of insulin antibodies is not fully understood. Lipoatrophy at insulin 
injection sites and substantial insulin resistance due to antibodies were largely a feature 
of treatment with beef insulin and are rare since the introduction of purified porcine 
insulins. Local and systemic allergic reactions to insulin are also rare but may be 
favourably treated by transfer to human insulin. However, it is possible that insulin 
antibodies may predispose to diabetic complications indirectly by affecting diabetic 
control. Whilst the amount and binding characteristics of anti-insulin antibodies have 
not been linked with the degree of metabolic control in individual patients, the 
presence of insulin antibodies in diabetic children has been associated with shortened 
‘honeymoon* remission period, higher insulin dosage and impaired endogenous insulin 
secretion. Indeed* insulin antibodies have the strongest relationship among various 
factors (these include HLA status, sex and age at onset) thought to influence residual B 
cell function. Insulin antibodies can prolong the intravenous half life of injected 
insulin. Patients with antibodies may show a delay in recovery from induced 
hypoglycaemia but on the other hand lose control less rapidly when insulin is 
withdrawn, suggesting that antibodies may protect from ketoacidosis (as reviewed by 
Pickup, 1986). Other postulated but not proven effects of insulin antibodies include a 
possible role in the development of microangiopathy and a suggestion that anti-insulin 
antibodies may cross-react with nerve growth factor and contribute to the development 
of autonomic neuropathy (as reviewed by Pickup, 1986).
Biosynthetic human insulin, being less immunogenic than animal insulins, is thus a 
justifiable choice of insulin for newly diagnosed insulin dependent diabetic patients 
and patients likely to require short-term or intermittent treatment, such as gestational 
diabetes or non-insulin dependent diabetic patients undergoing surgery. However, the 
role of human insulin in the treatment of established diabetics, particularly those with 
complications is not established. It is not known whether treatment with human insulin 
in the short or long-term would confer any advantage in this group of patients.
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1-9 THE AIMS OF THE STUDIES PRESENTED IN THIS THESIS
Progress in the prevention of the vascular complications of diabetes mellitus requires a 
fuller understanding of the pathogenesis of diabetic vascular damage. The subject 
matter of this thesis consists of aspects of blood rheology and haemostatic function and 
of peripheral blood flow in diabetes mellitus. The aims of the studies are threefold.
First, in view of conflicting reports using disputable methods, to establish, using a 
dilute erythrocyte suspension filtration technique, whether a) a specific defect of 
erythrocyte deformability exists in diabetes mellitus and b) to define any relationship 
of impaired erythrocyte deformability to the presence of hyperglycaemia and insulin 
treatment.
Second, as the benefits of improving diabetic control in patients with pre-existing 
micro vascular disease are now in question, to examine a) the relationship of control of 
blood glucose levels and the effects of improving diabetic control using intensified 
conventional multiple subcutaneous insulin regimes as can be acheived in normal 
clinical outpatient practice, on rheological factors, haemostatic function and peripheral 
blood flow in established diabetic subjects with evidence of microvascular disease and
b) to monitor the effects of this regime on the progression of diabetic retinopathy.
Third, to establish whether treatment with biosynthetic human insulin, again 
administered by standard multiple subcutaneous injection regimes on an outpatient 
basis, produced any therapeutic advantage with regard to its effects on the haemostatic 
system, peripheral blood flow and peripheral nerve function in diabetes mellitus.
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CHAPTER 2
RECRUITMENT OF PATIENTS AND STUDY PROTOCOLS
2-1 RECRUITMENT OF DIABETIC PATIENTS
All the diabetic patients who took part in the studies presented in this thesis were 
recruited from the diabetic clinic at Leeds General Infirmary. Three groups of 
diabetic patients were recruited:
a) newly diagnosed insulin-dependent diabetic patients presenting with weight loss 
and ketosis and also patients who had failed to obtain satisfactory control of 
blood glucose on treatment with oral hypoglycaemic drugs (see 2-1-1)
b) established Type 1 and Type II diabetic subjects receiving treatment with either 
insulin or with oral hypoglycaemic drugs (see 2-1-2)
c) established Type 1 diabetic subjects with evidence of microangiopathy on 
screening of the retinal vessels (see 2-1-3).
Patients from groups (a), (b) and (c) participated in the studies of the effects of 
improving diabetic control and in the studies of erythrocyte deformability. Only 
patients in group (c) participated in the double-blind crossover study of the effects of 
treatment with Biosynthetic Human Insulin (BHI) and Purified Porcine Insulin (PPI). 
Clinical diagnosis of Type 1 and Type II diabetes were assumed, as C peptide levels 
were not available on patients to provide confirmation.
2-1-1 Newly Diagnosed Type 1 Diabetic Subjects and Oral Agent Failures
These were patients in whom the diagnosis of insulin-requiring diabetes mellitus had 
just been made. The author usually saw them within 24 hours of diagnosis. These 
patients participated in the studies of the effects of improved diabetic control on both 
haemostatic function and peripheral blood flow, and also in the studies of erythrocyte 
deformability.
The following selection criteria were applied:
i) Newly diagnosed diabetes mellitus based on the World Health Organization 
criteria (1980, Second Report) with a history of weight loss and polyuria with 
findings of fasting whole blood glucose above 6.7 mmol/1 or random blood 
glucose above 10.0 mmol/1, glycosuria and significant ketonuria. Also, patients 
previously treated with oral hypoglycaemic drugs, whose blood glucose levels 
remained continuously greater than 10 mmol/1 and HbAjC levels more than
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10% despite optimum treatment with diet and maximum doses of glibenclamide 
(20 mg) day and metformin (1500 mg day).
ii) Age above 12 and under 70 years
iii) Either sex
iv) Generally active and in good physical health apart from diabetes mellitus
The exclusion criteria were:
i) Physical or mental disability likely to hinder participation
ii) Current malignant disease
iii) Pregnancy
iv) Drug treatment apart from oral hypoglycaemic drugs or antihypertensive agents
2-1-2 Established Type 1 (Insulin-Dependent) and Type II (Non-Insulin Dependent) 
Patients i
This second group of diabetic patients participated in the studies of erythrocyte 
deformability. Some of this group also participated in the studies of the effects of 
improved blood glucose control or haemostatic function and peripheral blood flow.
The selection criteria for this group of subjects were as follows:
i) The presence of diabetes mellitus as defined by the World Health Organization 
(1980, Second Report)
The exclusion criteria were the same as for group a.
2-1-3 Established Diabetic Patients with Evidence of Microvascular Disease
The third group of patients participated in the studies of the effects of improved blood 
glucose control and in the double-blind crossover study of treatment with biosynthetic 
human insulin and purified porcine insulin on haemostatic function, blood rheology 
and peripheral blood flow and peripheral nerve conduction times.
The selection criteria for this group of subjects were as follows:
i) The presence of diabetes mellitus as defined by the World Health Organization 
(1980, Second Report)
ii) Evidence of diabetic retinopathy on screening of the retina by a trained 
ophthalmologist
iii) Age between 20 to 70 years
iv) Either sex
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The exclusion criteria were the same as for groups described in 2-1-1 and 2-1-2.
2-2 RECRUITMENT OF NORMAL VOLUNTEERS.
Normal volunteers for study were recruited from members of staff of the Department 
of Medicine at Leeds General Infirmary. Additional subjects were recruited through 
the Blood Transfusion Service. Medical histories and examinations were performed to 
ensure subjects were in good health and not on any medications. A note was made of 
alcohol and cigarette consumption. Verbal consent was obtained for the tests 
performed, which consisted of venesection and non-invasive measurements of blood 
flow by venous occlusion plethysmography and laser doppler flow-meter. These 
subjects were not fasted before venesection.
2-3 PROTOCOL OF THE TRIAL OF IMPROVED DIABETIC CONTROL
The purpose of the studies of improved diabetic control was to examine the effects of 
lowering blood glucose levels on:
1) blood rheology
2) haemostatic function
3) peripheral blood flow
4) peripheral nerve function.
These patients were studied on two occasions, 1) at entry to the study and 2) after a 12 
week period of attempted improved diabetic control. A heterogeneous group of 
diabetic patients was examined including newly diagnosed Type 1 and established Type -■ 
1 and Type II diabetic patients. The object of the study was to improve diabetic 
control by attention to diet, patient education, the introduction of regular home glucose 
monitoring, intensive outpatient supervision and optimization of multiple daily 
subcutaneous insulin and oral hypoglycaemic regimes. In established insulin treated 
patients this period formed the run-in to a double-blind crossover study of treatment 
with BHI and PPI insulins (see Figure 2-1)
Patients participating in the studies had all procedures explained to them in detail by 
the author and gave informed signed consent. Diabetic care was managed by the 
author and patients were seen separately from the main diabetic clinic. The patients 
were examined clinically and weight and height were measured. Blood urea, 
electrolytes, liver function tests and haematology were checked and the urine was 
examined for proteinuria and haematuria. A note was made of alcohol and cigarette 
consumption. The hospital diabetic dietitian saw patients at entry to the study and 
made a record of the current dietary habits and supplied advice where necessary.
Dietary allowances were appropriate to individual needs, and did not to aim to achieve 
weight reduction.
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Diabetic control was monitored by the patients own tests and by laboratory 
measurements. Patients were taught to use Ames glucometers and were required to 
keep regular records of capillary blood glucose levels. They performed fingerprick 
tests pre-prandially, one hour post-prandially and at bedtime and were asked to make a 
note of the time and frequency of any hypoglycaemic attacks. Blood tests were 
checked on three days of the week and urine daily. Patients treated with insulin were 
instructed to alter daily insulin dosages by up to 8 units, and to aim for fasting blood 
glucose levels of less than 7 mmol/1 and one hour post-prandial blood glucose levels of 
less than 10 mmol/1. The patients were seen monthly to review their diabetic control 
and to take blood for HbAjC and laboratory whole blood glucose measurements. 
Adjustments in medication were made by the author at these visits. Additional clinic 
visits to provide support and advice were arranged as necessary. The newly diagnosed 
insulin dependent diabetic patients were initially managed as in-patients.
As radical improvement of blood glucose levels has been associated with paradoxical 
deterioration of diabetic microvascular disease, particularly in the eye, regular review 
of the patients’ retinal state was carried out throughout the studies of improved blood 
glucose control. In the double- blind crossover study of insulin treatment, fluorescein 
angiograms of the retinal circulation were performed at the beginning and at the end 
of the study to assess whether any deterioration or improvement of the retinal state 
occurred in association with improvement of diabetic control.
2-4 PROTOCOL OF THE DOUBLE-BLIND CROSSOVER STUDY OF THE 
EFFECTS OF TREATMENT WITH BIOSYNTHETIC HUMAN (BHI) AND 
PURIFIED PORCINE INSULINS (PPI).
The aim of the Double-Blind Crossover Study of BHI and PPI was to assess the effects 
of treatment with these insulins on:
1) blood rheology
2) haemostatic function
3) peripheral blood flow
4) peripheral nerve function
5) diabetic control.
The patients participating in these studies were managed as described in 2-2 and 2-3 
(see Figure 2-1 for schematic representation of the protocol)
The factors under study were measured on four occasions:
1) the first, at entry to the study
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2) the second, after a three month run-in period of attempted improved diabetic 
control on twice daily subcutaneous injections of quick and intermediate acting 
porcine insulins (actrapid and monotard)
3&4) the third and fourth occasions, after three months respective treatment with 
each study insulin.
The trial insulins were supplied by Eli Lilli Company labelled as insulin one and 
insulin two, with identical formulations of porcine and human soluble and isophane 
insulins. The sequence of allocation of insulin had been randomized by Eli Lilli and 
patients were entered sequentially on recruitment to the study, to receive the insulin 
prepared for patient number 1, patient number 2 etc. Sealed code cards were not 
broken until after completion of the study.
2-5 PROTOCOL OF THE STUDIES OF ERYTHROCYTE DEFORMABILITY
The aims of the studies of erythrocyte deformability were to determine whether there 
was a specific abnormality of erythrocyte deformability in diabetes mellitus and to 
examine the relationship of erythrocyte deformability to diabetic control. Patients 
participating in these studies were recruited from the diabetic clinic at Leeds General 
Infirmary. Verbal consent was obtained and patients were asked to attend for 
venesection in the early morning, fasting, before taking their usual medication. Blood 
for glucose and HbAjC levels was taken at the same time.
2-6 ETHICAL COMMITTEE APPROVAL
Local ethical committee approval was obtained for all the studies presented in this 
thesis.
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CHAPTER 3
METHODS
3-1 DIABETIC CONTROL AND ROUTINE BIOCHEMISTRY, HAEMATOLOGY 
AND INSULIN LEVELS.
3-1-1 Whole Blood Glucose
This assay was performed by the laboratory staff of the chemical pathology laboratory 
of Leeds General Infirmary using a modification of Trinder’s method. Blood for the 
assay was collected into Brunswick Fluoride/Oxalate tubes containing 3 mg of 
potassium oxalate and 1 mg of sodium fluoride.
3-1-2 Haemoglobin A ^C
These were measured by Mr M Stickland of the Department of Medicine at Leeds 
General Infirmary using an Isoelectric Focussing Method (Stickland et al 1982).
Normal non-diabetic HbA^C levels ranged from 5.4-7.2% and the intra-assay 
Coeffcient of Variation (CV) for measurements was 2.8%.
3-1-3 Urea and Electrolytes and Liver Function Tests
These were measured by the chemical pathology laboratory at Leeds General Infirmary 
using an automated SMA II analyzer.
3-1-4 Full Blood Counts
These were measured by the haematology laboratory in Leeds General Infirmary using 
a Coulter S Plus Counter.
3-1-5 Insulin Assay
Plasma-free insulin levels were measured by Mr M Stickland of the Department of 
Medicine of Leeds General Infirmary. Blood for the assay was collected into lithium 
heparin tubes and plasma was separated off and stored at -30°C until the time of 
measurement. All the samples were assayed on the same run. Insulin was measured 
using a radioimmunoassay kit supplied by the Immuno Nuclear Corporation, Stillwater, 
Minnesota. The option A assay procedure was followed. The samples were treated 
with PEG before the assay procedure to precipitate out insulin antibody-bound insulin. 
Guinea pig anti-insulin serum (first antibody) and Iodine /insulin (tracer) were 
then added to the specimens and incubated for 16-20 hours at 2-8°C . A pre­
precipitated second antibody complex (rabbit anti-guinea pig precipitating complex)
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was added to the specimens which were centrifuged and decanted, after 15-25 minutes 
incubation at 20-25°C, and finally the precipitate was counted in a gamma scintillation 
counter. Normal insulin levels for the kit assay were less than 25 u/ml and the intra­
assay CV was 5.3%. Insulin standard, zero standards, non-specific binding standards 
and total count tubes were run along with the test specimens.
3-2 WHOLE BLOOD VISCOSITY 
3-2-1 Introduction
Measurements of whole blood viscosity were made by the author using the Contraves 
Low Shear 100 viscometer (Contraves Instruments Ltd, Ruislip, England) at shear rates 
of 2.62 secs- * and 0.130 secs- *. Viscosity is a measure of the ease with which flow 
occurs in a fluid in response to an applied force. This concept was suggested by 
Newton in 1713 (see Usami, 1982) and simple fluids which flow proportionally faster 
when more force is applied, maintaining a constant viscosity, are called Newtonian. 
Whole blood is a non-Newtonian fluid (Dormandy, 1970); its viscosity is greater at low 
flow rates and decreases with increasing flow rates. This property is demonstrated in 
Figure 3-1 which shows whole blood viscosity in a diabetic patient (measured in the 
Contraves Low Shear Rate Viscometer) plotted against a range of different shear rates. 
Each point in Figure 3-1 represents the mean of single measurements from 3 separate 
aliquots of blood.
3-2-2 Determinants of Whole Blood Viscosity
The main determinants of whole blood viscosity are the plasma proteins, the 
erythrocytes and other cellular elements and the temperature of the sample at the time 
of analysis (as reviewed by Merrill, 1969 and by Stuart & Kenny, 1980). Numerically, 
erythrocytes are the most important of the cellular elements of blood and viscosity 
increases with increasing haematocrit (Begg & Hearns, 1966). This property is also 
demonstrated in Figure 3-1, which shows the effects of shear rate on whole blood 
viscosity. A second blood sample obtained from the same individual at a later date, 
with a slightly lower haematocrit, is less viscous at any given measuring shear rate. 
Leucocytes are more resistant to flow than the erythrocytes but being present in much 
smaller numbers are less important except where the number is pathologically raised 
(Lichtman, 1973).
The tendency of erythrocytes to aggregate at low flow rates and to deform and to align 
at higher flow rates accounts for the non-Newtonian properties of whole blood (see 
Merrill, 1969). As with other non-Newtonian fluids a minimum force has to be 
applied to blood to initiate flow. This force is known as the yield stress (see Merrill, 
1969; Kiesvetter et al, 1982). Thus in order to obtain meaningful measurements of the 
viscosity of non-Newtonian fluids, such as whole blood, standard conditions with
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defined forces or flow rates must be applied. Samples have to be measured at a 
constant temperature and the haematocrit of the sample has to be taken into account.
3-2-1 Contraves Viscometer
Whole blood viscosity was measured in the Contraves Low Shear 100 viscometer
— 1(Contraves Instruments Ltd, Ruislip, England) at shear rates of 2.62 secs and 0.130 
—1secs . A diagram of the instrument is shown in Figure 3-2. The Contraves is a 
rotational viscometer which operates on the same principle as the Wells Brookfield. A 
stainless steel bob is suspended by a wire into a stainless steel specimen cup which is 
kept at a constant temperature by a water jacket connected to a thermostatically
controlled water bath. The cup is rotated by a geared electric motor at different
—1  •speeds on shear rates of 0.1- 5.0 secs in 15 stages. The torque applied to the bob is
transmitted to the wire which then tends to twist. A photoelectric mechanism, detects 
the twist of the wire and controls an electromagnet which supplies an equal and 
opposing torque to prevent movement. The current from the electromagnet is 
proportional to the shear stress. A graph of shear stress against time was recorded by a 
chart recorder. An example is shown in Figure 3-3. This demonstrates the typical 
initial peak on applying shear, followed by a slow fall of the measured shear stress 
with time. These phenomena are thought to represent the thixotropic properties of 
blood caused by disaggregation of the red cells during the period of measurement 
(Stuart and Kenny, 1980). Viscosity was measured 24 seconds after commencing shear 
as this was found to be the most consistent point (Milligan, 1983 [b]). The coefficient 
of variation (CV) for 11 consecutive measurements was 3.2% at shear rate 2.62 secs 
but the lower shear rate of 0.130 secs showed a much wider variation in CV from 
3.8-11.2%, see table 3-1.
3-2-4 t Protocol for Measurements of Whole Blood Viscosity
Whole blood for viscosity measurements was collected into ethylene diamine tetra acetic 
acid 4m.mol/L (EDTA) from fasting patients and mixed on a roller mixer prior to 
measurement. The measurements were performed within three hours of venesection. 
The viscometer was placed on a solid weigh bench to reduce vibration and a perspex 
shield was placed round the apparatus to prevent draughts. The instrument was zeroed 
on air and then the calibration checked with a standard oil (7.78 mPa’s at 37°C, 
Brookfield Engineering Inc, Stoughton, Ma. USA). Using an automated pipette, 0.35 
ml of sample was placed in the cup, taking care to avoid bubbles, and the bob was 
lowered into the sample. Equilibration of temperature occurred rapidly. The chart 
recorder was started, then the drive to the viscometer was switched on at the pre­
determined rate. Measurements of whole blood were made in triplicate and the results 
expressed as means.
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3-3 ERYTHROCYTE DEFORMABILITY 
3-3-1 Introduction
Measurements of erythrocyte deformability were made by the author. Erythrocyte 
deformability is the ability of erythrocytes to change shape under fluid shear and it is 
this property which accounts for the low viscosity of blood during flow despite its high 
cellular content. Deformability has been assessed using a variety of techniques 
including 1) the micropipetting of cells, 2) subjecting cells to fluid shear and observing 
the change in shape, 3) filtration techniques, 4) centrifuge techniques and 5) by direct 
examination of membrane fluidity - although it is not clear how these very different 
techniques are related qualitatively and quantitatively.
3-3-2 The Ervthrocvte Filtration Technique
For the experiments presented in this thesis, deformability was measured indirectly by 
an erythrocyte filtration technique. Erythrocytes are passed through filters which are 
micropore sieves having pores of similar diameter to the smaller nutritive capillaries. 
Pore sizes of 3-5 microns, the size of the smallest capillaries in the body,are considered 
suitable (Chien, 1981). The erythrocyte has a diameter of about 7 microns and, in 
order to pass through the filter, it has to change shape. Deformability is measured as 
the ease with which erythrocytes pass through the filter, either by recording the 
volume of cells filtered under the influence of a fixed force (Schmid-Schonbein, 1973), 
or conversely, the pressure which develops on fixed rate filtration (Kenny et al, 1981).
The first erythrocyte filtration experiments were by Protheroe and Burton in 1962, 
using filters manufactured by Millipore. The quality of these coarse surfaced filters, 
whose pores are angulated, irregular, of variable diameter and variably placed, made 
standardized measurements difficult. The introduction of more uniform polycarbonate 
filters by Gregerson et al, (1967) allowed more reliable study of erythrocyte filtration. 
Even so, inter-batch variation between these filters has led to recommendations that 
filters from the same batch should be used in comparison studies. Other filter 
materials, such as reusable silver membranes (Baar, 1976), have been used but most 
filtration studies have used polycarbonate Nucleopore filters (Pleasanton Corporation, 
USA) (Schmid-Schonbein et al, 1973; Usami et al, 1975; Reid et al, [b] 1976; Barnes et 
al, 1977; Juhan et al, 1981).
3-3-3 Factors Influencing Ervthrocvte Filtration
Filtration studies have been performed on both whole blood and on erythrocytes in 
suspension. It is recognized that different factors influence the outcome in each 
situation. Whole blood filtration is affected by haematocrit, plasma proteins and lipids, 
erythrocyte aggregation and plugging of the filter pores by platelet aggregates and
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leucocytes (Boisseau, 1981). Anticoagulants which chelate calcium, such as EDTA, 
theoretically minimize the platelet and leucocyte effects and are generally 
recommended (Lucas et al, 1983 [a]). However others have suggested that calcium 
levels may affect membrane fluidity (Mitkadu and Shuji, 1982). Despite these 
drawbacks, whole blood filtration is considered by some being more representative of 
erythrocyte flow in vivo, although it is not a specific test of erythrocyte function.
The study of erythrocyte suspensions permits standardization of both the haematocrit 
and suspending medium; preparing washed erythrocyte suspensions largely removes the 
potential leucocyte and platelet plugging effects and, in dilute suspension in buffer, the 
problem of erythrocyte aggregation is overcome. The disadvantages are that 
preparation of the cell suspensions may remove a sub-population of cells with reduced 
deformability. Indeed, it has been shown that washing of erythrocytes affects 
deformability by altering extra membranous factors (Rampling and Sirs, 1972). 
Filtration techniques provide an integral assessment of the cell population, and little 
information about the specific deformability of individual cells. Despite these 
criticisms, the study of dilute erythrocyte suspensions is now recommended for the 
measurement of erythrocyte filterability (Boisseau, 1981). Low pressure filtration, with 
forces approaching those to which the erythrocyte is subjected to in the capillary 
circulation, is felt to be a physiological test of deformability (Schmid-Schonbein et al, 
1973), (although abrupt entry to a capillary sized channel does not mimic the tapering 
of the vasculature).
3-3-4 The Ervthrocvte Filtration Apparatus
In this study, erythrocyte filterability was measured by the washed-erythrocyte,
positive-pressure method developed by Kenny and Stuart (1981) as adapted by Milligan
(1983 [a]). This method complies with the criteria discussed above for accurate
assessment of erythrocyte filterability. A photograph of the apparatus is shown in
Figure 3-4, and is labelled as described. A 20 ml syringe (a) containing a dilute
12erythrocyte suspension (0.1 x 10 cells/1) is attached via a three-way connection to 
(b) a ‘Pop-Top’ filter holder containing a 5 micron pore size polycarbonate membrane 
filter (Nucleopore Corporation, Pleasanton, California). Fine bore pressure tubing of 
1-2 mm diameter (c) connects a part of the three-way connection to (d) an "Intra flo" 
continuous flushing device attached to (e) a pack of isotonic saline held within a 
pressure infuser. The "Intra-flo" continuously releases a small amount of fluid which 
prevents contamination of the system with erythrocytes. Pressure changes occurring 
over the nucleopore filter were measured by (f) a Hewlett-Packard venous pressure 
transducer which was calibrated electronically to read between 0-20 mm Hg and (g) 
amplifier. The syringe is driven at a fixed rate by (h) a Harvard pump and the 
pressure rise with time is recorded on (i) a chart recorder. The accuracy of the 
transducer was checked periodically by a mercury manometer. In the Stuart and
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Kenny method, filterability was measured as the ratio of the area under the time- 
pressure graph obtained on filtering buffer, to that obtained on filtering cell 
suspension. In the Milligan adaptation, filterability was measured as the rate of rise of 
pressure between 06-66 seconds as this was found to be consistent parameter.
3-3-5 Protocol for Measurements of Ervthrocvte Filtration
Blood samples for measurement of erythrocyte filterability were collected in 4 mmol/L 
EDTA and measurements of deformability were made within three hours of 
venesection. The cell count of the sample was estimated on a Coulter S Plus Counter. 
In most of the experiments, the anticoagulated whole blood was then pre-filtered over 
a cotton wool leucocyte removal filter (Imugard Leucocyte Removal Filter, Termuno 
Corporation, Japan) as follows: 2-3 mm filter material was packed in the barrel of a 5 
ml syringe and soaked with phosphate-buffered saline after which 3 mis of whole 
blood was placed in the barrel of the syringe and allowed to drip into a collecting 
chamber. Residual erythrocytes were washed through the filter material by placing a 
further 3 mis of phosphate-buffered saline over the used filter material.
The filtrate was washed 3 times in PBS by centrifugation in a bench centrifuge at 2000 
rpm, residual buffy layer and supernatant were aspirated and the erythrocytes were re­
suspended in PBS. The suspension cell count was then rechecked in the Coulter S Plus 
Counter. This method removed almost all the leucocytes and all the platelets.
The washed erythrocytes were then made up to a concentration of 1.0 x 10 and the 
residual concentration of the leucocytes was calculated from the dilution factor. The 
cell measurements of suspension were then drawn up in a 20 ml syringe and placed in 
the filtration apparatus. The pump was operated to fill the top pop holder with 
suspension and to wet the surface of the nucleopore filter. A stable baseline was 
obtained and the pump was then started at a rate of 3.5 ml/minute and the rise in 
pressure on filtration recorded on the chart. The resulting graph of pressure against 
time (see Figure 3-5) showed (1) a variable initial deflection on commencing filtration 
followed by (2) a rise in pressure against time. The initial deflection was excluded 
from measurements of filterability which was therefore taken as the rise of pressure 
occurring from 6-66 seconds of filtration. Figure 3-5 shows examples of erythrocyte 
suspension filtration recordings: (a) with a low residual leucocyte count showing a slow 
rise in pressure against time and sample (b) with a high residual leucocyte count 
showing a sharper rise of pressure against time. Effects of residual leucocytes on the 
measurement of erythrocyte filtration are discussed in detail in chapter 4.
3-3-6 Intra-Assav Coefficient of Variation of Ervthrocvte Suspension Measurement
The initial pressure deflection, on commencing filtration of suspensions, is 
recommended by some as the most sensitive measure of erythrocyte deformability
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(Skalak et al, 1983). In the system used by the author, the mechanical artifact of 
starting the pump produced a large intra-assay CV f over 34%. The intra-assay CV 
for 7 consecutive measurements of the pressure rise from 6-66 seconds of starting the 
pump, (excluding the initial pressure deflection which occurs on starting the system, 
see figure 3-5) was 10.5% (see Table 3-2)
3-3-7 Inter Assay Variation of Ervthrocvte Suspension Measurement
Erythrocyte suspension filterability was measured on blood samples collected from 2 
normal non-diabetic subjects on 3 separate week days. Filterability of the suspensions 
was found to vary greatly and in subject (A) ranged from 1.1 - 3.5 mm Hg and in 
subject (B) from 1.0 - 9.0 mm Hg. It was noted, that, in each individual the sample 
containing the highest calculated number of residual leucocytes was the least filterable 
(see Table 3-2). This suggested that part of the variation in filterability could have 
been caused by differences in the number of leucocytes contaminating the suspensions 
on each occasion.
3-3-8 The Influence of the Ervthrocvte Suspension Medium and the Sensitivity of the 
Ervthrocvte Filtration System to the presence of Hardened Ervthrocvtes
a)Buffer
Most filtration studies now employ EDTA for whole blood anticoagulation and isotonic
phosphate-buffered saline as the suspending medium. Phosphate-buffered saline (PBS)
was used as a buffer in the erythrocyte filtration experiments unless otherwise stated.
It was prepared fresh as required from commercial tablets of ion concentrate (Dulbecco
A, Oxoid Company). The buffer contains NaCl 8 gm/litre, KC1 0.2gm/litre, NaHP04
1.15 gm/litre and KH 2 PO4 0.2gm/litre. Measurements of pH and of Na and K
concentration were made, using a pH meter and the automated SMA II analyzer (see
section 3-1), to check the quality of the buffer made up from ion concentrate tablets.
The buffer pH was 7.4, Na content 152 mmol/1 and K content 4.1 mmol/1. The
osmolality of PBS was also checked and was found to vary from 285 -  291 mosmol kg" 
1
In order to assess the integrity of the erythrocytes prepared for the filtration 
experiments, the intracellular Na and K contents of erythrocytes, washed in PBS and 
passed over the leucocyte removal filter, were checked by flame photometry. These 
measurements were made by the Department of Chemical Pathology at Leeds General 
Infirmary. Loss of intracellular K and rise of intracellular Na is an indication of 
impairment of the cell membrane Na - K pump and the overall integrity of the cell 
membrane. The erythrocytes showed a small rise in intracellular Na and a fall in 
intracellular K, (see table 3-3). The magnitude of these changes, which were within
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the normal intra-assay coefficient of variation, were not considered to be significant 
and thus the processed erythrocytes were considered functionally intact.
PBS made up from Dulbecco tablets does not contain calcium, unless this is added 
separately. In experiments of the effects of insulin on erythrocyte filtration, Tyrodes 
solution was used as a buffer, as calcium may be necessary for insulin to bind to cell 
membranes. Tyrodes buffer contains NaCl 8.0 gms/1, KC1 0.2 gms/1, N a^P O '^H  0.05 
gms/1, CaCl 0.2gms/l, MgCl 0.047 gms/1 and glucose 1.0 gms/1. In practice, Tyrodes 
buffer was found to contain Na 153 mmol/1, K 2.8 mmol/1 and the osmolality was 291 
mosmol.kg"*. Tyrodes is a weaker buffer than PBS as it contains less phospate. The 
pH was 7.3, but as addition of cells, in 3 separate samples, was found to result in an 
average rise of pH 0.38, Tyrodes solution for filtration experiments was prepared at a 
pH of 7.0.
b) Protein
The addition of albumin to buffers has been recommended to prevent cell crenation 
(Talstad, 1971). The filterability of cells in PBS with added bovine albumin 0.5% was 
30.0% less than that of cells suspended in plain PBS. The concentration of albumin (5 
gm/1) was higher than usual physiological levels and the interaction with cells may have 
blocked the Nucleopore filter pores. Therefore albumin was not added routinely.
c) Glucose
The effects of glucose were examined by comparing filterability of erythrocyte 
suspensions containing different concentrations of added glucose: 0 mmol/1, 5.0 mmol/1, 
10.0 mmol/1, 20.0 mmol/1 and 30.0 mmol/1. Results are shown in Table 3-4. There 
were no statistically significant effects of the presence of glucose in the suspending 
medium on suspension filterability. Glucose was not added to buffers used in the 
control and diabetic patient studies.
d) pH
Lowering the pH from 7.0 to 5.0 did not cause deterioration of filterability (n = 3) but 
the cells were not incubated for any length of time.
e) Gluteraldehyde
To check whether the filtration system could detect the presence of less deformable 
erythrocytes, the filterability of gluteraldehyde hardened erythrocytes was checked. 
Gluteraldehyde treatment hardens the erythrocyte membrane by crosslinking proteins. 
When erythrocyte suspensions were treated with 1.0% gluteraldehyde, no cells passed 
through the 5 micron Nucleopore filters and the filtration pressure rose rapidly to the
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maximum recordable. This indicates that only erythrocytes capable of membrane 
deformation are able to pass through the 5 micron Nucleopore filter.
3-3-9 Changes in the Cellular Composition of the Ervthrocvte Suspension and 
Destruction of Cells following Treatment with Leucocyte Removal Filter.
It is possible that the passage of erythrocytes over a leucocyte removal filter and the 
repeated washing of cells might result in the destruction of the least deformable cells, 
thus invalidating subsequent measurements of erythrocyte filterability.
a) Changes in Erythrocyte MCV.
To check for changes in the erythrocyte population during preparation of test 
suspensions the mean corpuscular volume (MCV) of cells was checked after three 
different methods of preparation:
1) washing the cells 3 times in PBS (as described above)
2) after filtering whole blood through Imugard Leucocyte Removal Filter (as 
described above)
3) after both processes combined, filtration first followed by washing
Results are given in Table 3-5. After washing, the mean — SD MCV of 8 samples of 
erythrocytes was 87.9 — 4.4 compared with the mean — SD MCV of 88.1 — 4.2 in 
whole blood (p=0.06). The mean — SD MCV of these same'erythrocytes when filtered 
was was 87.6 — 4.5 (p=0.263). After combined washing and filtering of 13 different 
blood samples, the mean — SD MCV was 90.8 — 5.2 compared with a mean — SD whole 
blood MCV of 90.5 — 5.3, [p=0.153]). Thus preparation erythrocyte suspensions by 
washing and pre-filtering of blood over leucocyte removal filter did not appear to alter 
the composition of the erythrocyte population of blood samples.
b) Destruction of Erythrocytes
Haemolysis is the destruction of erythrocytes and thus any haemolysis occurring during 
the processing of erythrocytes is also an indication of loss of potentially less 
deformable cells. Visible haemolysis in the supernatant of spun cells occurred rarely 
and the blood sample was discarded. Light spectrophotometry, at a light emission of 
415 nanometres, was used to detect if there was any minor haemolysis.
The method used was as follows. First, the light reflectance of standards of lysed 
solutions of known concentrations of erythrocytes in PBS were measured (see Figure 3- 
5A (1)). Second, the background light reflectance of the sample plasma at various 
dilutions with saline was measured (see Figure 3-5A, (2)). It is necessary to take the 
dilution of the test sample with PBS into account, as plasma gives a background light 
reflectance reading that varies directly with its dilution, whereas saline and PBS read 
zero. During the filtration procedure, the leucocyte removal filter was pre-moistened
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with PBS and residual erythrocytes were flushed through with more PBS resulting in 
considerable dilution. Third, the light reflectance of the supernatant of test filtered 
blood samples was measured (Figure 3-5A, (3)).
The erythrocyte concentration of backround and test samples, before separation of the 
supernatant, was measured on a Coulter S plus counter to give an estimate of dilution. 
Light reflectance results were plotted on a graph with the erythrocyte concentration on 
the x axis and the light reflectance value of samples on the y axis (see Figure 3-5A). 
The background light reflectance of the test samples due to plasma was calculated by 
extrapolation (see Figure 3-5A (4)) and subtracted from the test reading. The 
difference between test and background readings was due to haemolysis and the 
amount of free haemoglobin was calculated by reading off a graph of light reflectance 
of standard lysed solutions of haemoglobin^ 3 —5 ” AQ'ty*
Free haemoglobin in the supernatant of cells passed through the leucocyte removal
filter was measured on 4^blood samples treated with leucocyte removal filter, as
described above. Three separate test filtration measurements and a background plasma
dilution graph were measured on each whole blood sample and light reflectance
+readings were made m duplicate. The mean — SD amount of free haemoglobin of 4 
separate blood samples filtered over leucocyte removal filter was equivalent to 0.3 — 
0.19% gm /dl, in the order of 0.25% of the sample. Thus a minor degree of haemolysis 
appeared to be inevitable on preparing the erythrocytes for the filtration experiments.
These results suggest that the preparation of samples for erythrocyte filtration 
experiments may result in the loss and destruction of some erythrocytes. It cannot be 
assumed that the diabetic erythrocyte population is not altered by the erythrocyte 
preparation process. Potentially, the erythrocyte preparation process may remove 
subgopulations of cells, which would otherwise influence the filtration assay.
3-3-10 Destruction of Ervthrocvtes during Passage over the Nucleopore Filter
1 O
Some destruction of erythrocytes occurred on filtration of a 0.1 x 10 /1 concentration
of erythrocytes over 3 micron nucleopore filters . There was visible haemolysis 
supernatant. (This was measured by spectrophotometry at a light emission of 415 
nanometres as described above). The free haemoglobin in the part of the specimen 
passed over the nucleopore filter was equivalent to 0.073 gm/dl. There was no visible 
or spectrophotometric detection of haemolysis on filtration over the 5 micron size 
nucleopore filters. The 5 micron nucleopore was used for the erythrocyte filtration 
experiments.
3-3-11 A Comparison of the Efficiency of Cell Washing and Imueard Leucocyte
Removal Filter in the Preparation of Leucocyte Free Ervthrocvte Suspensions
In order to establish the most efficient method fbr the removal of leucocytes from the 
erythrocyte suspensions, a comparison was made of the efficiency of leucocyte removal 
by:
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1) repeated cell washings (3 washings in PBS as described above)
2) pre-filtering the blood specimen over Imugard leucocyte removal filter (as 
described above)
3) a combination of 3 washings and pre-filtering over Imugard leucocyte removal 
filter.
Results are shown in Table 3-6. Almost all the platelets and 89% of the leucocytes 
(range 80.7 - 96.8%) were removed by 3 washes. After filtering over Imugard filter 
fewer platelets were removed, (the residual count was 82.3 — 13.3) and 71% of the 
leucocytes were removed, (range 59.2 - 90.8%). A combination of cell washings and 
pre-filtering over Imugard Leucocyte removal filter removed 93.6%, (range 90.8 - 
96.4%) of the leucocytes and all the platelets. The combination of cell washing and 
pre-filtering was the most efficient method of removing leucocytes and platelets from 
the erythrocyte suspensions and was used in studies of normal and diabetic erythrocyte 
suspension filtration.
3-4 HAEMOSTATIC FUNCTION FACTORS
These were measured by the laboratory staff of the Department of Medicine in Leeds 
using standard assays. Blood for the assays of haemostatic factors was collected 
without stasis using a "Butterfly'1 cannula to allow rapid repeated sampling. Blood 
samples were collected into 120 mM trisodium citrate, 1 part citrate to 9 parts of blood 
unless otherwise stated. Two individuals were always involved in the collection of the 
blood samples; these were the author, who performed all the venesections and a 
member of the laboratory staff from the Department of Medicine at Leeds, who mixed 
the samples, placed them on melting ice, if appropriate, and arranged for immediate 
separation and storage of the plasma where necessary. Samples for the assay of 
Fibrinopeptide A were always collected first, followed by samples for other haemostatic 
factors, and then samples for blood chemistry and haematology. Before blood 
sampling, all volunteers and patients were required to lie quietly supine for 30 minutes.
3-4-1 Factor VIII
Factor VIII has been studied extensively for a possible role in the development of 
vascular disease. It is a very complex molecule consisting of two components which, 
although linked, appear to be under separate genetic control (as reviewed by Hoyer, 
1981). The first component, factor VIII:C (the factor VIII procoagulant protein or the 
antihaemophiliac factor) is the procoagulant property of normal plasma that is 
measured in standard coagulation assays. Factor VIII procoagulant antigen levels are 
closely associated with assays of factor VIII:C activity. The site of synthesis of VIII:C 
is unknown but studies suggest it may be released by the liver (Owen et al 1979, Bloom 
1979). It is generally agreed that VIII:C accelerates blood coagulation by its cofactor
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role in the enzymatic activation of factor X by factor IXA and it is likely that 
thrombin activation is essential for VIII:C activity (Huftin and Nemerson 1978).
The bulk of the factor VIII complex consists of factor VUI-related protein, von 
Willebrand factor. Its structure and function have been reviewed by Hoyer (1981). 
Von Willebrand factor is a heterologous group of glycoproteins with a wide range of 
molecular weights. Von Willebrand factor is thought to bind to platelets and have a 
role in normal platelet aggregation and adhesion to damaged endothelium. The 
prolonged bleeding time in patients with Von Willebrand’s disease is corrected by 
transfusion of Von Willebrand rich cryoprecipitate and there is a good correlation 
between this abnormality and that of ristocetin cofactor measurements of von 
Willebrand levels (Weiss et al, 1973). Thus ristocetin cofactor activity is essentially a 
measure of the biological activity of von Willebrand factor. However it is not known 
whether von Willebrand factor binds to platelets in the absence of ristocetin, nor how 
reduced level of factor VIII protein results in a prolonged bleeding time. Ristocetin 
cofactor activity does not always reflect the in vivo biological function of von 
Willebrand factor, as in some variants of von Willebrand’s disease with near normal 
measurements of ristocetin cofactor activity, prolonged bleeding is still a problem (as 
reviewed by Hoyer, 1981). Thus, whilst it is believed that von Willebrand factor 
binding plays an important role in platelet aggregation and adhesion of platelets to 
damaged endothelium, there is no hard evidence.
Von Willebrand factor can also be measured by estimating antigen levels of factor VIII 
related protein, as distinct from measures of biological activity by ristocetin cofactor 
activity. A notable feature of factor VIII related protein is that it is partly synthesized 
by endothelial cells (Jaffe et al, 1973) and it has been suggested that the plasma level 
may be a useful marker for vascular endothelial damage (Boneu et al, 1975) even in 
early diabetic retinopathy (Porta et al, 1981)
a) Factor VIII:C
This was measured by a two-stage assay based on the thromboplastin generation 
technique. The basis of the technique is that clotting occurs when a substrate plasma is 
added to a pre-incubated mixture of Factor V, XII, XI, X and phospholipid (Factor 
VIII reagent, Diagen Kit) and Factor VIII supplied by the test plasma. The speed of 
clotting is determined by the amount of Factor VIII present in the test plasma. A 
simplified semi-automated version of the method was used (Denson & Wilkins, 1980).
In this method, apart from the manual dilutions of test and standard plasmas, the 
procedure is automatic and more accurate than fully manual methods. The substrate 
plasma was treated with a resin and this dispenses with the need for additional calcium 
chloride in the second stage of the assay.
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Blood for the assay was collected, without venous occlusion, into citrate. Doubling 
dilutions of the test plasma were made up in citrate saline, ranging from 1/16 to 1/256, 
and 0.05 //litres of each dilution was added to each of two cuvettes of a Coag-a-Pet 
tray. A Coag-a-Pet Dual channel machine (General Diagnostics) was primed to deliver 
0.2 ml of Factor VIII reagent. The test plasma and Factor VIII reagent mixture were 
incubated for 150 seconds (first stage) and then the machine delivered 0.1 ml of 
substrate plasma and the time to clot formation was recorded (second stage). A 
standard of fresh normal pooled plasma was run with each test plasma. The results of 
time to clot formation were plotted against the plasma dilution factor on log/log graph 
paper for both test and standard plasmas. The standard plasma was assigned a value of 
100 percent and the test plasma value was extrapolated from the graph.
b) Factor VIII, von Willebrand related antigen (vWf:Ag)
This was measured by immunoelectrophoresis using the method of Laurell (1966). 
During electrophoresis of an antigen in an antibody-containing medium, antigen- 
antibody complexes will precipitate in a rocket-shaped zone. The height of the rocket 
will be proportional to the amount of antigen. In this assay agarose gel was used as the 
medium for containing the antibody to vWf:Ag. Pooled normal plasma was used as a 
standard. Dilutions of the standard and patient’s plasma were prepared in 0.05 ml 
barbitone buffer and 5 //litres of these were placed in small holes punched in the gel. 
After electrophoresis and staining with coomassie blue, ’rockets’ of antigen-antibody 
complex appeared and their height measured. The standard curve was plotted on 
log/log paper and the concentration of vWf:Ag in the patient’s plasma was extrapolated 
from this curve.
c) Ristocetin Co-factor
The basis of this assay is that ristocetin quantitatively agglutinates washed fixed human 
platelets in the presence of human Factor VIII, von Willebrand related protein. The 
method of Zuzel et al (1978) was used. Platelet-rich plasma was prepared and the
g
platelet count adjusted to contain 200-250 x 10 /litre platelets. A Payton 
Aggregometer was set for use at 37°C with a stirring speed of .900 rpm. A cuvette 
with platelet-rich plasma and a cuvette containing platelet poor-plasma were used to 
set the limits on the recorder scale. 0.5 ml of platelet rich plasma was placed in a 
cuvette, which was then warmed to 37°C. The cuvette was placed in the aggregometer 
and the ristocetin added. The platelet aggregation was recorded as a graphic 
representation of changes in the optical density of the cuvette. A standard reference 
curve was constructed by measuring the effect of different dilutions of pooled normal 
plasma on the aggregation of formalin-fixed platelets in the presence of ristocetin. The 
test plasma was then aggregated in duplicate in the presence of ristocetin and its 
percentage change in optical density noted. This was read off the standard curve and
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expressed as a percentage of the activity of the normal pooled plasma (which was 
defined as 100%).
3-4-2 Fibrinopeotide A (FPA)
Fibrinopeptide A is the 16-residue amino-terminal peptide that is cleaved from the A- 
alpha chain of fibrinogen by the action of thrombin, which is the initial step in the 
conversion of fibrinogen to fibrin (Nossel et al, 1971). Measurement of 
fibrinopeptide-A is thought to be a sensitive measure of in vivo thrombin activity 
(Nossel et al, 1974[a]). Less than perfect venesection technique results in spuriously 
high levels of fibrinopeptide-A presumably because the coagulation mechanism is 
activated at the site of venepuncture or within the needle and syringe. FPA was 
measured by radioimmunoassay using a commercial kit supplied by Imco (Sureden).
The principle of the assay depends on separating the FPA by dialysis. It can then be 
quantified using 125-Iodine-labelled desaminotryrosyl-FPA with albumin-coated 
charcoal to separate the free and bound fractions.
Venous blood 4.5 ml was collected into a tube containing chilled anticoagulant (the 
dilution with blood forming final concentrations of EDTA 10m.mol/l, heparin 100 
units/ml and trasylol 100 units/ml) and gently mixed and placed in a flask containing 
melting ice. Platelet-poor plasma was obtained by centrifugation at 2000g for 20 
minutes at 4°C. The whole of the supernatant was removed and stored at -70°C until 
sufficient samples were available for assay by the kit.
3-4-3 Fibrinogen
This was measured using the method of Ratnoff and Menzies, (1951). Fibrinogen is 
converted to a fibrin clot by the addition of thrombin to the test plasma. The fibrin 
clot is washed and treated with alkali. The amount of tyrosine present in the alkali- 
digested fibrin protein is read as a colour reaction in a spectrophotometer. A tyrosine 
standard is read at the same time as the test sample. The plasma fibrinogen is 
calculated by dividing the spectrophotometer reading of the sample by the 
spectrophotometer reading of the standard and this value is multiplied by a constant 
based on the standard amount of tyrosine in the fibrinogen/fibrin.
3-4-4 Euglobulin Clot Lvsis Time
Fibrinolytic activity in the author’s studies was assessed by measurement of Euglobulin 
Clot Lysis Time, ECLT. This is a measure of plasminogen activators present in plasma 
and is based on the capacity of plasminogen activators to cause lysis of fibrin clots in 
the presence of plasminogen (Nilsson et al, 1978). The euglobulin clot lysis method is 
affected by both the fibrinogen and plasminogen content of the sample and the amount 
of inhibitor co-precipitated with the euglobulin fraction (Kluft,1979). The ECLT
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method has some limitations in the assessment of fibrinolytic capacity, which is 
generally equated with measurements of plasminogen activator. ECLT in effect 
measures the overall activity of the fibrinolytic plasminogen-plasmin system and 
apparent hypofibrinolysis cannot be attributed simply to a deficiency of plasminogen 
activator. Measurements of dilute euglobulin lysis times are not direct measurements 
of plasminogen activator nor can they be considered a complete assessment of 
fibrinolytic activity.
Dilute resting ECLT generally show a very wide range of resting values, and 
stimulation tests, provoking release of plasminogen activator, are thought to be a more 
accurate measure of the function of the fibrinolytic system. Release of plasminogen 
activator following venous occlusion forms the basis of the most commonly used test of 
fibrinolytic potential (Clarke et al 1960, Robertson et al 1972). Plasminogen activator 
is localized in the walls of small vessels and high levels of activity are also found in the 
vasa vasorum of the adventitia of large vessels (Todd, 1959). The media of large veins 
is moderately active and intimal cells only active when detached (as reviewed by 
Ogston, 1983 [c]). Besides venous occlusion pressure, other stimuli (including exercise, 
electric shock, nicotinic acid or des d-amino vasopressin (DDAVP) administration) also 
result in release of plasminogen activator by the vascular endothelium. The actual 
mediators of all these responses are unknown and their exact physiological significance 
is uncertain.
In the ECLT method, the test plasma is diluted and acidified to precipitate euglobulins. 
The euglobulin fraction contains most of the plasma fibrinogen and plasminogen, as 
well as the plasminogen activators and plasmin. The euglobulin precipitate is re­
suspended in buffer, clotted by the addition of thrombin and incubated at 37 °C  and 
the lysis of the euglobulin clot recorded. The lysis of the clot was measured in the 
Mallin automatic ECLT recorder. Tests were duplicated and the results expressed in 
minutes. Blood samples were collected without using venous occlusion after fasted 
subjects had rested supine for 30 minutes for measurements of resting basal ECLT, (R 
ECLT). Measurements of post-venous occlusion ECLT (PV ECLT) were taken from 
the opposite arm. Venous occlusion of 90 mm Hg was applied for 10 minutes. In 
some studies, measurements of ECLT were made 1 hour after subcutaneous injection of 
insulin (PI ECLT), and these samples were taken from a different vein where possible.
3-5 PERIPHERAL BLOOD FLOW AS MEASURED BY PLETHYSMOGRAPHY
3-5-1 Introduction to the Principles of Plethysmography
%
Measurements of peripheral blood flow in the calf and forefoot were made by by the 
author, using an ECG triggered Periflow plethysmograph (Janssen Pharmaceutica, 
Janssen Scientific Instruments Division). In plethysmography the increase in volume of
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a limb, which occurs with arterial input when venous output is occluded, is assumed to 
be a measure of the arterial inflow. The principle of plethysmography was conceived 
at the beginning of this century by Brodie (1905), as reviewed by Hyman and Windsor, 
(1961). Originally volume changes were measured by fluid displacement by the limb. 
Whitney introduced the strain gauge in 1951 and greater accuracy and semi-continuous 
measurement were made possible by the development of ECG triggering by Barendsen 
et al in 1971. The Periflow was developed in 1976 (Brugmans et al 1977).
3-5-2 The Periflow Plethvsmograoh
In the Periflow plethysmograph, the change in circumference of the limb on venous 
occlusion is measured by mercury filled silastic rubber gauges. The gauges are 
extremely light and stretchy and do not constrict the limb to any extent. Stretch of the 
gauge alters the electrical resistance of the fixed volume mercury column, as any 
change in length has to be accompanied by a corresponding change in area. The 
change in the electrical resistance of the mercury column is proportional to the change 
in volume of the limb and hence limb blood flow. A Bridge circuit converts the 
resistance variation into voltage variations and allows automatic zeroing of the mercury 
gauges. Thus measurements are independent of the initial strain or elongation of the 
mercury gauge. Good correlation has been obtained between distension of the gauge 
and limb volume (Englund et al, 1972) but the non-distensible part of the gauge, which 
measures 2.4 cm, does introduce error into the volume change measurements, greatest 
for small gauges. Venous occlusion is applied to the limb under study by automatic 
inflation of limb cuffs with air supplied from a compressed air source and a series of 
valves and reservoir drums which allow rapid cuff inflation and deflation. The casing 1
for this part of the apparatus doubles as a table on top of which the patient lies for the
. i ■
examination. The fast acting pneumatic system of the Periflow allows rapid changes of 
venous occlusion and recovery periods which are timed by the ECG trigger or a 
manual programme.
3-5-3 Operation of the Periflow Plethvsmograoh
The Periflow pressure programme can be operated by either ECG triggering or by a 
manual programme with fixed rate occlusion at 3 or 60 beats per minute. The ECG 
triggering mechanism incorporates a variable delay. The arterial pulse takes longer to 
arrive at the feet than the forearm and the variable delay allows timing of cuff 
inflation to coincide with the arterial pulse for the limb under examination. The 
control panel contains separate venous and arterial occlusion programmes. The number 
of beats of venous occlusion and recovery can be varied from a range of 1 to 9 beats, 
but is generally set to supply venous occlusion for three beats and to deflate for two 
beats of the cardiac cycle. The venous occlusion pressure can be set from 0-99 mmHg 
but usually a pressure of 50 mmHg, which suppresses venous outflow but not arterial
a) photograph of calf flow measurement
b) photograph of foot flow measurement
FIGURE 3-6
The Set-up for Pleythsmographic Measurements of Peripheral Blood Flow
MERCURY
STRAIN
GAUGE
OCCLUSION
CUFF
E C O
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COMPUTERA M PLIFIER CHARTRECORDER
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c) diagram of apparatus
FIGURE 3-6
The Set-up for Pleythsmographic Measurements of Peripheral Blood Flow
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inflow, is selected. This has to be checked in individual patients. The arterial pressure 
programme used to apply arterial occlusion for measurements of reactive hyperaemia 
allows a wide range of occlusion pressures and times of occlusion. Generally a pressure 
at least 50 mmHg above the systolic pressure is chosen. After the variable time period 
for arterial occlusion the Periflow reverts automatically to the venous occlusion 
programme during which measurements of reactive hyperaemia are made. A re-set 
button allows instant cancellation of any programme. An integrated calculator converts 
the volume signal into a peripheral flow measurement taking into account settings on 
the occlusion programmes. Plethysmographic recordings of blood flow are usually 
recorded by chart recorder but may also be viewed by oscilloscope with addition of the 
relevant unit. The recorder selector module permits selection from several output 
signals including the Hg-gauge amplified output calibration signal, the differentiated 
input signal of the Hg-gauge amplifiers, the calculated volume changes by venous 
occlusion-calibration, the calculated volume changes of initial volume after arterial *
occlusion, a QRS monitoring signal, the triggering delay of the ECG, and the cuff 
pressure calibration. Photographs of a subject positioned for plethysmographic 
measurements of blood flow of (a) the calf and (b) the foot are shown in figure 3-6 
and schematically represented in figure 3-6 (c).
3-5-4 Protocol for Plethysmographic Measurements of Blood Flow.
Blood flow in the peripheries is affected by temperature (Freeman, 1935; Felder er al, 
1954) and limb position in relation to the heart is also important (Barendsen et al,
1971). In order to introduce some uniformity blood flow measurements of diabetic 
patients were always performed in the morning, after breakfast and the patients were 
allowed to acclimatize for 30 minutes at 24.5+0.5°C in the constant temperature room. 
Skin foot temperature was measured by a thermocouple attached to the skin of the 
dorsum of the foot below the web between the first and second toes. In individual 
patients the same strain gauge was used to record flow on each occasion and was placed 
in the same position for each recording. Measurements were made of resting calf 
blood flow and resting forefoot blood flow and reactive hyperaemia of the forefoot 
after a 4 minute period of arterial occlusion. The calf gauge was placed round the 
broadest part of the calf muscle, and a note was made of the distance from the lower 
patella border to allow accurate placement in repeat studies. The foot gauge was 
placed round the broadest part of the foot, measured down from the medial malleolus 
and was fastened over the bony dorsum of the foot. The patients were assessed in the 
supine position with the shoulders on the bed and head on a double pillow. The legs 
were elevated at the feet by 15 cm and allowed to rest held straight in slight external 
rotation. ECG leads were attached and the plethysmograph was operated by ECG 
triggering. The cuffs of the plethysmograph were attached round the thighs for 
assessment of calf flow and just above the ankles for assessment of foot flow. The
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measurements of flow were generally made in the right leg but if varicosities or some 
other abnormality was present (e.g. previous injury) measurements of the left leg were 
made. The plethysmograph was programmed to inflate for 3 beats of the cardiac cycle 
and to deflate for 2 beats of the cardiac cycle. The venous occlusion pressure was 50 
mmHg. Resting calf flow was recorded over a period of 3 minutes. After calf flow 
measurements, the thigh cuffs were removed and the ankle cuffs and gauges positioned 
for the forefoot measurements. Resting forefoot flow was measured over a 3 minute 
period. The reactive hyperaemia following a 4 minute period of arterial occlusion was 
then recorded over a 3 minute period. The arterial occlusion pressure was 250 mmHg. 
The recorder selector programme was set to the output from the mercury strain gauge 
and to the computerized flow values on the second channel. The results were recorded 
on a two-pen graph recorder, and before commencing measurements calibration signals 
for the computerized flow value - equivalent to 30 ml blood per 100 ml tissue and for 
the mercury strain gauge output 0.1, 0.5 and 1% volume change were obtained. 
Examples of the blood flow recording graph are shown in Figure 3-7.
Resting flow values of the calf, Resting Foot Flow (RCF) and foot, Resting Foot Flow 
(RFF) were calculated by using a planimeter to measure the area under the graph of 
the computerized flow output signal. Flow values per 100 ml tissue per minute were 
calculated by taking a ratio of the area under the rest flow area to the area under the 
calibration signal. Reactive hyperaemia was assessed by measuring the time to each 
peak flow values, (TPF) the peak flow value following arterial occlusion (PF) and peak 
flow minus resting flow (PF-RF) and the time for the peak flow value to reach half its 
value, T50, see figure 3-7. For some of the flow recordings the arterial debt was 
calculated by multiplying rest flow by the time of arterial occlusion. The rate of pay 
off of the arterial debt was then calculated by looking at the percentage paid back in 
0- 30 seconds.
3-6 LASER DOPPLER FLOWMETER MEASUREMENTS OF SKIN BLOOD 
FLOW IN THE PAD OF THE GREAT TOE
3-6-1 Introduction and Principles of the Laser Doppler Flowmeter
Blood flow at the great toe pad was measured by the author with a Periflux Laser 
Doppler Flowmeter, which is a helium neon laser. The principle of the laser doppler 
flowmeter is that a laser light beam incidence on tissue is scattered both on static 
structures and on moving structures, i.e. red cells. Light beams scattered on moving 
matter undergo a frequency shift according to the Doppler effect, whilst beams 
scattered in static tissue alone maintain the same frequency. A portion of the back 
scattered light is brought to impinge on the surface of a photodetector where beat notes 
produced by mixing of waves scattered in different structures are formed. From the
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alternating portion of the photocurrent, an output signal that is related to the flux of 
red cells in a specific tissue volume is generated (Tenland, 1982).
The laser doppler measures movement within a hemisphere volume some 1-1.5 mm 
from the laser’s circular measuring head front surface. The signal records movements 
mostly of erythrocytes but lesser contributions are received from all other cellular 
components and from vessel walls and other membranes. The periflux flowmeter does 
not react to the flow of fluids, such as plasma, which have a uniform refractive index. 
The signal obtained is independent of direction of structure movement but in vitro 
correlates positively with the number of blood cells in motion and their velocities 
(Nilsson et al, 1980). Movement of the measuring head towards or away from the 
tissue to be studied also gives rise to a signal. The primary signal is converted into an 
analogue voltage and displayed, graduated in percent on an analogue meter. A chart 
recorder is attached to the recorder output to obtain a permanent record of blood flow 
recordings. The reading and output signals are proportional to blood cell flux and is a 
relative rather than absolute value.
3-6-2 Factors Influencing Laser Doppler Measurements of Blood Flow.
The use of the laser doppler flowmeter for measuring skin blood flow was suggested by 
Stern in 1975. The thickness of the overlying keratin layer will affect the depth of 
dermal penetration by the laser beam and hence the vessel in which blood movement is 
recorded. In the skin of the fingers a 200-400 pm keratin layer separate the capillaries 
which measure 0.2-0.4 mm from the laser doppler. Thus theoretically blood flow 
measurements will be predominantly of capillary flow but flow in deeper vessels may 
well be recorded. Skin blood flow is extremely variable from site to site and in 
individuals day to day variations are very great making it impracticable to define 
normal flow levels (Tenland, 1982). Rhythmical variations in human skin blood flow 
occur which are non-synchronous with respirations and heart rate and these too vary 
between different sites and individuals. These are thought to be due to spontaneous 
rhythmical contractions of smooth muscles surrounding the small vessels (Salerud et al,
1983). The effects of various standard stimuli such as ischaemia and deep inspiration 
on skin blood flow can be demonstrated by measurements with the laser doppler 
flowmeter. The advantages of the laser doppler flowmeter are that it does not interfere 
with the tissue under study but disadvantages include sensitivity to movement artifact, 
the unknown relationship of measurements with tissue pigmentation, epidermal 
thickness and blood haemoglobin and the poor reproducibility and enormous variations 
within individuals which make repeated follow-up studies difficult and establishing a 
normal range difficult.
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3-6-3 Protocol for the Measurement of Toe Pad Blood Flow
Toe pad blood flow measurements were performed by the author in the constant 
temperature room at an ambient temperature of 24°C. The set-up for the laser 
doppler flow measurements is represented schematically in Figure 3-8. Subjects were 
acclimatized for approximately forty-five minutes before measurements were made 
(which followed directly on from the plethysmographic recordings of resting calf flow). 
The subject was positioned as for plethysmographic blood flow measurements, supine 
with the leg elevated by approximately 15 cm and supported at the ankle.
Automatically inflating ECG triggered pressure cuffs from the periflow 
plethysmograph were attached around the ankle. The laser doppler probe was attached 
to the great toe pad for measurements by means of a double-sided adhesive ring and 
plastic probe head holder. Temperature was recorded from the web between the great 
and second toes. The laser doppler flow meter was allowed to warm up for 15 minutes 
before use. The record output channel was attached to a graph recorder, paper speed 
50 mm/minute, and the 100% signal was calibrated to 10 volts. The periflux zero was 
obtained by first attaching the probe head to the solid white front of the console panel 
of the laser doppler panel. The gain was set at X3 and the frequency limit at 4 kHz, 
output circuit time constant 3.0 seconds.
Measurements were made of resting toe pad flow and reactive hyperaemia during 
plethysmographic recordings of resting foot flow and reactive hyperaemia following 
arterial occlusion at the ankle for 4 minutes. Movements of the plethysmograph gave 
rise to considerable artifact therefore the only feature of toe blood flow measured was 
time taken to reach peak flow values following release of the arterial tourniquet. Peak 
flow was defined as the maximum deflection following release of the tourniquet. 
Examples of Laser Doppler Flowmeter recordings are shown in Figure 3-9.
3-7 ELECTROPHYSIOLOGICAL STUDIES OF NERYE FUNCTION
The electrophysiological studies were made by Dr A Twomay of the Department of 
Neurophysiology in Leeds General Infirmary. Electrophysiological studies consisted of 
motor conduction velocities (MCY) and F response latencies of the Ulnar and Common 
Peroneal nerves, and sensory conduction velocities (SCV) of the Ulnar and Sural nerves 
using the methods described in Lenman and Ritchie (1983). Motor nerves were 
stimulated maximally with fixed-duration square wave pulses and the responses 
recorded using surface electrodes. Sensory nerve action potentials were recorded 
antidromically in the hand (using stimulating ring electrodes) and orthodromically in 
the legs. The F response latency was measured as the fastest latency in a group of 20 
responses. All electrophysiological measurements were performed in a well heated 
room using a Medelin MS6 Recorder. Surface temperature was recorded at each visit 
using an Edale digit 1 thermometer.
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3-8 ASSESSMENT OF DIABETIC EYE DISEASE
Assessment of diabetic eye disease was performed by members of staff of the 
Department of Ophthalmology at Leeds General Infirmary. Visual acuity was measured 
and the eyes were examined by an ophthalmologist (after dilation of the pupils using a 
short acting mydriatic), both by slit lamp and by ophthalmoscope. A note was made of 
the presence or absence of cataract, haemorrhages, hard exudates, cotton wool spots, 
microaneurysms, new vessel formation and other retinal abnormalities.
Colour slide photographs and fluorescein angiograms of the retinae were taken at the 
beginning and at the end of the trial to provide a record of progression of 
microvascular disease. The eyes were fully dilated as before and the plain photographs 
were taken with a Canon Fundus camera model CF-60Z using a 60 degree field of 
view centre on the macula. An injection of 5 ml of 20% fluorescein (SAS 
Pharmaceutical, Wycombe End, Beaconsfield, Bucks) was given intravenously by rapid 
bolus injection by the author. Photographs (black and white) were taken commencing 
seven seconds after the injection at a rate of one frame a second for twenty seconds. 
The right eye was usually photographed first and then a few late shots of the left eye 
were taken. Residual shots were taken of both eyes five minutes after the fluorescein 
injection.
The colour slides and fluorescein angiograms of the retinae were assessed by a second 
ophthalmologist. Assessments were made by viewing the negatives through a magnifier 
and counting the number of lesions in the whole field. A record was made by simple 
counting of the presence or absence and severity of the following lesions:
1) microaneurysms
2) haemorrhages
3) hard exudates
4) cotton wool spots
5) areas of capillary non-perfusion
6) new vessels
7) areas of laser treatment.
The number of microaneurysms was classified as
+ = sparse lesions <5;
++ = moderate number of lesions <20;
+++ = numerous lesions >20.
Each eye was classified as having either background or proliferative retinopathy 
(Benson et al, 1981) and a note was made of advanced background disease considered
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to be pre-proliferative on the basis of areas of capillary non- perfusion, presence of 
large blot haemorrhages and multiple cotton wool spots (Kohner, 1976). The presence 
of maculopathy was also recorded. A comparison of the state of the eyes at 
recruitment to the trial and at the end was made on the basis of changes in the plain 
fundal photographs, fluorescein angiograms and clinical events by the second 
ophthalmologist and the author. Examples of the fluorescein angiograms and plain 
fundal photographs are shown in Figures 3-10, 3-11 and 3-12.
3-9 STATISTICAL ANALYSIS
Details of the statistical tests used are given separately for each results section. As 
biological data cannot be assumed to be normally distributed, non-parametric statistical 
tests were often employed in order to avoid errors due to skewed data. Where 
appropriate parametric statistical tests were also used. The analysis were made using a 
statistical package, OXSTAT: except where statistics for small numbers were performed 
manually. The multiple and stepwise linear regression analyses were performed using 
the statistical package MINITAB.
a) RG, background retinopathy
b) RoK, advanced background retinopathy
FIGURE 3-10 
Plain Fundal Photographs of Diabetic Retinae
F I G U R E  3-11
Fluorescein Retinal Angiogram of Background Diabetic Retinopathy
a) early sequence
FIGURE 3-11-
Fluorescein Retinal Angiogram of Background Diabetic Retinopathy
b) late sequence
FIGURE 3-12
Fluorescein Retinal Angiogram of Advanced Background Retinopathy
a) early sequence
FIGURE 3-12
Fluorescein Retinal Angiogram of Advanced Background Retinopathy
b) late sequence
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TABLES TO CHAPTER 3
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TABLE 3 - 1
Reproducibility of Whole Blood Viscosity Measurements
Shear 
Rates_j 
(secs )
Graph
Reading
Mean C.V. Mean whole 
blood viscosity 
(centipolse)
Conversion 
f&ctor 
(Reading to 
Centipoise
2.62
Sample 1 
N = 10
42
42
42 
41
40.5
44.5 
44
43
41.5
44
42.6 3.2% 12.8 0.301
0.13O
Sample 2 
N = 3
60
57
62
59.7 4.2% 72.69 1.22
O.130
Sample 3 
N = 4
45
40
52
49
46.5 11.2% 56.7 1.22
0.130
Sample 4 
N = 5
53
55
56
47
51
52.4 6.8% 63.9 1.22
0.130
Sample 5 
N = 4
46
48 
43
49
‘46.5 5.7% 56.8 ; 1.22
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Table  3 - 2 A .  and 3 -  2B ■
R e p r o d u c i b i l i t y  of  Ery t hr oc y t e  Suspens ion F i l t r a t i o n  
3 -  2A I n t r a - A s s a y  C o - e f f i c i e n t  of  V a r i a t i o n
Suspens ion
WCC
1°7 / l
Suspens ion
RBC
i o 12/ l
F i l t  e r a b i l i t y  
mmHg
mean SD 
mmHg
CV%
2.2 1. 0 2 . 4 2 . 4 8  0 . 2 6 10.5%
2.2 1 . 0 2.3
2. 2 1 .0 2 .4
2 . 2 1 . 0 2.6
2 . 2 1 . 0 2 . 5
2 . 2 1.0 2 . 2
2 . 2 1 . 0 3 . 0
3 -  2B Inter-Assay Variation
Specimen Suspens ion
WCC
10?/ L
Suspens ion
RBC
1012/ l
F i l t e r a b i l i t y  
mmHg
A Day 1 2 . 2 1 .0 2 .5
Day 3 1 . 5 1 . 0 1.1
Day 5 2.7 1.0 3 . 5
B Day 1 0 . 8 2.0 1 .0
Day 3 3 . 1 5 2.0 1 . 2
Day 5 9 . 0 2 . 0 9 . 0
Suspens ion WCC -  t h e  c a l c u l a t e d  s u s p e n s i o n  l e u c o c y t e  c o n c e n t r a t i o n  
107 / l obt  a ined from m u l t i p l y i n g  t h e  l e u c o c y t e  count  of  washed'  
and f i l t e r e d  c e l l  p r e p a r a t i o n s  by t h e  d i l u t i o n s  f a c t o r  used to  make 
up 1 .0  = 1012/^ rbc s u s p e n s i o n s .
Suspens ion RBC -  e r y t h r o c y t e  count  1012/^.
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Table 3 -3
Changes in  In tra ce llu la r  Ion Content o f Erythrocytes 
prepared for C ell F iltr a t io n
Sample In tra ce llu la r  sodium
m.mol/L
In tra ce llu la r  potassium  
m.mol/L
Whole Blood 1 11.45 82.78
2 11.32 79.90
X 11.38 81.34
Washed C ells 1 11.36 80.30
2 12.11 74.50
X 11.73 77.4
F iltered  C ells 1 11.33 82.32
Washed and 1 11.38 77.64
F ilte r e d  C ells  2 12.11 76.22
X 11.74 76.93
* Whole blood for samples 1 and 2 was c o lle c ted  from the same 
individual on 2 separate occasions.
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Table 3 - 4
The E f f e c t s  of  Varying Glucose  Concentrat ions  of  t he  Suspending  
Buf fe r  on Erythrocyte  Suspension F i l t e r a b i l i t y  mean ( + SD)
Bu f f e r  Glucose
c o nc e nt r a t i on
mmol/L
0 5 10 20 30
F i l t e r a b i l i t y  
mmHg 
N = 9
1.8  
( + 1.0)
2.1  
( + 1.1)
F i l t e r a b i l i t y  
mmHg 
N = 6
3 .9  
( + 3 . 4 )
3 .1  
( + 3 . 0 )
3 . 1  
( + 2 .9)
2.6  
( + 2.2)
F i l t e r a b i l i t y  
mmHg 
N = 12
2.
( + 2.3)
2.9  
( + 2.8)
F i l t  e r a b i l i t y  
mmHg 
N = 10
2.3  
( + 3 . 0 )
2.1  
( + 1.8)
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Table 3 - 5
Changes in Erythrocyte M.C.V. during Preparations 
of Erythrocyte Suspensions
M.C.V. mean.± SD
Blood Samples Whole Blood Washed RBC Filtered RBC Washed and 
Filtered  RBC
G
OII52 88.1 
+ A.2
87.9 
+ A. A
87.6 
+ A.5
N = 13 90.5 
+ 5.3
90.8
± 5 . 2
Microcytic 
Blood Sample 
N = 1
62.2 68.0 68.0
Macrocytic 
Blood Sample 
N = 1
■
105.5 105.8
-
86
&
&
H.
W
as
he
d 
an
d
 
P
re
-f
il
te
re
d
93
.6
 
+ 
2
.8
2
.7
 
+ 
1.
1
8
6
.2
 
+ 
4.
9
Q)p
a) CM ro+j o  • ro  • i • i—i
i—i • r - • ro • •
•r-l rH  rH CM rH vo inr - 00 00 . .I +1 +1 +  1VUP
■8 rH in rH£} O  • ro  • cn •
UJ • 00 • (—1 • into < J \ CM inS. 00 + | +  1 00 + |
(U «rt 0 \
rH  Q • • o  o
O 0 o VO CM • •
-C  rH ^  ro vo in
S£ CQ CO oo
+  1 + 1
w
m
-P
H & ,0)
g 8 +* o  Q) Z*
O 3 i—1
ro I S >II « * q UcfP O o s
87
CHAPTER 4 
ERYTHROCYTE FILTERABILITY RESULTS
4-1 INTRODUCTION
The studies of erythrocyte filterability presented in this thesis were commenced at a 
time of growing controversy concerning the authenticity of filtration techniques as a 
measure of erythrocyte deformability. Plasma proteins, leucocytes, platelets and 
erythrocyte aggregation had been shown to influence measurements of erythrocyte 
deformability made by whole blood and concentrated erythrocyte suspension filtration 
(as reviewed by Boisseau, 1981), and much of the evidence for reduced erythrocyte 
deformability in diabetes mellitus has been based on studies using these techniques 
(Schmid-Schonbein & Volger, 1976; Barnes et al, 1977; Juhan et al, 1978). In diabetes 
mellitus, plasma fibrinogen levels are commonly elevated (see chapter 1, section 1- 6) 
and poorly controlled diabetic patients may have high leucocyte counts. These 
observations suggest that the currently held hypothesis, that microvascular damage in 
diabetes is partly a consequence of i) restricted entry of less deformable erythrocytes 
into small blood vessels, so leading to impaired tissue nutrition and ii) vessel wall 
damage consequent on shear stress injury caused by hardened erythrocytes (reviewed 
by McMillan, 1983), might be invalid.
However, Juhan et al, (1982) reported that insulin, either in vivo or in vitro, could 
reverse the impaired filtration of diabetic erythrocytes in 40% suspensions. This effect 
was apparently a consequence of a direct insulin effect on erythrocyte membrane 
(Bryszewska & Leyko, 1983). These findings apparently confirmed the established 
hypothesis. In order to resolve these issues, the following studies were undertaken:
1) the effect of leucocyte contamination on erythrocyte suspension filtration was 
measured
2) the effects of insulin on erythrocyte suspension filterability were determined
3) the filterability of erythrocyte suspensions prepared from blood of normal and 
diabetic subjects was compared
4) the relationship of diabetic control and erythrocyte filterability was determined
4-2 METHODS 
4-2-1 Statistical Analysis
The data from the erythrocyte filtration experiments was analyzed using non- 
parametric statistical methods because of the distribution of the data. The association
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of filterability with various factors was analyzed with Spearman’s test of rank 
correlation, differences between diabetic and normal groups was analyzed with the 
Mann Whitney U test and the effects of incubation of erythrocytes with insulin on 
filterability with Wilcoxon’s test. Simple linear regression lines were calculated from 
the data of filtration pressure and the calculated residual count of the suspension.
4-2-2 Ervthrocvte Suspension Filtration
Details of the methods are given in chapter 3-3.
4-3 RESULTS OF ERYTHROCYTE SUSPENSION FILTRATION IN NORMAL 
VOLUNTEERS
Fourteen normal non-diabetic volunteer subjects donated blood samples for the 
erythrocyte suspension studies. The median age was 28.0 years, (range 1 7 - 6 2  years). 
There were 7 males and 7 females. Details of subjects studied and results are given in 
table 4-1. The median filterability of the dilute erythrocyte suspensions was 0.7 mm
Hg., range 0.2 - 2.5 mm Hg. and the median calculated residual leucocytes of the
7 7erythrocyte suspensions was 1.4 x 10 /L , range 0.5 - 2.8 xlO /L . The results were
analyzed for any association between the calculated number of residual leucocytes in
the erythrocyte suspension and the filterability of the suspension in mm Hg..
Spearman’s test of correlation just failed to reach statistical significance with an Rs of
0.5127, p=0.0574, (linear regression analysis from the data y=0.28 + 0.44x, r=0.487,
n=14, p=0.0772).
4-4 RESULTS OF ERYTHROCYTE FILTERABILITY IN DIABETIC PATIENTS
Erythrocyte suspension filterability was also examined in 20 insulin requiring diabetic 
patients of whom 4 were female and 16 male. Seven of the subjects had newly 
diagnosed diabetes and were examined within a month of diagnosis. The remainder 
were established diabetics with known disease of more than five years duration. The 
median age was 42, range 25 - 62 years. Details of patients and results are given in 
table 4-2. Two patients suffered from background retinopathy, one of whom also had 
evidence of peripheral neuropathy. One of the newly diagnosed diabetic patients, B.F. 
had hypertension and moderately impaired renal function secondary to a congenital 
renal abnormality, and another, L.C., had mild essential hypertension.
Fasting blood glucose levels and HbA^C% were estimated on blood sampled at the 
same time as venesection for the filterability experiments. The median whole blood 
glucose was 10.1 mmol/1, (range 4.3 - 73 mmol/1) and the median HbA^C was 11.3% 
(range 8.7 - 25%). The median filterability pressure was 1.6 mm Hg. (range 0.5 - 9.0 
mm Hg). The median calculated residual leucocyte count of the erythrocyte suspension
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7 7was 1.7 xlO /L  (range 0 - 7.3 xlO /L). There was no association between HbA-^C
levels or whole blood glucose levels and the measured filterability but there was a
strong association between suspension filterability and the calculated residual leucocyte
count of the suspension, (p < 0.0001), see figure 4-1. There was no significant
difference between the filterability of normal and diabetic erythrocyte suspensions (see
figure 4-1).
4-5 THE EFFECT OF IMPROVED DIABETIC CONTROL ON ERYTHROCYTE 
SUSPENSION FILTERABILITY
The effect of improved diabetic control was examined in 12 diabetic subjects of whom 
6 were newly diagnosed and the rest poorly controlled diabetics who received 
intensified treatment to improve their blood glucose levels. The time between 
measurements of filterability varied from 30 - 90 days and in all individuals there was 
a significant fall in HbA^C^o, median 2.8%, (see table 4-3). There was no significant 
change in the erythrocyte suspension filterability or any association between the change 
in HbA1C% and the change in suspension filterability. Analysis of the relationship 
between the calculated residual leucocyte count and the suspension filterability, before 
and after the period of improved diabetic control, showed that the main determinant of 
filterability was the calculated residual leucocyte count on each occasion. The 
difference in the filterability between visits one and two correlates positively with the 
difference of the leucocyte concentration of the suspensions on each occasion (see 
figure 4-2).
4-6 THE EFFECT OF VARYING THE CONCENTRATION OF LEUCOCYTES 
AND ERYTHROCYTES ON SUSPENSION FILTERABILITY
To determine the effect of leucocytes on erythrocyte suspension filterability,
suspensions of various concentrations of erythrocytes and leucocytes were prepared in
the following manner: whole blood samples were centrifuged at 300 G for 30 minutes
and the platelet-rich plasma removed. The erythrocytes and buffy layer were
resuspended in PBS and then one part of each specimen was pre-filtered over a
leucocyte removal filter before washing which increased the removal of leucocytes,
whilst the other part was only washed in PBS. The pre-filtered (virtually leucocyte-
free) suspensions and the washed cell preparations containing residual leucocytes were
made up in different proportions to obtain suspensions of independently varying
TOerythrocyte concentrations, 1.25 - 40.0 xlO /L  and leucocyte concentrations, 1.06 -
710.0 xlO /L  (see table 4-4). Normal and diabetic samples were examined. There was 
no relationship between the erythrocyte concentration of the suspensions and the 
pressure generated on filtration. However the relationship between the leucocyte 
concentration and the measured filterability was linear despite an independent variation
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in erythrocyte concentration by a factor of 32 in the normal and a factor of 8 in the 
diabetic blood samples tested (see figure 4-3).
4-7 THE EFFECT OF INCUBATION WITH INSULIN ON ERYTHROCYTE 
SUSPENSION FILTERABILITY
The effect of incubation with insulin on erythrocyte filterability was examined in 10 
Type II diabetic patients. The buffer used in this set of experiments was Tyrodes with 
calcium, as calcium may be necessary for insulin to bind to membrane receptors. The 
erythrocyte suspensions were prepared as described in chapter 3 and after dilution to
1.0 xlO /L  erythrocytes, the sample was split into two parts, to one of which was
o
added insulin 10 U/ml and to the other an equivalent volume of buffer. The test 
and control specimens were drawn up into 20 ml size syringes, capped and placed in an 
agitating water bath, temperature 37 °C, where they were incubated for one hour.
The mean filterability of the control samples was 1.7 mm Hg and that of the insulin 
treated samples was 2.2mm Hg, an average of 33% less filterability, p<0.0005, (see 
figure 4-4).
4-8 DISCUSSION
4-8-1 The Effects of Leucocytes on the Ervthrocvte Filtration System
The main conclusion from this series of cell filtration experiments is that the calculated 
number of residual leucocytes contaminating the erythrocyte suspension is the major 
determinant of its filterability. This relationship for the residual suspension leucocytes 
and filterability was first apparent in the large inter-assay variation of suspension 
filterability in normal subjects (see Chapter 3-3). These subjects were examined on 3 
separate occasions during the course of one week and in each instance the number of 
contaminating leucocytes in the suspension was different. In repeated examination of 
erythrocyte suspension filterability in 12 diabetic subjects, (before and after a period 
of improved diabetic control) in every case the suspension containing the larger 
number of contaminating leucocytes was less filterable. In diabetic suspension samples 
there was a linear relationship between filterability and the calculated residual 
leucocyte concentration, although in normal controls this relationship failed to reach 
statistical significance. In experiments, where the erythrocyte suspensions were 
enriched with leucocytes, a linear relationship between the number of residual 
leucocytes and suspension filterability was found which was independent of the 
erythrocyte concentration. Whilst, no measurements were made of erythrocytes of 
known reduced deformability, such as sickle cells (Usami et al, 1975; Chien, 1977), 
when a suspension of artificially hardened gluteraldehyde treated cells was filtered, the 
cells were unable to pass through the Nucleopore filter. A rapid rise of filtration 
pressure occurred. Thus, the erythrocyte filtration test was sensitive to the presence of
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hardened erythrocytes, but the contribution of normal and diabetic erythrocytes to 
measurements of suspension filterability appeared to be small.
The effects of leucocyte interference, even on filtration measurements of dilute 
erythrocyte suspensions, was suggested by Milligan (1983 [a]), who studied patients 
with polycythaemia rubra vera and thus high leucocyte counts. The fact that 
measurements of filterability were made of the rise in pressure occurring during the 
first 66 seconds of cell filtration suggests that the system was not in equilibrium and 
that progressive holdup at the filter was occurring. This rate of holdup appears to 
correspond to the concentration of leucocytes present. Buffer, when filtered, produces 
a graph of a small initial deflection on starting the system followed by a steady plateau 
(see Milligan, 1983 [a]). Suspensions with a high residual leucocyte concentration show 
a similar sharp initial pressure deflection followed by a steady rise of pressure with 
time, see figure 3-5, which eventually reaches a plateau (not shown in Figure 3-5). It 
is speculated that this sequence of events might represent a progressive blockage of 
filter pores by leucocytes. As gradually more filter pores are occupied and fewer are 
available for entry the rate of rise of pressure decreases. When the pressure over the 
filter reaches a critical point, it is sufficient to dislodge leucocytes from the filter pores 
and an equilibrium or plateau of pressure is reached. In the suspensions with low 
leucocyte concentrations the rate of rise of pressure is slower and the state of 
equilibrium will take longer to reach and may not be attained. Other workers have 
postulated that the rate of rise of pressure is a function of the presence of less 
deformable erythrocytes which also block filter pores (Jones J.G. et al 1984). Stuart et 
al (1983) have suggested that by using regression line data of the relationship of 
filterability and the leucocyte concentration, results can be adjusted to a standard 
leucocyte count, and hence the contribution of erythrocytes to the suspension 
filterability can be calculated. However, this assumes that leucocyte filterability is 
constant and not affected by disease states, an assumption which cannot be made due 
to lack of the appropriate studies. It has also been suggested that below a certain
Q . . .critical level of contamination, <0.025 xlO /L  (Stuart, 1985) that contamination with
leucocytes is unimportant. In this authors experiments, a manipulation of the
erythrocyte count by a factor of 32 did not influence the relationship of the rate of
rise of the pressure on filtration and the calculated number of residual leucocytes in
the suspension. In both normal and diabetic subjects, when virtually all the leucocytes
were removed, the pressure generated on filtration suspension was minimal. Normal
leucocytes are known to be much less deformable than erythrocytes, (Lichtman, 1973)
and in the microcirculation erythrocytes flow in trains held up behind a leucocyte.
The in vitro measurements of filterability presented in this thesis appear to be primarily
sensitive to the presence of leucocyteSj and oqly when grossly sffected by gluteralaehyde 
do etythrocytes influence readings.
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4-8-2 Ervthrocvte Deformability in Diabetes Mellitus
Until the early 1980’s, it was firmly believed that erythrocyte deformability was 
reduced in diabetes mellitus, but most of the evidence came from studies of filtration 
of erythrocytes suspended in plasma, where no particular steps had been taken to avoid 
the effects of leucocyte contamination or blood proteins (Schmid-Schonbein & Volger, 
1976) and from studies of whole blood filtration (Barnes et al, 1977, Juhan et al ,
1978). Following presentation of this data at the International Conference of 
Biorrheology in Baden-Baden in 1983, subsequent publications of studies of erythrocyte 
suspension filterability have reported that erythrocyte deformability is not reduced in 
diabetes mellitus, neither on filtration of dilute leucocyte depleted erythrocyte 
suspensions, (Stuart et al, 1983) nor on examining shear stress induced deformation of 
erythrocytes (Williamson et al, 1985).
However, it might be argued that the extensive processing of blood samples before 
filtration tests, which it is now felt essential to carry out, may well have destroyed the 
least deformable erythrocytes, negating the test. Centrifugation of blood separates the 
cellular elements of blood by density, with the least dense cells migrating to the upper 
layer of the centrifugation tube, (Murphy, 1973). Even during careful removal of the 
buffy layer, small quantities of the least dense cells might be removed. These cells are 
usually the youngest and have a higher MCV. However young cells are, if anything, 
more deformable than older cells (Pfafferott et al, 1982; Sutera et al, 1985).
Nevertheless, changes in the average MCV might indicate selective removal of 
subpopulations of erythrocytes. It is also possible that less deformable erythrocyte are 
destroyed or retained during passage over leucocyte removal filter. Therefore, evidence 
of erythrocyte destruction during preparation of erythrocyte suspensions was looked for 
by comparing the processed erythrocyte MCV with that of whole blood erythrocyte 
MCV, and by examining the supernatant of erythrocyte suspensions for evidence of 
haemolysis. In the authors experiments, there was no significant change in the cell size 
of normal erythrocytes prepared for filtration studies. However, light 
spectrophotometric measurements of the plasma supernatant of erythrocytes passed over 
the leucocyte removal filter suggested that some haemolysis had occurred. Thus the 
processed erythrocytes may not be representative of the original population.
Other recent studies of the use of Leucocyte Removal Filter apparently contradict these 
findings. The Imugard technique was not found to cause significant retention of sub- 
populations of gluteraldehyde hardened erythrocytes which were flushed through the 
Leucocyte Removal Filter (Kenny et al, 1983) nor to affect the density fractionation of 
cells after passage through a cotton wool filter, (Baar et al, 1986).
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4-8-3 New Techniques for Measuring Ervthrocvte Deformability
These problems in assessing erythrocyte deformability by dilute erythrocyte suspension 
filtration techniques have stimulated interest in developing more reliable techniques. 
The immediate rise in pressure on commencing suspension filtration has been suggested 
as a more sensitive measure of erythrocyte deformability, (Hanss, 1983). The initial 
rise in pressure thought to be dependent on several factors including disaggregation of 
erythrocytes and alignment in the direction of flow and deformation of erythrocytes at 
the filter pore. The mechanical artifacts of the system used in the studies in this thesis 
made this initial pressure rise an unreliable parameter. Modifications to the apparatus 
including addition of a stirring magnet to the suspensions to prevent erythrocyte 
aggregation and inclusion of a double infusion system of buffer in one line and 
erythrocyte suspension in the other might have overcome some of these mechanical 
artifacts by permitting smooth transition from filtration of buffer to filtration of cell 
suspensions. It should thus be possible to record the rise in pressure due to 
deformation of cells at the filter but even in this system, it would be necessary to 
exclude the presence of pore occlusion. In a comparison study of initial flow rate 
measurements and positive pressure filtration methods for the study of erythrocyte 
deformability, the final pressure measurements, which this author believes largely 
represent the presence of occluded filter pores, were found to be more sensitive to the 
presence of abnormal cells, (Lucas et al, 1983 [b]). This suggests that the initial 
pressure system may also simply be measuring early pore occlusion. A system which 
does appear to have overcome the deficiencies of suspension filtration, is the single 
erythrocyte rigidometer (Kiesewetter et al, 1981) in which a profile of the passage time 
of erythrocytes is documented. Cells blocking the filter pore can be removed and this 
system allows a fuller assessment of the whole cell population. Recently, an innovative 
filtration technique, the St George’s Blood Filtrometer as been introduced (Matrai et al,
1984). This filtrometer discriminates between cell transit time and pore occlusion and 
is reported to distinguish between erythrocyte and leucocyte filtration. Using this new 
more sensitive technique, Ernst & Matrai (1986) have examined erythrocyte suspension 
filterablilty in 23 Type II diabetic patients. They found a small but significant 
reduction of both erythrocyte and leucocyte filterability in diabetes mellitus.
4-8-4 Conclusions
Given the main conclusions of the leucocyte concentration dependability on filtration 
pressure, it is not possible to comment on the effects of diabetes mellitus on 
erythrocyte filterability, other than to note that the leucocyte effect was of similar 
magnitude in both normal and diabetic subjects, though studies of leucocytes in 
diabetes mellitus may themselves prove interesting. Experiments of the effect of 
incubation with insulin on suspension filterability suggested that supra-physiological
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concentrations of insulin impaired filterability. It is not possible to say whether this 
was due to leucocyte or erythrocyte effects. The erythrocyte has no nucleus or protein 
manufacturing capacity but its membrane has insulin receptors. When insulin binds to 
a membrane receptor, the insulin-receptor complex is believed to be internalized and in 
theory changes in the cell membrane may alter membrane fluidity, (Gambhil et et al 
1978), but the major effects may be on the leucocytes and this requires further 
investigation.
The evidence, from the studies presented in this thesis, would support the view that 
there is no gross impairment of erythrocyte deformability in diabetes mellitus.
However, the results cast considerable doubt on the sensitivity of positive pressure 
filtration techniques as a measure of erythrocyte deformability and the normality of 
erythrocyte deformability in diabetes mellitus requires further confirmation by 
different methods.
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APPENDIX 
TABLES TO CHAPTER 4
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Table 4 - 1
Normal Range of D i lute  Erythrocyte Suspension F i l t e r a b i l i t y
S ubject Sex Age WCC
io 7/ l
F i l t e r a b i l i t y
mmHg
1 F 17 1.6 0 .6
2 M 23 0.5 0.6
3 M 28 0.5 0.7
4 F 22 1.4 0.6
5 F 24 1.4 0.4
6 F 62 0.9 0 .2
7 F 34 2.8 1 .0
8 M 52 1.2 2.0
9 M 23 2.2 1 .1
10 M 28 1.6 0.7
11 M 24 2.8 1 .6
12 M 31 1.0 0 .2
13 F 28 1.2 1.1
F 28 2.2 2.5
WCC = The calculated leucocyte concentrations of the suspension 10 /L 
and F i l t e r a b i l i t y  -  Rise in pressure on f i l t e r i n g  the suspensions at  
a constant rate of 3.5  mls/minute from 6 - 6 6  seconds expressed in 
mm Hg.
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Table 4 - 2
D etai l s  of the Diabetic Subjects and Erythrocyte 
Suspension F i l t e r a b i l i t y  Results expressed in mm Hg.
Subj ect Sex Age N/E B.G. HBAxC WCC F i l t e r a b i l i t y
NU F 62 N 5.3 15.1 N.A. 2.0
BE F 25 N 6.0 11.2 0.44 0.7
CL F 55 N 13.0 12.5 1.6 0.6
FA M 44 N 73.0 25.0 0.0 0.5
KI M 26 N 7.9 9.9 1.7 0.6
LI M 31 N 8. 2 13. 1 0.7 1.0
BR M 44 N 5.7 12.5 1.9 1.5
RC F 35 E 10. 9 10. 1 2. 2 1.9
RO M 44 E 8.9 11.6 0.7 1. 8
FI M 40 E 13. 1 9.0 3 .8 4.4
WH M 39 E 10.1 11.4 0.4 0.5
MI M 47 E 13.7 10.7 1.7 2.4
FO M 55 E 5.2 8.7 0. 8 0. 8
WA M 25 E N.A. 9.4 2.0 0.5
HA M 62 E 11.4 13.7 0.4 1. 2
MD M 24 E 19.0 12.0 3 .4 1.7
WA M 50 E 14.3 17.3 3.7 4.3
RE M 35 E 5.5 9.5 2.4 3 .0
MA M 26 E 18. 8 10.9 4.2 2. 8
SM M 48 E 10.0 10.0 7.3 9.0
Se£ M = male, F = female, N = newly diagnosed, E = e s tab l ished  
diabetes m e l l i tu s ,  W.C.C. = the ca lculated  leucocyte  
concentration o f . t h e  suspension 107/^ and F i l t e r a b i l i t y  = 
r i s e  in pressure on f i l t e r i n g  the suspension at a constant  
rate of 3 .5  mls/minute from 6-66 seconds expressed in mm Hg. 
N.A. = not av a i lab le .
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Tabl e  4 -  3
The Change i n  E r y t h r o c y t e  F i l t e r a b i l i t y  b e t w e e n  1) Poor  C o n t r o l  
o f  D i a b e t e s  M e l l i t u s  HbA-jc >10/'  and 2) a f t e r  a P e r i o d  o f  
Improved  D i a b e t i c  C o n t r o l  c o n f i r m e d  by a s i g n i f i c a n t  f a l l  i n  
HbAr C
S u b j e c t F i l t e r a b i l i t y  1-2 WCC 1-2
----
Hb Ai C
MU - 0 . 7 0 -  0 . 8 0 2 . 3
BE 0 .20 h- 0 . 2 0 1 . 9
FA + 0 . 3 0 0 7 . 3
KI “ 0 . 6 0 -  1 . 25 1 .6
LI - 6 . 8 -  2 . 7 9 5 . 2
BR 0 . 3 + 1 . 3 2 4 . 3
WII - 1-7 -  2 . 2 6 0 . 8
HA - 0 . 2 - 0 . 2 5 3 . 9
FO :• 0 . 4 0 . 0 4 1 .7
WA i- 2 . 1 5 + 2 . 5 0 5 . 6
RE - 2 . 0 0 -  1 . 28 1 . 5
HE + 1. 4 -  4 . 0 0 3 . 3
S u b j e c t  H.E , a newly d i a g n o s e d  f e m a l e d i a b e  t i c p a t i e n t  age  14,
i s  n o t  i n c l u d e d  i n  t a b l e  4 - 2 ,  a s  e r y t h r o c y t e  f i l t e r a b i l i t y  was 
m e a s u r e d  u s i n g  a d i f f e r e n t  b a t c h  number  o f  n u c l e o p o r e  f i l t e r s .  
F i l t e r a b i l i t y  1-2 i s  t h e  f i l t e r a b i l i t y  o f  t h e  s u s p e n s i o n  
e x p r e s s e d  a s  mmHg on 1,  v i s i t  1 d u r i n g  p o o r  d i a b e t i c  c o n t r o l ,  
mi nus  t h e  f i l t e r a b i l i t y  o f  t h e  s u s p e n s i o n  (rninllg) on 2 ,  v i s i t  2 
a f t e r  a p e r i o d  o f  i mp r o v emen t  d i a b e t i c  c o n t r o l .  WCC 1-2 i s  
t h e  c a l c u l a t e d  l e u c o c y t e  c o n c e n t r a t i o n  o f  t h e  s u s p e n s i o n  1 0 ? / ^  
on v i s i t  1, v i s i t  1 mi nus  t h e  c a l c u l a t e d  l e u c o c y t e  c o n c e n t r a t i o n  
on v i s i t  2 ,  v i s i t  2.  HbA-|C 1-2 i s  t h e  f a l l  i n  HbA-]C % 
b e t we e n  v i s i t s  1 and 2.
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CHAPTER 5 
WHOLE BLOOD VISCOSITY RESULTS
5-1 INTRODUCTION
The presence of raised whole blood viscosity in association with diabetes mellitus is 
well documented, but whether the magnitude of these viscosity changes is sufficient 
to affect blood flow in vivo is unknown. Under abnormal blood flow conditions, 
where shear rates are low, whole blood viscosity may have an enhanced role in 
determining blood flow. The increase in whole blood viscosity described in 
diabetes has been noted to be greatest in vitro when measured at low shear rates 
(Barnes et al, 1977; McMillan et al, 1980), conditions which might occur in vivo, in 
the presence of diabetic vascular damage or in the post capillary venules where the 
first changes of diabetic microangiopathy are found. Under these circumstances, a 
raised viscosity might serve to increase hypoxia and ischaemia of endothelial cells 
by causing microvascular sludging, so decreasing local blood flow further and, by 
increasing intracapillary pressure, thus leading to leakage of serum contents into 
tissue space. Raised whole blood viscosity has been reported in association with 
poor diabetic control (Skovborg and Nielsen, 1969; Schmid-Schonbein and Volger, 
1976; Paisey et al, 1980) but Isogai et al (1976) have suggested that raised blood 
viscosity occurs only with diabetic vascular complications. However, the changes of 
whole blood viscosity described in diabetes are small and although the mean value 
whole blood viscosity is increased, values are generally not outwith the normal 
range (Poon et al, 1982) and can be accounted for by a small increase in 
haematocrit. Whether a raised blood viscosity in diabetes mellitus is an important 
factor in the development of microvascular damage, or indeed aggravates 
circulatory insufficiency (see McMillan, 1983) and potentiates vascular damage is 
still a subject of speculation.
The studies of whole blood viscosity were undertaken to examine the magnitude of 
blood viscosity changes in diabetes mellitus and to establish whether any significant 
change could be achieved by therapeutic manipulations, including 1) that of 
improving diabetic blood glucose control and 2) the influence of treatment with 
biosynthetic human insulin. At the outset of these studies, little was known of the 
therapeutic gains to be obtained from treatment with biosynthetic human insulin 
but it was hoped that this hormone would prove less immunogenic than animal 
insulins and possible effects on plasma proteins might influence whole blood 
viscosity in diabetes mellitus. Lastly, it was hoped to establish if whole blood 
viscosity was related to peripheral blood flow in vivo in diabetic patients.
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5-2 AIMS OF THE STUDIES
The aims of the studies of whole blood viscosity in diabetes mellitus were as 
follows:
a) to establish a normal range of whole blood viscosity at low shear rates 2.62
—i —1secs and 0.130 secs
b) to measure whole blood viscosity in diabetic patients and to determine the 
relationship with blood haematocrit and fibrinogen levels
c) to determine the effects of improving diabetic control on whole blood 
viscosity
d) to establish whether treatment with biosynthetic human insulin had any 
effect on whole blood viscosity in diabetic patients
e) to establish whether there is any relationship between whole blood viscosity 
and peripheral blood flow in the lower limb in diabetes mellitus.
5-3 DETAILS OF THE NORMAL CONTROL AND THE DIABETIC 
SUBJECTS STUDIED
5-3-1 Normal Control Subjects
Twenty normal control subjects, 7 females and 13 males, age range 24 - 65 years, 
were studied, all of whom were healthy and gave no history of previous illness. 
Details of this group are given in Table 5-1.
5-3-2 Diabetic Patients
Twenty-one diabetic subjects, consisting of the 15 established diabetic patients who 
took part in the double-blind study of treatment with BHI and PPI (details of 
whom are supplied in Table 6-3) and 6 Type II patients with evidence of 
microangiopathy (details of whom are given in Table 5-2) were studied. There 
were 14 males, 7 females and the median age was 52, range 27 - 68 years. Results 
of whole blood viscosity are given in table 5-3. The characteristics of the normal 
control subjects and diabetic patients are summarized in Table 5-4.
5-4 METHODS AND STATISTICAL ANALYSIS
5-4-1 Methods
Details of the Whole Blood Viscosity method are given in Chapter 3-2. The normal 
control subjects attended the Department of Medicine to donate post prandial blood 
samples for the viscosity measurements, because this proved logistically easier. The
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diabetic patients were all studied fasting before any morning medication at entry to 
the study and after a 3 month period of attempted improved diabetic control 
achieved through intensive advice and manipulation of their usual treatment, see 
chapter 2-3 for details of management. Samples for haematocrit, fibrinogen whole 
blood glucose and HbA^C levels were taken at the time of sampling for viscosity 
measurements. The 15 insulin requiring diabetics who participated in the double - 
blind study of treatment with purified porcine and biosynthetic human insulins 
were studied after 3 months treatment with each of the trial insulins and were 
managed as described in chapter 2-4. These patients were thus examined 4 times 1) 
at entry to the study, 2), after a run-in period of optimized diabetic control and 3) 
and 4) after treatment with BHI and PPI respectively. Unfortunately, because of 
equipment failure, data for the effects of improved control during intensified 
normal treatment are only available on 12 patients (3 Type II and 9 Type I) and of 
treatment with BHI and PPI in 14 patients. The relationship of peripheral blood 
flow and whole blood viscosity was examined in 13 normal subjects and in all 21 
diabetic patients. Full details of the measurements of foot flow are given in 
chapter 3-5. Blood for the viscosity measurements was collected one hour before 
the blood flow measurements and viscosity was measured within 3 hours.
5-4-2 Statistical Analysis
The whole blood viscosity results were analyzed using non- parametric statistical 
methods because of the distribution of the data. In the discussion section, the 
results are also expressed as mean values, to allow comparison with other published 
data. The diabetic subjects were compared with normals using the Mann Whitney 
U test and the relationships between whole blood viscosity with diabetic control and 
plasma fibrinogen were examined using Spearman’s test of rank correlation. Linear 
correlation analysis was used to examine the relationship of the logarithm of 
viscosity with haematocrit. The effects of improved diabetic control on whole 
blood viscosity were examined using the Wilcoxon rank signed test. In order to 
eliminate the influence of any sequential trend throughout the double-blind 
crossover study of BHI and PPI, the change in whole blood viscosity which 
occurred on transfer to each insulin (compared with the immediately preceding 
measurement of blood viscosity) was analyzed using Wilcoxon’s rank signed test.
5-5 RESULTS
5-5-1 Comparison of Normal Volunteers and Diabetic Subjects
Results of the whole blood viscosity measurements and sample haematocrit and 
fibrinogen levels on individual normal subjects and diabetic patients are shown in 
Tables 5-1 and 5-3 respectively and summarized in Table 5-4. In both the controls
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and the diabetic patients haematocrit was the most important predictor of whole
blood viscosity. There was a linear relationship of the logarithm of whole blood
—1viscosity measured at a shear rate of 2.62 secs and haematocrit, (p < 0.01 in each
_ *i
case, see Figure 5-1). At the lower shear rate 0.130 secs , this relationship was 
weaker in the control group (p = 0.0183) and did not reach significance for the 
diabetic patients. For any given haematocrit, whole blood viscosity measured at
_ q
shear rate, 2.62 secs was significantly higher in the diabetic patients, median 
value 13.3 cp versus control group, median value 11.2 cp (p = 0.0029). Fibrinogen 
was shown to be higher in the diabetic patients, median 2.24gm/l, than in the 
control subjects, median 1.85 gm/1 (p=0.05) but fibrinogen levels bore no 
relationship to whole blood viscosity measurements.
5-5-2 The Effect of a Period of Improved Diabetic Control on Whole Blood 
Viscosity
A period of 12 weeks of improvement of diabetic control, confirmed by a small but 
significant fall in HbA^C % from 10.6% to 9.5%, was studied in 12 patients. This 
did not result in any significant change in whole blood viscosity or changes in 
fibrinogen levels or haematocrit, (see Table 5-5).
5-5-3 The Results of the Double-Blind Crossover Study of Treatment with 
Biosynthetic Human Insulin and Purified Porcine Insulin
Whole blood viscosity at shear rate 2.62 secs was essentially unchanged on 
treatment with BHI, median change BHI - 0.68 cp compared with a median change 
on treatment with PPI of - 0.90 cp. There was no significant differences of change
_n
in whole blood viscosity measured at 0.130 secs , median change BHI +3.54 cp, 
median change PPI -0.31 cp. HbA^C, haematocrit and fibrinogen levels were not 
significantly different on treatment with BHI compared with treatment with PPI,
(see Table 5-6 ).
5-5-4 Relationship of Whole Blood Viscosity to Peripheral Blood Flow:
The whole blood viscosity measurements of 13 normal volunteers and 21 diabetic 
subjects were examined statistically to see if there was any relationship of blood 
viscosity measurements to peripheral blood flow in the lower limb as measured by 
venous occlusion plethysmography. Spearman’s test of correlation was performed 
on viscosity measurements and resting foot flow, time to peak flow ,peak post 
stimulus (calculated as the measured peak post stimulus flow - the basal resting 
flow) and the half life of reactive hyperaemia values (see Table 5-7). In the 
normal control subjects there was a‘correlation between resting foot flow and whole
—iblood viscosity measured at shear rate 0.130 secs , (p=0.0108) but this association
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. 1
just failed to reach statistical significance at shear rate 2.62 secs , (p=0.0709). In
the diabetic patients there was no association with resting foot flow and whole
blood viscosity measured at either shear rate. A statistical relationship between the
duration of reactive hyperaemia and whole blood viscosity at shear rate 0.130 secs-  
1
just failed to reach significance in both the normal (p = 0.0568) and diabetic 
subjects (p= 0.0736). There was no association of time to peak flow values and the 
peak post stimulus flow values with whole blood viscosity. Blood flow results are 
given fully in chapter 7
5-6 DISCUSSION
These studies have shown, as is well recognized (Begg and Hearns, 1966), that the logarithm
\
o f measurements of whole blood viscosity : i s  proportional to haematocrit.
However, at comparable haematocrit, whole blood viscosity is higher in diabetic 
patients, as previously described (Skovborg et al, 1966; Hoare et al, 1976; Barnes et 
al, 1977; Lowe et al, 1980; Poon et al, 1982). Shorterm improvement of diabetic 
control, as can be achieved by close outpatient supervision had no discernible 
effects on whole blood viscosity measurements. Neither did treatment with BHI or 
PPI have any effect on whole blood viscosity. There is an apparent relationship of 
resting foot flow and whole blood viscosity in normal subjects, but not in diabetic 
patients.
5-6-1 The Physiological Significance of Alterations of Whole Blood Viscosity
When the complex interaction of factors affecting blood flow in the circulation is 
considered, it is difficult to extrapolate the in vivo dynamic effects of alterations in 
whole blood viscosity as measured in vitro. In vitro measurements of whole blood 
viscosity are determined by plasma factors, the number and properties of 
erythrocytes and other cellular elements, and the temperature of the sample at the 
time of analysis, (as reviewed by Stuart and Kenny 1980). Plasma viscosity is 
primarily a function of the plasma protein concentration. Protein molecules behave 
as rigid particles in solution and their effective volume does not change with 
increasing shear - thus plasma is a Newtonian solution. Among plasma proteins, 
fibrinogen, which is a molecule with a large axial asymmetry is a major component 
in determining viscosity (Usami, 1982). Another major contribution of the plasma 
proteins to whole blood viscosity is by their interaction with the erythrocytes.
Large macromolecular proteins, which are absorbed onto erythrocyte surfaces, can 
form bridges between the cells leading to the formation of erythrocyte aggregates 
(Chien and Jan 1973). Fibrinogen sis particularly effective in producing 
erythrocyte aggregation as its large absorbed surface increases the surface absorptive 
force and the longer inter-cellular distance decrease the electrical repulsive forces
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between cells. Cell aggregation is also dependent on the properties of the 
erythrocyte and is counteracted by mechanical shearing. Erythrocyte aggregation 
only appears to be important at low flow rates. At low shear rates the rouleaux 
behave like rigid rods but at higher shear rates, they bend and break up leading to 
a progressive fall in blood viscosity. Cell aggregation is also limited by vessel size. 
In vessels wider than erythrocytes, a three dimensional network of aggregated 
erythrocytes may form leading to an increase in the effective cell volume. In small 
vessels, only slightly larger than the erythrocyte, rouleaux formation is limited in a 
linear fashion, aligned with flow, thus decreasing the effective cell volume and 
viscosity (as reviewed by Usami, 1982).
In vitro, erythrocytes are numerically the most important of the cellular elements 
determining blood viscosity and blood viscosity, when transformed logarithmically, 
is linearly related to the blood haematocrit (Begg and Hearns 1966). In vivo, blood 
haematocrit is a less important predictor of viscosity in the microcirculation, where 
vessel size plays an important role in determining viscosity. In small vessels, of less 
than 300 /mi, the haematocrit is only 15-20%, and the apparent viscosity is lower 
than in large vessels where the haematocrit is 45%. This well known phenomenon, 
described by Fahreus and Lindquist in 1931, is the result of erythrocytes flowing 
preferentially in the centre of the tube where they can travel faster within the layer 
of plasma lining the vessel wall. In vessels of less than 29 /mi the haematocrit is 
further decreased as a result of relatively fewer erythrocytes being deformed and 
entering these smaller capillaries. In vessels which are less than the diameter of the 
erythrocyte, considerable cell deformation is required before the cells can pass 
through the vessel. Under normal flow conditions in these small capillaries, high 
velocity results in high shear stress at the cell surface causing the necessary 
erythrocyte deformation but the less deformable leucocytes appears to play an 
important regulatory role (as reviewed by Schmid-Schonbein 1981). Erythrocytes 
are held up behind the leucocyte, with a red cell depleted region forming 
downstream of the leucocyte. On entering a wider vessel, the erythrocytes push 
past the leucocyte pushing it against the endothelium and it is prevented from re­
entering the central stream by the continuing stream of erythrocytes. Nucleated 
leucocytes are much less deformable than erythrocytes and when their number is 
pathologically raised, as in leukaemia, hyperviscosity syndrome can result 
(Lichtman, 1973)
In normal flow conditions shear rates are lowest in the post capillary venules and 
small veins but viscosity may not be much higher than in the post capillary segment 
as shear rates are still high. In low flow states, relative blood viscosity is increased 
because of erythrocyte aggregation and lack of shear induced erythrocyte 
deformation. This results in a much higher viscosity in the post capillary venule
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and increased capillary pressure. However in low flow states leucocytes also adhere 
to the endothelium and it is this factor which is thought to result in the massive 
elevation in intravascular resistance seen with low flow. This increase in resistance 
is accentuated if haematocrit is also increased. Counteracting the effects of high 
haematocrit is the red cell screening effect whereby at low shear rates fewer 
erythrocytes are sufficiently deformed to enter the smaller branch vessels and hence 
the relative viscosity is lowered (as reviewed by Usami 1982).
5-6-2 Whole Blood Viscosity and Diabetes Mellitus
Alterations of many of the determinants of whole blood viscosity have been
reported in diabetes mellitus. Erythrocyte aggregation and fibrinogen levels are
reported as being increased, erythrocyte deformability as decreased and these
changes may account for the more marked increase of whole blood viscosity noted
in vitro at low shear measurements in diabetes mellitus (Barnes et al, 1977;
MacMillan et al, 1980). In the studies presented in this thesis, measurements of
whole blood viscosity were made at exceptionally low shear rates, such as might
occur in hypoperfused diseased vessels. Whole blood viscosity was increased in the
diabetic patients. The uncorrected (for haematocrit) median value was 17.8%
_ ■]
higher, when measured at a shear rate of 2.62 secs than that of normal control 
subjects. To compare this data with other published studies, mean values were 
calculated and regression lines of the relationship of whole blood haematocrit and 
the logarithn of whole blood viscosity was plotted for both diabetic and normal 
subjects (Figure 5-2). By extrapolation from Figure 5-2, it can be seen that the 
mean whole blood viscosity of the diabetic patients was approximately23.0% higher 
than would have been anticipated for normal subjects with similar mean 
haematocrits. These results are comparable to those of Lowe et al (1980) whose 
data give an 11.2 % increase in corrected whole blood viscosity at low shear in 14 
diabetic patients without retinopathy and a 16.6% increase in 14 diabetic patients 
with retinopathy.
By projection from the linear regression lines in figure 5-2, it can be seen that the 
difference in mean whole blood viscosity between normal and diabetic subjects 
could be accounted for by a small overall increase in haematocrit of the order of 
4%. Similar findings are those of Poon et al, (1982), who reported a 12.8% increase 
in mean low shear whole blood viscosity in diabetes mellitus but suggested that 
these changes could be produced by only a 1.7% increase in packed cell volume. It 
seems unlikely that changes, equivalent to a normal variation in haematocrit, will 
have any significant effects on blood flow in the microcirculation.
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—1Measurements of whole blood viscosity at the lower shear rate of 0.130 secs were
much more widely distributed and the relationship of viscosity with blood
haematocrit was much weaker. Whilst this may reflect on different factors
influencing viscosity at this very low shear rate, it seems more likely that
mechanical problems simply introduced a greater degree of error. The CV for
_ •]
viscosity measurements at 0.130 secs ranged from 4.7 - 13.7% compared with a
—1CV of 0.96% for viscosity measurements at shear rate 2.62 secs .
The failure to demonstrate a consistent improvement of whole blood viscosity with 
improvement of diabetic control may well reflect on the small overall improvement 
of diabetic control achieved and the small number of patients studied. The main 
determinants of viscosity, the haematocrit and the plasma fibrinogen did not change 
during the period of improved control nor during treatment with BHI. Treatment 
with BHI had no significant effects on whole blood viscosity. These results are in 
agreement with Leiper et al, (1984) who also found no difference in whole blood 
viscosity on treatment with BHI.
The relationship of whole blood viscosity with blood flow was examined in the foot
where a large component of distension on venous occlusion plethysmography is due
to skin blood flow as opposed to the calf, where measurements are predominantly
of muscle flow. There was a statistically significant relationship of higher rates of
resting foot flow and lower blood viscosity in normal subjects. However significant
associations of blood flow and viscosity were only noted at the less accurately recorded
-1
lower shear rate of 0.130 secs measurement (see section 3-2-3) and the total numbers 
examined were small. There was no relationship of resting flow rates and blood 
viscosity in diabetic subjects. In both normal and diabetic subjects there was a trend, 
which just failed to reach statistical significance, of longer half life of reactive 
hyperaemia following arterial occlusion and higher whole blood viscosity. Other 
measures of reactive hyperaemia, such as the time taken to attain peak flow values and 
the peak post stimulus flow value, did not show any relationship with blood viscosity. 
Prolongation of reactive hyperaemia following ischaemic stress is a feature of vascular 
insufficiency; it takes longer to recover from ischaemia when the vascular supply is
impaired. However the capacity of the vasculature to vasodilate and the presence of
Y*\
large vessel disease are other important determinants of blood flow and reactive 
hyperaemia. The associations of blood flow and whole blood viscosity described here, 
although interesting, require further confirmation before suggesting that minor 
variations in whole blood viscosity such as occur in diabetes, might significantly 
influence blood flow in vivo. (Blood flow results are described in detail in Chapter 7)
5-6-3 Conclusions
In these studies a small increase in whole blood viscosity in diabetes mellitus, 
equivalent to a 4.0% increase in haematocrit has been noted but no relationship 
between foot blood flow and this mild hyperviscosity has been demonstrated. No 
special effects of treatment with BHI on whole blood viscosity were noted. Future 
studies of whole blood viscosity in diabetes mellitus might be best advised to address 
the problem of determining the physiological significance of whole blood viscosity 
changes in diabetes mellitus.
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TABLE 5 - 5
RESULTS OF A PERIOD OF IMPROVED BLOOD GLUCOSE 
CONTROL ON WHOLE BLOOD VISCOSITY (Median and Range)
Median
(range)
B e fo r e A f t e r
Haemoglobin A^C 
%
10.6  
( 8 . 4  -  13. 8)
9 . 5
( 7 . 8  -  1 3 .4 )
Haematocri t  % 43 .6  
( 3 7 . 2  -  4 9 .7 )
4 2 .9  
( 3 7 . 4  -  4 9 .8 )
F ib r ino g en
gm/1
2 .3 4  
( 1 . 4 4  -  3 .3 9 )
2. 25 
( 1 .4 6  -  3 . 6 8 )
V i s c o s i t y  (0 .1 3 0  
s e c s “ l )  cp
5 9 .4  
(48 .  8 -  7 8 .3 )
6 2 .6  
(4 2 .7  -  8 0 .5 )
V i s c o s i t y  ( 2 . 6 2  
s e c s - ! )  cp
13 .9  
(1 0 .3  -  21 .4)
14 .1  
( 9 .7  -  2 1 .9 )
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TABLE 5 - 6
THE RESULTS OF TREATMENT WITH BHI AND PP1 ON WHOLE BLOOD 
VISCOSITY ( i )  MEDIAN AND RANGE ( i i )  A MEDIAN AND RANGE OF 
OF THE CHANGE OCCURRING ON TRANSFER TO EACH TREATMENT
Median
(Range)
BHI
i-----------------------------------------_j
PP1
Haemoglobin A^C 
%
1 0 .4  
( 8 . 1  -  1 1 .9 )
10. 1 
( 7 . 0  -  1 1 .7 )
H aem atocr i t  % 4 1 .1  
( 3 8 . 6  -  4 9 .6 )
4 2 . 4  
( 2 6 .7  -  4 9 . 8 )
F ib r in o g e n  gm/1 2 .0 1  
( 1 . 5 4  -  3 . 4 9 )
2 .07  
( 1 .1 7  -  3 . 6 6 )
i V i s c o s i t y
( 0 .1 3  s e c s " l )  cp
5 7 .0  
( 4 3 . 9  -  1 0 1 .3 )
5 9 .7  
( 2 8 . 1  -  9 2 . 1 )
V i s c o s i t y  
( 2 . 6 2  s e c s “ l )  cp
13.3  
( 9 . 5  -  1 8 .1 )
12.3  
( 9 . 9  -  1 9 .8 )
*
i
Median
(Range)
A BHI A PPI
A Haemoglobin A^C 
%
+ 0 . 6  
( - 2 . 4  -  + 3 .9 )
-  0 .1  
( - 1 . 4  -  + 0 .8 )
A H aem atocr it  % -  0 . 9  
( - 4 . 6  -  +2 .1 )
+ 0 .3  
( - 1 2 . 4 -  + 1 .4
A F ib r in o g e n  gm/1 + 0 . 0 2  
( - 1 . 2  -  + 0 .5 9 )
-  0 .0 3  
( - 1 . 1 0  -  + 1 .3 6 )
A V i s c o s i t y  (0 .1 3  
s e c s “ l )  ,c p
+ 3 . 5 4  
( -23  .7 9 -  +41. 27)
-  0 . 3 1  
( - 2 9 . 2 8  -  + 2 7 .4 5 )
A V i s c o s i t y  ( 2 . 6 2  
s e c s ~ l )  Cp
+ 0 . 6 8  
( - 3 . 9 9  -  +6 .8 5 )
-  0.  90 
( - 9 . 4  -  + 1 .7 3 )
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TABLE 5 - 7
SPEARMAN'S TEST OF RANK CORRELATION OF WHOLE BLOOD VISCOSITY 
AND PERIPHERAL BLOOD FLOW (p values)
Whole Blood V is c o s i ty  Shear Rate 0.130  
secs-1
Normal Diabetic
RFF 0.0108 0.7651
Tpjs 0.9000 0.4026
PPSF 0.3 0 84 0.887 5
T50 0.0568 0.0736
Whole Blood V is c o s i t y  Shear Rate 2.62  
secs~ l
Normal Diabetic
RFF 0.0709 0.7492
TPF. 0.4233 0.9911
PPSF 0.4810 0.9  844
TSO 0.1482 0.2340
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CHAPTER 6
HAEMOSTATIC FUNCTION RESULTS
6-1 INTRODUCTION
Abnormalities of the haemostatic system in diabetes mellitus have been postulated as 
leading to a hypercoagulable state which, in turn, has been implicated as a causative 
factor in the development of diabetic vascular complications. But it has not yet been 
established whether the abnormalities of haemostatic factor levels previously described 
are a cause, a consequence of, or are irrelevant to the development of diabetic vascular 
damage. Whilst there is general agreement that activities of the factor VIII complex 
and fibrinogen levels are increased in diabetes mellitus, there is at present confusion as 
to the influence of metabolic control, treatment and vascular disease on these 
haemostatic variables. Furthermore, studies of the fibrinolytic system have provided 
apparently inconsistent results of normal, raised and lowered activity in diabetes 
mellitus. Whilst treatment with insulin has been reported to affect the fibrinolytic 
system and with rebound shortening of euglobulin clot lysis times (Fearnley et al, 1959), 
it is not known if these effects are directly attributable to insulin or mediated 
indirectly through its metabolic effects.
6-2 AIMS OF THE STUDIES 
The studies of haemostatic function were aimed to establish:
i) normal ranges for the haemostatic factors under study and the relationship of 
factors with age, obesity and blood pressure
ii) the effect of the presence of diabetes mellitus on haemostatic function and the 
relationship with age, obesity and blood pressure compared with that in normal 
healthy volunteers
iii) the effect of the improved control of blood glucose which can be achieved by 
standard out-patient treatments, with either multiple daily subcutaneous 
injections of insulin or oral hypoglycaemic agents, on haemostatic function in 
both newly diagnosed diabetics without microangiopathy and established 
diabetics with proven microangiopathy
iv) the therapeutic effect, if any, of biosynthetic human insulin on haemostatic 
function in the treatment of established diabetics with proven microangiopathy
v) the effect of treatment with insulin on haemostatic function in established 
diabetic patients whose diabetes is normally controlled by treatment with oral 
hypoglycaemic agents
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vi) the degree of activation of the coagulation pathway in diabetes mellitus as 
assessed by measuring fibrinopeptide A.
The haemostatic factors which were investigated were as follows:
i) Factor VIII coagulant activity, (VIII:C)
ii) Factor VIII von Willebrand related antigen levels, (vWF:Ag)
iii) Factor VIII von Willebrand related activity as measured by its ristocetin 
cofactor activity
iv) Fibrinogen levels, (Fib)
v) Blood fibrinolytic capacity as assessed by euglobulin clot lysis times, (ECLT), 
measured on blood samples under the following conditions:
a) fasting resting state, no venous occlusion (Resting Euglobulin Clot Lysis 
Time, R ECLT)
and in selected patients
b) after a standard period of venous occlusion, (Post Venous occlusion, PV 
ECLT)
c) one hour after administration of insulin by subcutaneous injection, (Post 
Insulin, PI ECLT).
vi) Fibrinopeptide A levels, (FPA).
Details of all methods used in the assessment of haemostatic factors are given in 
Chapter 3.
6-3 DETAILS OF NORMAL VOLUNTEER SUBJECTS AND PATIENTS 
STUDIED
6-3-1 Normal Volunteer Subjects
Special care was taken in attempting to recruit an appropriate control group of age 
matched healthy normal control subjects. It was the practice of the laboratory at Leeds 
at the time of these studies to obtain a "normal" plasma pool, on which the standard 
value of haemostatic function assays was based, from hospital out-patients attending 
for venesection on whom clinical details were not available. Whilst this is of little 
importance when testing for the presence of gross deficiency of any one factor, studies 
of the diabetic patients will be biased if the "normal" populations have minor 
alterations of coagulation factor levels and activities due to intercurrent illness.
Normal volunteers were recruited from members of the Department of Medicine at 
Leeds General Infirmary and from blood donors attending the local blood transfusion 
centre as described in Chapter 2-2. Details and results of this group are given in Table
6-1. There were 15 subjects in the group with 9 males and 6 females. The median
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age was 48 (range 24-62 years). None of this group were smokers and none gave any 
history of significant illness. The median weight index (weight in kilograms divided 
by the square of the height in metres) was 23.0% (range 19.9-26.5%), where values of 
roughly between 20% to 25% indicate the ideal range of weight for height (Garrow,
1981). Two subjects were overweight for height by this calculation. For practical 
reasons, the normal subjects were studied post prandially, as opposed to the fasting 
state, but were required to rest supine for 30 minutes before blood sampling. Possible 
dietary effects on haemostatic function are considered in the discussion section of this 
chapter. Post insulin haemostatic function measurements were not made in this group. 
These subjects were studied once. Owing to technical difficulties, data is incomplete 
in 4 cases.
6-3-2 Newlv Diagnosed Diabetic Patients with Short Known Duration of Diabetes 
Mellitus (Type I)
Nine newly diagnosed insulin requiring diabetics, all assumed to be Type I insulin 
dependent, on the basis of clinical presentation and findings, were recruited as 
described in Chapter 2-1. Details and results are given in Table 6-2. There were 4 
females and 5 males, the median age was 44 years (range 18- 63 years) and median 
weight index 19.3% (range 16.9-28.9%). Five patients were below ideal weight and 1 
above ideal weight for height.
Only one patient (B.F.) was severely ill from diabetes mellitus at diagnosis and he also 
had mild renal failure and hypertension secondary to a congenital renal abnormality 
(horseshoe kidney). He was on treatment with atenolol and cyclopenthiazide for 
hypertension. His creatinine clearance was 32 ml/minute per metre2 (normal range 40 
- 90 ml/minute per metre2). B.F.’s plasma was noted to be hyperlipaemic at the time 
of diagnosis but plasma lipids returned to normal with diabetic diet and treatment. 
Another patient (L.C.) had mild hypertension for which she was receiving treatment 
with a pinodol/clopamide combined preparation (Viscaldix). No other patient in this 
group had a history of significant illness. One patient, (H.R.) was a smoker. All these 
patients were examined at diagnosis by an ophthalmologist using direct fundoscopy and 
slit lamp examination and none had evidence of diabetic eye disease.
Results of one additional subject (S.H.), who was studied at the time of diagnosis but 
who had evidence of background retinopathy and diabetic vascular disease in the foot 
at that time are included in Table 6-2. S.H. was treated with oral agents for one week 
before being transferred to insulin treatment and was studied whilst receiving insulin.
119
6-3-3 Established Insulin Requiring Diabetic Patients with Micro vascular Disease 
(Tvoe I)
There were 15 patients in this group which consisted of 4 females and 11 males. They 
were recruited as described in Chapter 2-1 and participated in the double-blind 
crossover study of treatment with BHI and PPI. Details and results are given in Table 
6-3. The median age was 51 years (range 27-67 years). The median known duration 
of diabetes mellitus was 17 years (range 3-35 years) and the median weight index was 
23.4% (range 19.5-30.0%) with 3 patients above the ideal weight for height. This 
group of patients included 4 subjects initially treated with oral hypoglycaemic agents 
but transferred to insulin because of failure to control blood glucose levels satisfactorily 
in 3 cases (G.S., M.W., and P.F.) and because of poor control and painful diabetic 
neuropathy in the last case (G.B.). The median insulin dose was 44 units, (range 20-80 
units).
All patients in this group had diabetic retinopathy on clinical examination confirmed 
by retinal fluorescein angiography. Details of the eye changes are given in Chapter 9. 
One patient (D.C.) also had persistent proteinuria assumed to be due to diabetic 
nephropathy and 2 others had intermittent proteinuria. Only 3 patients had 
symptomatic neuropathy but all had abnormal peripheral nerve function on 
electrophysiological testing. One patient (W.H.) had chronic diabetic foot ulcers. Two 
patients were hypertensive, on treatment, and one patient was on hormonal replacement 
therapy for menopausal symptoms. One patient (G.B.) gave a history of gout which 
was quiescent throughout the course of the study and did not require any specific 
treatment. None of the patients had symptoms of ischaemic heart disease or 
intermittent claudication but one subject (C.H.) gave a past history of myocardial 
infarction 21 years prior to entering the study. No clinical notes were available to 
confirm the diagnosis and the patient has been asymptomatic since then with a current 
normal electrocardiogram. Electrocardiograms and examination of the peripheral pulses 
were normal in all the patients. One patient (G.T.) smoked.
6-3-4 Established Diabetic Patients Treated with Oral Hypoglycaemic Agents (Type II)
These patients were recruited as described in Chapter 2-1. Details are given in Table 
6-4. There were 9 males and 3 females in this group, median age 55.5 (range 38-68). 
The median weight index was 23.2% (range 18.5-34.8%) with 4 patients overweight 
assuming a normal range of 20-25%. Four patients (P.W., K.F., A.L., A.H.) had poorly 
controlled diabetes and were transferred to insulin after the investigations of 
haemostatic function. The HbA^C level of (A.H.) was over 10% but was not given in 
Table 6-4 as it was measured by an outside laboratory with a different normal range. 
M.B. also had poorly controlled diabetes mellitus but this was due to diet failure.
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Three patients had evidence of atherosclerotic vascular disease; A.L. - on enquiry 
admitted to symptoms of intermittent claudication in the calf muscles and on 
examination had diminished peripheral pulses; B.R. - gave a 10 year history of angina 
and previous myocardial infarctions and was receiving treatment with propranolol, and 
M.B. - gave a history of hypertension, atrial fibrillation and heart failure diagnosed six 
years before this study. M.B. was receiving treatment with methyldopa for control of 
hypertension. M.B. also had bilateral cataracts and two years after the study had 
developed proliferative retinopathy and suffered a cerebrovascular accident. G.M. was 
hypertensive and was receiving treatment with methyldopa and cyclopenthiazide 0.25 
mg/potassium chloride 600 mg (Navidrex K). K.G. had a history of epilepsy and 
although fit- free for many years was taking anticonvulsants (phenobarbitone). P.W. 
had a history of several attacks of pancreatitis (the last attack was ten years before this 
study) and was presumed to have secondary diabetes mellitus. M.W. had a history of 
mild hypercalcaemia which investigations suggested was due to primary 
hyperparathyroidism and her corrected calcium at the time of study was 2.53 m.mol/1, 
(normal range 2.13-2.43 m.mol/1). M.W. also suffered from depression for which she 
was receiving treatment with amitryptiline. M.D. gave a history of irritable bowel 
syndrome and occasionally took codeine phosphate for control of diarrhoea and she was 
also receiving treatment with oestradiol valerate (Progynova) prescribed by her general 
practitioner for control of hot flushes, presumed menopausal symptoms. Five patients 
had evidence of background retinopathy, (P.W., G.M., J.S. M.D. and M.W.) and one 
patient (J.Q.) had proliferative retinopathy at the time of study. Only one patient, 
(A.L.) was a smoker.
6-3-5 Summary of Diabetic Patients Studied
Thus a total of 37 diabetic patients were studied, 25 of whom were being treated with 
insulin and 12 with oral hypoglycaemic agents. The diabetic patients consisted of a) 9 
newly diagnosed assumed Type I and an additional patient SH who was initially treated 
with oral agents for a week before being transferred onto insulin treatment (see Table 
6-1), b) 15 established insulin requiring patients, including 12 with classical Type I 
diabetes mellitus and 3 oral agent failures (who all had evidence of microvascular 
complications, see Table 6-3) and 12 established diabetics, all treated with oral 
hypoglycaemic agents, of whom 4 subsequently required treatment with insulin because 
of poor diabetic control (see Table 6-4). To simplify the discussion, insulin requiring 
treated patients are referred to as Type I and patients on oral therapy agents as Type 
II, although C peptide levels are not available to confirm these diagnoses. However, 
this was not considered important, as the aim of the study was to consider the effect of 
the type of treatment, insulin versus oral hypoglycaemic agent, rather than the type of 
diabetes.
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The newly diagnosed patients tended to be the thinnest and youngest, the Type II 
patients the oldest and fattest but there were no significant differences of age and 
weight index between the diabetic groups. Diabetic control, as measured by H b A ^ , 
was however significantly better in the Type II patients, mean 9.6% compared with 
mean 12.6% in Type I patients, p=0.0033, (unpaired t test). This reflects the inclusion 
of newly diagnosed diabetic patients in the Type I group. Fasting blood glucose levels, 
taken simultaneously with blood for haemostatic factor assays were not significantly 
different amongst the Type I and Type II patients.
6-4 METHODS AND STATISTICAL ANALYSIS
Methods of measuring the haemostatic function factors are described in Chapter 3.
The normal and diabetic population results involved small numbers and it could not be 
assumed that the data was normally distributed. Therefore the statistical analysis was 
performed using non-parametric statistical methods. These included the Mann Whitney 
U test for the comparison of different subgroups, the Wilcoxon rank sign test for 
testing the effects of improved diabetic control and Spearman’s test of rank correlation 
to examine the influence of variables on haemostatic function. To avoid bias from any 
sequential trend occurring throughout the study, the results of the double blind 
crossover study of treatment with biosynthetic human and porcine insulins was 
examined by doing a Wilcoxon test on the changes in the haemostatic factors which 
occurred on transfer to each insulin.
The effects of the presence of diabetes mellitus, the influence of other variables such 
as age, obesity, blood pressure, diabetic control and the effects of a period of improved 
diabetic control on haemostatic function were examined in the diabetic patients as a 
whole. Because the patients were a very heterogeneous mixture the analysis was 
repeated and the results presented separately for the different groups of:
a) newly diagnosed assumed Type I patients, who had no evidence of vascular 
disease
b) established insulin requiring patients with proven microvascular disease 
(assumed Type I)
c) the diabetic patients on treatment with oral therapy, of whom 6 had some 
evidence of microangiopathy.
In addition data from all the insulin treated patients were analyzed separately. A 
stepwise multilinear linear regression analysis of the effects of multiple variables 
including age, weight index, blood pressure (systolic and diastolic), duration of 
diabetes, HbA^^C, blood glucose, type of treatment for diabetes (whether insulin or 
tablets), plasma insulin levels, and the presence of diabetic microangiopathy (and 
whether this was background, proliferative or deteriorating and requiring
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photocoagulation treatment) was made. A stepwise multilinear regression of the effects 
of age, weight index and systolic and diastolic blood pressure was made in the normal 
control subjects.
6-5 RESULTS OF HAEMOSTATIC FUNCTION TESTS IN NORMAL
VOLUNTEERS (CORRELATIONS WITH AGE, FATNESS AND BLOOD 
PRESSURE)
Haemostatic function tests demonstrated an extremely wide range of normal values.
The results of haemostatic function tests on normal volunteers are shown in Table 6-1 
and summarized in Table 6-5 and correlations with age, weight index and blood 
pressure are given in Table 6-6.
6-5-1 Factor VIII Complex
This was measured in 12 subjects of whom 1 female showed abnormally low levels.
She had no family history of bleeding disorders. The median factor VIII:C activity was 
107.5% (range 36-150%), median vWF:Ag was 119% (range 26-167%) and the median 
ristocetin cofactor was 89.5%, (range 36-195%). There was no statistical association of 
age, weight index or blood pressure with factor VIII complex activities.
6-5-2 Fibrinogen Levels
These were measured in 15 subjects and the median value was 1.69 gm/1 (range 1.28- 
2.5 gm/1). In keeping with previous studies, (see discussion) there was a positive 
association (on Spearman’s test) of increasing age with higher levels of fibrinogen (p = 
0.0106) and of higher weight index values with higher levels of fibrinogen (p =
0.0152). Higher blood pressure both systolic (p=0.0048), and diastolic (p=0.02210), 
showed a positive correlation with higher levels of fibrinogen. A stepwise multilinear 
regression analysis suggested that the independent variables were diastolic blood 
pressure, p < 0.05 and weight index p < 0.02.
6-5-3 Fibrinopeptide A
FPA was only measured in 11 subjects as the assay was not available at the time of 
study of some normal controls. The median value was 1.2 pg/ml, (range 0.3-14.5 
pg/ml), The upper limit of normal for the assay in the laboratory was 3 pg/ml. Three 
normal healthy subjects had FPA values over 3 pg/ml, suggesting that activation of 
thrombin had occurred during venesection. There was no relationship of age or weight 
index with FPA. On Spearman’s test, there was a suggestion of an association of 
higher blood pressure with higher levels of FPA but p values for the correlation of 
systolic and diastolic blood pressure with FPA just failed to reach statistical
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significance. However a stepwise multilinear regression analysis of the relationship of 
FPA and systolic blood pressure did reach statistical significance, p < 0.05.
6-5-4 Fibrinolytic Activity
The median R ECLT was 101 minutes (range 34 to over 500 minutes) and the median 
PV ECLT was 70 minutes (range 15 to over 500 minutes). Increasing age was 
associated with longer PV ECLT (p = 0.0058) suggesting that fibrinolytic capacity, the 
release of plasminogen activator from the vein vessel wall in response to venous 
occlusion stimuli, is reduced with aging. In 3 subjects no increase in fibrinolytic 
activity occurred after venous occlusion, suggesting that the stimulus was not optimal. 
Higher weight index (as has been noted by others, reviewed by Ogston, 1983 [b]) was 
associated with longer resting ECLT, suggesting that fatness is associated with lower 
basal fibrinolytic activity, (p = 0.0425). A multilinear regression analysis confirmed 
the association of higher weight index and longer basal R ECLT, and of age and longer 
PV ECLT. It also revealed that higher systolic blood pressure tended to be associated 
with shorter PV ECLT, although this just failed to reach statistical significance. High 
systolic blood pressure may be a sign of stress, which results in high circulating 
adrenaline levels and hence increased fibrinolytic activity.
In one individual (E.H.) there was no measurable fibrinolytic activity either at rest or 
after venous occlusion stimuli. The test was repeated with identical results. E.H. had 
no history of thromboembolic disease and remains in good health! The possible causes 
of this prolonged ECLT are discussed in section 6-10.
6-6 RESULTS OF HAEMOSTATIC FUNCTION IN DIABETIC PATIENTS
Median haemostatic function factors and the results of a Mann Whitney U test 
comparing all the diabetic subjects with the normal controls are given in Table 6-5. 
Results of a Spearman’s test of correlations of haemostatic factors with various 
variables in all diabetic patients are shown in Table 6-7 and in the 24 insulin treated 
patients in Table 6-8.
6-6-1 Factor VIII Related Activities
a) Comparison with Normal Volunteers
Factor VIII related activities in all diabetic patients were not significantly different 
from those of normal controls. The median VIII:C was 100% (range 38 -300), the 
median vWF:Ag 97% (range 34 - 320%) and the median ristocetin co-factor 100%
(range 29 - 235%). However 4 patients had higher levels of VIII:C, and 5 patients 
higher levels of ristocetin co-factor than the respective upper limits in normals.
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b) Comparison of New versus Established and Insulin Treated versus Oral Agent 
treated Diabetes Mellitus
Sudivision of diabetics into Type I and Type II revealed that the median Factor VIII:C, 
vWF:Ag and ristocetin co-factor activities were lower in patients treated with oral 
agents Type II, compared with insulin treated Type I patients. The median VIII.C in 
Type II was 90%, versus 110% in Type I diabetics, (p=0.0198), the median vWF:Ag in 
Type II patients was 72.5% versus 113% in Type I diabetics (p=0.0016) and the median 
ristocetin co-factor in Type II diabetics 79% versus 118% in Type I diabetics 
(p=0.0005). The median levels of factor VIII activities in Type II patients were not 
significantly lower than those of normal controls.
A separate analysis of Type I patients compared with normals was made. Whilst VIII:C 
and vWF:Ag levels in Type I diabetics (both new and established) were similar to those 
of normal control subjects, ristocetin co-factor in these insulin treated patients (median 
118%) was 32% elevated compared with that of the normal control subjects (p = 0.0398) 
and highest in established Type I patients with microvascular disease (median 126%).
It has been suggested that ristocetin co-factor may be a marker of microvascular 
disease (Boneu et al, 1975). However ristocetin co-factor levels were lowest in Type II 
patients of whom half had microvascular disease, 5 with background retinopathy and 1 
with proliferative retinopathy.
6-6-2 Results of Spearman’s Analysis of Correlation of Factor VIII with Various 
Variables
a) All Diabetic Patients
Association of diabetic control with factor VIII activities was suggested by statistical 
correlations (Spearman’s test) of factor VIII with HbA^C and blood glucose levels. In 
the diabetic patients as a whole, poor diabetic control as measured by HbA^C levels 
was associated with higher levels of factor VIII:C (p =0.0122) but not with the other 
Factor VIII activities, (see Figure 6-1).
b) Patients Treated with Insulin
In Type I insulin treated patients diabetic control, as assessed by HbAjC, was 
associated with vWF:Ag (p = 0.0165), see Figure 6-2 but less significantly with VIII:C 
levels (p = 0.0591). There was no association between HbA^C% and ristocetin co­
factor activity (see Table 6-8).
However in Type I patients, the fasting blood glucose level was correlated with 
ristocetin cofactor activity (p = 0.00376), see Figure 6-3. As acute diabetic 
decompensation has been reported to result in high levels of Factor VIII (Paton 1981),
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separate analysis of the association of diabetic control and Factor VIII activities was 
made using Spearman’s test in new and established Type I diabetic patients. In 
established Type I patients there was a strong association of VIII:C and HbA^C, p = 
0.0064 and also between vWf:Ag and HbA^C, p = 0.0058. In newly diagnosed Type I 
patients, there was also a correlation between HbA^C and vWF:Ag (p < 0.05).
c) Patients Treated with Oral Agents
In the Type II diabetic patients, there was no association of diabetic control as assessed 
by HbA^C and Factor VIII:C of vWF:Ag but an association of HbA^C and ristocetin 
co-factor was noted, with poor diabetic control being associated with higher levels of 
ristocetin co-factor (p = 0.0217). In these Type II patients it was also noted that fatter 
patients had higher levels of vWF:Ag (p = 0.0307).
6-6-3 Stepwise Multilinear Regression Analysis of the Association of Factor VIII and 
various Variables
a) VIII:C
A stepwise multilinear regression analysis of the data from all the diabetic patients 
revealed that independent predictors of high levels of VIII:C were poorly controlled 
diabetes as measured by both blood glucose and HbA^C, long duration of diabetes and 
deteriorating retinopathy, p < 0.05 in each instance.
b) VIII:Ag
The multilinear regression analysis revealed that high VIIIrAg levels were also 
associated with long duration of diabetes and the presence of deteriorating retinopathy, 
p < 0.05, in each instance, and with poorly controlled diabetes as measured by HbA^C 
levels, p < 0.001 There was no independent association with blood glucose levels.
c) Ristocetin Cofactor
The independent predictors of high levels of ristocetin cofactor were high blood 
glucose levels, p < 0.01, high diastolic blood pressure, p < 0.05, and treatment with 
insulin as oppose to oral agents p < 0.001. There was no association of HbA^C and 
ristocetin cofactor levels.
6-6-4 Fibrinogen Levels
Fibrinogen levels were 41% higher in the diabetic patients, median 2.38 gm/1 compared 
with normals, median 1.69 gm/1, (p=0.0005). Fourteen patients had fibrinogen levels 
higher than the upper limit of the normal control subjects. Fibrinogen levels were 
significantly higher in all diabetic groups compared to normal control subjects,
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established Type I median 2.32 gm/1, Type II, median 2.34 gm/1 and newly diagnosed 
Type I median, 2.7 gm/1.
Unlike the normal control subjects, there was no association of fibrinogen levels and 
weight index or age; but poor diabetic control as measured by HbA^C levels was 
associated with higher levels of fibrinogen on both Spearman’s test, p = 0.0347 (see 
Figure 6-3) and on multilinear regression of all variables, p < 0.05. This association of 
diabetic control with fibrinogen levels appeared to be stronger in insulin treated Type I 
patients, p < 0.01 for both new and established patients but was not noted in the Type 
II patients when the data was analyzed separately. Stepwise regression revealed that 
independent variables predicting higher levels of fibrinogen were poorly controlled 
diabetes as measured by HbA^C, p < 0.001, high diastolic blood pressure, p < 0.02, the 
presence of deteriorating retinopathy, p < 0.01 and treatment with oral agents as 
oppose to insulin, p< 0.02.
6-6-5 Fibrinopeptide A
This was measured in the 15 established diabetic subjects with retinopathy. Four serial 
measurements were taken on each patient (see Table 6-12). The FPA measurements 
taken at the first attendance contained 9 abnormally high results which may be 
artifactual. A batch of anticoagulant was employed which gave unpredictable results. 
As the samples were stored and then measured in batch assays the effects of the faulty 
anticoagulant were not detected immediately. All the samples for FPA measurement 
taken at the last visit were collected into reliable anticoagulant and only 3 abnormal 
results were obtained. Data from the last visitrwas used to compare diabetic and 
normal control subjects in whom the same anticoagulant and methods were used. 
Diabetic patient FPA levels, median 2.19 pg/ml (range 0.3-60 pg/ml) were not 
significantly different from those of normal subjects. There was no association of FPA 
and measures of diabetic control*. In the diabetic patients FPA showed a relation to 
blood pressure, being positively related to both the systolic (p = 0.038) and diastolic 
blood pressures (p = 0.0357).
6-6-6 Fibrinolytic Activity
a) Comparison with Normals
Fibrinolytic activity as assessed by resting and PV ECLT was not significantly different 
in diabetic subjects and all results fell within the range defined for the normal control 
subjects. There were no significant differences in fibrinolytic capacity as assessed by 
ECLTs between the diabetic patient groups. (PV ECLTs from the new Type I patients
1 Data from the final visit was used in the analysis of association of FPA and Diabetic 
control etc., not the data presented in Table 6-3
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were not included in the analysis, see section 6-7). Post insulin ECLTs were examined 
in the established Type I patients. One hour after injection of insulin there was a 
shortening of ECLT from a median of 111 to 86 minutes indicating an increase of 
blood fibrinolytic activity. At the time of PI ECLT measurement the median blood 
glucose was 15 mmol/1, range 11.2 - 27.3 mmol/1 and thus the changes in fibrinolytic 
activity would not appear to be mediated by hypoglycaemia.
b) Spearman’s Analysis of Correlations with various Variables
In the diabetic patients as a whole, Spearman’s test did not reveal any association of 
diabetic control (as assessed by HbA^C and blood glucose levels) with resting ECLT 
but it was noted that diastolic blood pressure showed a positive association with R 
ECLT, p = 0.0459. In insulin treated patients, diabetic control, as assessed by HbA^C 
levels was significantly related to resting basal ECLTs (p = 0.0316) but the relationship 
with diastolic blood pressure failed to reach statistical significance. In Type II patients, 
Spearman’s test did not reveal any association of diabetic control or blood pressure and 
fibrinolytic activity, but fatter patients had less basal fibrinolytic activity as indicated 
by a positive association with resting ECLT, p=0.0307.
c) Stepwise Multilinear Regression
A stepwise multilinear regression of all variables on all patients revealed that the 
independent variables associated with less basal fibrinolytic activity in blood were high 
diastolic blood pressure p < 0.05 and poor diabetic control as measured by HbA-^C p < 
0.05.
6-7 RESULTS OF THE EFFECTS OF A PERIOD OF IMPROVED DIABETIC 
CONTROL ON HAEMOSTATIC FUNCTION
6-7-1 All Patients
The effects of a short period of improved diabetic control was examined in 31 of the 
patients, 14 established Type I who participated in the BHI - PPI study, 10 newly 
diagnosed patients including SH and 6 Type II established diabetic patients. The 
protocol for studies of improved control is given in chapter 2-3. The newly diagnosed 
patients and SH were examined at diagnosis and after 14 and 40 days of good control, 
and the others at entry to the study and after 90 days. Results on are given in Table 
6-9. Improvement in diabetic control was confirmed by a fall in the median HbA^C% 
from 12.1 to 9.8% (p < 0.0001) and of the median blood glucose from 10.8 to 8.1 
m/mol/1 (p < 0.05). The significant effects on haemostatic function factors were a 
13.0% fall in the median level of vWF:Ag, (p=0.0065), whilst ristocetin cofactor activity 
showed a statistical increase of 3.5%, (p=0.0268) but such a small change is of dubious 
biological significance.
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6-7-2 Newly Diagnosed Type I Patients
The haemostatic investigations were carried out in 9 patients, a) at diagnosis, before 
commencing treatment with insulin, b) at 14 days and c) 40 days after starting 
treatment with insulin. Post venous occlusion ECLT and FPA measurements were not 
made in this group. Results are given in Table 6-10.
Improvement in the diabetic control in the newly diagnosed diabetic patients over the 
ensuing 40 days was confirmed by a steady fall in HbA^C levels (p < 0.01) and 
significant sustained reduction in blood glucose levels (p < 0.01). Fibrinogen levels 
remained elevated compared with normal individuals at both day 14 and day 40.
The resting ECLT was significantly prolonged at day 14 (p < 0.05) compared with day 
of diagnosis. Changes in ECLTs have to be interpreted with caution in these 9 patients 
because venous occlusion tests were performed at diagnosis using both a prolonged 20 
minute period of venous occlusion and a higher occlusion pressure than in subsequent 
experiments. The patients found this procedure very uncomfortable and the protocol 
was altered. In its original form the test is likely to have produced maximum release 
and secondary depletion of plasminogen activator from the venous wall. The apparent 
prolongation of resting ECLTs at day 14 may be partly explained by incomplete 
recovery from the first venous occlusion test. Factor VIII:C and vWF:Ag levels both 
fell but only the changes in the vWF:Ag levels were statistically significant (p<0.05). 
Ristocetin cofactor levels were not significantly altered over the 40 day period.
6-7-3 Established Insulin Treated Diabetic Patients with Microvascular Disease
Haemostatic function was examined on 4 occasions: at entry to the study, after a 90 
day period of attempted improved diabetic control and after 90 days treatment with 
each of purified porcine and human insulins (for protocol see 2-4).
Results of Improved Diabetic Control are given in Table 6-11. Following the 90 day 
period of improved diabetic control, which formed the run-in period to the double­
blind crossover BHI-PPI study, median H b A ^  levels showed a small but significant 
fall from 10.7% to 10.1%, (p < 0.05). Fasting blood glucose levels were not 
significantly different. There was a small fall in the median resting ECLT from 111 to 
85 minutes indicating an increase in resting blood fibrinolytic activity (p = 0.0393) and 
the median PV ECLT also fell from 62 to 29 minutes but this change was not 
significant. The PI ECLT values were unchanged. Fibrinogen levels remained elevated 
compared with the normal control subjects. The median factor VIII:C, vWF:Ag and 
ristocetin cofactor levels all fell but the changes were not statistically significant. FPA 
levels fell from a median value of 4.6 to 3.4 pg/ml (p<0.05) but these changes 
represented part of an overall trend which continued throughout the double blind study
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of PPI and BHI and the changes were probably due to improved methods of collecting 
blood samples for this assay, (see Table 6-12)
6-8 COMPARISON OF HAEMOSTATIC FUNCTION ON TREATMENT WITH 
PURIFIED PORCINE AND BIOSYNTHETIC HUMAN INSULINS
The protocol in chapter 2-4 was followed. Data from all 15 established type I patients 
was analyzed. Results are shown in Table 6-13. During treatment with purified 
porcine and biosynthetic human insulins in the double blind phase of the study, there 
was no further improvement in diabetic control. There were no detectable differences 
of any of the parameters of haemostatic function on either insulin.
6-9 THE EFFECTS OF TREATMENT WITH INSULIN ON HAEMOSTATIC
FUNCTION IN DIABETIC PATIENTS NORMALLY TREATED WITH ORAL 
HYPOGLYCAEMIC AGENTS
The effects of a 90 day period of treatment with purified porcine or biosynthetic 
human insulins was examined in 3 patients normally well controlled on oral 
hypoglycaemic agents (see Table 6-14 for results). The period of insulin treatment was 
preceded by a 90 day period of attempted improved control of blood glucose levels 
through advice and education and adjusting oral hypoglycaemic therapy as necessary. 
Haemostatic function tests were measured at the beginning of the study, after the run- 
in period on oral hypoglycaemic drugs and after 90 days treatment with insulin.
Diabetic control as assessed by HbA^^C and fasting whole blood glucose levels 
improved during the run-in period but deteriorated on transfer to treatment with 
insulin in two patients. There were no consistent changes in the factor VIII related 
activities, fibrinogen levels or resting ECLTs on treatment with insulin.
6-10 DISCUSSION
One problem with haemostatic function factors studies is the interpretation of 
laboratory tests which may not reflect the in-vivo interactions and dynamic changes of 
the haemostatic mechanism. Recent data suggests that the vascular endothelium is 
actively involved in the synthesis of factors that prevent and limit blood coagulation, as 
well as others that lead to the activation of platelets and the plasma clotting system (as 
reviewed by Porta et al, 1987). Descriptions of levels of plasma clotting factors may 
not accurately reflect local vascular interactions, and as haemostatic function factors 
are normally present in great excess, the significance of mild elevation of any one 
factor has to be interpreted with caution. Proponents for the theory, that the excess of 
haemostatic factors in diabetic blood results in a hypercoagulable state, argue (on the 
basis of Virchow’s classical triad) that disturbances of haemostatic variables, in 
association with abnormalities of endothelial function and disturbances of blood flow
130
and micro vascular reflexes, might convert a temporary obstruction of capillary flow 
into a pathological capillary closure by promoting thrombosis (see Chan et al, 1982; 
Haitas et al, 1984[a]; Stenberg et al, 1984). The combined effects of these disturbances 
may explain the susceptibility of diabetic patients to vascular disease.
Reliable and accurate haemostatic assays have only been available relatively recently. 
During the 1970’s, general principles of biological standardization were applied to the 
measurement of haemostatic components and stable reference standards for the most 
important factors were established. However, virtually all collaborative studies carried 
out by the National Institute for Biological Standards and Control in the field of 
Haemostasis have found striking discrepancies between different laboratories potency 
estimates on the same samples (Barrowcliffe & Kirkwood, 1981). A particular problem 
has been found with regard to estimates of Factor VIII (Kirkwood & Barrowcliffe, 
1978). Therefore it was felt important to establish ranges for the coagulation factors in 
normal healthy volunteers.
6-10-1 Normal Ranees for the Haemostatic Factors under Study and the Relationship 
of Factors with Age. Obesity and Blood Pressure
a) Normal Fibrinogen
For practical reasons, only small numbers of normal control subjects could be 
examined. However the findings are consistent with those of much larger series, 
supporting the validity of these studies. In normal healthy adults, association of higher 
fibrinogen levels with increasing age and fatness was found. Similar findings are 
reported by a) Bailesien et al, (1985), b) Meade et al, (1979), and c) Korsan-Bengtsen 
et al, (1972), who all examined large series containing several thousand (a and b) and 
several hundred patients (c). The reasons why fibrinogen levels alter with age are not, 
as yet, understood. In the all three studies mentioned, fibrinogen levels were also 
higher in cigarette smokers. In the authors studies, none of the normal controls 
smoked although 2 of the patients did. However the author found a strong association 
of fibrinogen levels with blood pressure, a finding which was also noted in the early 
study by Hamilton et al (1974), who showed a positive of correlation fibrinogen levels 
with blood pressure, with older patients being more hypertensive.
b) Normal Fibrinolytic Activity
In the current studies fibrinolytic activity, (as measured by ECLT) was less in older 
and fatter control subjects. Reduced fibrinolytic activity in the obese, is a well- 
recognized but poorly understood phenomenon (as reviewed by Ogston, 1983[a]). Most 
studies have not found any association with age (as reviewed by Ogston, 1983 [b]) but 
Meade et al (1979), reported a decrease in blood fibrinolytic activity on comparing 20-
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25 year olds with 50- 55 year olds. Again, the reasons for these age and obesity 
related changes of fibrinolytic activity remain uncertain.
In the author’s studies, there was one normal individual, (a 62 year old male, weight 
index 26%, with a normal plasma fibrinogen), whose ECLT did not show any activity, 
either in the basal sample or after venous occlusion testing, indicating marked 
hypofibrinolysis. Abnormal plasminogen activator and faulty generation of plasmin has 
been linked with susceptibility to recurrent deep venous thrombosis (see Davidson & 
Walker, 1981), but there was no history of DVT in this healthy control. Further 
investigations into the cause of the abnormally prolonged ECLT were not pursued.
Venous occlusion stimulates release of plasminogen activator from vein wall, and is 
used as a measure of fibrinolytic capacity. The original test, introduced by Robertson 
(1972), was uncomfortable and poorly tolerated by subjects. A modified venous 
occlusion test, using a shorter period of occlusion and lower pressure than that first 
described, was employed by the author. In 2 of the normal control subjects, there was 
no increase in fibrinolytic activity on venous occlusion, indicating that the occlusion 
stimulus was not optimum. However, more prolonged venous occlusion test was 
undesirable, because of the plan to repeat the studies in the diabetic test group. After 
prolonged stimulation by venous occlusion, the fibrinolytic capacity of arm veins is 
exhausted and does not return to normal for over fourteen days (Keber and Stegnar,
1982).
c) Normal Factor VIII Activity
The normal ranges of Factor VIII activities, defined by the author, were essentially a 
comparison of the selected normal controls’ plasma with the pooled plasma obtained 
from hospital outpatients which was used to define the 100% activity values. In 
healthy individuals, raised levels of factor VIII:C and von Willebrand factor have been 
reported in association with increasing age (Bailesien et al, 1985; Aillaud et al, 1986).
In the normal control subjects studied by the author, no associations of factor VIII:C or 
von Willebrand factor, as measured by its antigen levels or associated ristocetin cofactor 
activity, were found with age or obesity.
d) Normal Fibrinopeptide A
FPA levels were only measured in ten normal control subjects. Abnormally high levels 
were found in 3 healthy subjects, suggesting that there had been activation of thrombin 
during venesection. No particular associations of obesity and age were found with 
FPA, though there was a trend which just failed to reach statistical significance of 
higher levels of FPA with higher levels of blood pressure.
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6-10-2 The Effect of the Presence of Diabetes Mellitus on Haemostatic Function and 
the Relationship with Age. Obesity. Blood Pressure Diabetic Control. Treatment 
and Presence of Diabetic Complications
a) Fibrinogen
Fibrinogen levels were elevated in diabetic patients studied, an expected finding, (as 
reviewed in chapter 1-6). Multilinear regression analysis revealed that diabetic control, 
as measured by HbA^C, was the most significant independent predictor of fibrinogen 
levels. Other independent variables were high blood pressure, the presence of 
deteriorating retinopathy and treatment with insulin as oppose to oral agents. Unlike 
normal subjects, no association with weight index or age was found. Fibrinogen levels 
were also found to be highest in diabetic patients with proliferative retinopathy in an 
earlier study by Lowe et al (1980). These strong associations, of fibrinogen with 
current diabetic control and severity of vascular disease, may reflect the role of 
fibrinogen as an acute phase reactant protein.
b) The Effects of Improving Diabetic Control on Fibrinogen Levels
As fibrinogen has a short plasma half-life of three to five days (reviewed by Reeve & 
Franks, 1974), improvement of diabetic control should result in a prompt fall of 
fibrinogen levels, if diabetic control is a significant determinant. In this study, no 
significant change of fibrinogen levels occurred on improving diabetic control. In an 
earlier study Tymms (1985) found the reverse - treatment with subcutaneous 
continuous insulin infusion for 10 days, to achieve near normalization of diabetic 
control, resulted in a marked increase of fibrinogen levels, in Type II patients 
previously poorly controlled on oral agents. There are several possible explanations for 
this apparent anomaly. First, insulin may stimulate fibrinogen production (this has 
been demonstrated in cultured chick embryos, see Ogston 1983, [d]) and thus 
introduction or intensification of insulin treatment may potentially increase fibrinogen 
production. However, the role of insulin in the physiological regulation of fibrinogen 
levels in humans is not known. Secondly, glycosylation of fibrinogen, as occurs in 
diabetes mellitus, has been reported to increase resistance to breakdown by plasmin and 
hence to slow removal of fibrinogen from the circulation (Brownlee et al,1983). But no 
alterations of glycosylated fibrinogen function, as measured by thrombin clotting time, 
plasmin digestion or heat stability were noted in an earlier study by McVerry et al 
(1981) and the findings of Brownlee’s group require further confirmation. In fact, 
other studies have suggested that fibrinogen survival is reduced in poorly controlled 
diabetes mellitus, and that this is rapidly reversible with improved control of blood 
glucose levels (Jones and Peterson, 1979). Suggested stimuli to fibrinogen production, 
also include trauma and tissue inflammation (effects perhaps mediated by leucocyte 
related factors, prostaglandins, growth hormone, ACTH, thrombin). In uncontrolled
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diabetes mellitus, associated hormonal and prostaglandin disturbances or vascular injury 
might provide the stimuli for increased fibrinogen production. Continuing over­
production in spite of decreased consumption seems the most likely explanation of the 
persistent hyperfibriginoaemia seen in the early days of improved blood glucose 
control. Fibrinogen levels have been shown to remain elevated for some months after 
commencing treatment in newly diagnosed diabetic patients before finally returning to 
normal (Barnes 1981). A possible explanation is, that cytotoxic damage to the vascular 
endothelium resulting from the acute diabetic state heals slowly, and 
hyperfibriginoaemia is again part of the subsequent acute phase protein reaction.
c) Fibrinolytic Activity in Diabetes Mellitus
Fibrinolytic activity in the diabetic patients of the author’s series was not significantly 
different from that of normal control subjects. Data on fibrinolytic activity after 
venous occlusion is incomplete, as the initial 20 minute venous occlusion test 
(Robertson et al, 1972), was poorly tolerated by subjects and as mentioned above, it 
was modified during the course of study. In the diabetic patients, high diastolic blood 
pressure was an independent predictor of lower basal blood fibrinolytic activity. 
Associations of low fibrinolytic capacity and high blood pressure, as found by the 
author, are not well recognized. Blood pressure is often higher in the obese and elderly 
and diabetic in whom fibrinolytic capacity is reported as being reduced.
The other independent predictor for lower levels of basal blood fibrinolytic activity 
was poor diabetic control as measured by HbA^C levels. On Spearman’s test of 
correlation, an association of HbA^C and fibrinolytic activity was noted in insulin 
treated diabetic patients, but not in patients treated with oral therapy agents. It has 
been suggested that sulphonlyurea and biguanide agents have a direct fibrinolytic effect 
(Fearnley et al, 1960; Banerjee et al, 1975), but in this series, treatment with oral 
therapy agents did not emerge as a independent determinant of fibrinolytic activity on 
the multilinear regression analysis. Other differences between patients may account for 
this discrepancy.
The many reports of basal resting fibrinolytic activity in diabetes mellitus give 
conflicting results, but series examining fibrinolytic capacity (on stimulation testing 
with adrenaline, venous occlusion and exercise) generally agree that activity is reduced 
(see chapter 1, section 6-7). This suggests that production of venous plasminogen 
activator is reduced in diabetes mellitus. As plasminogen activator is released from 
vascular endothelial cells, impairment of this response may be an indication of 
impaired endothelial cell function. However, it has not been established whether 
decreased fibrinolytic capacity is due to reduced synthesis of plasminogen activator, 
impaired release from vascular endothelial stores, increased production of inhibitors or 
a combination of these mechanisms. In diabetes mellitus, plasminogen activator
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secretion may be first enhanced through a variety of stimuli, including associated 
hormonal disturbances, treatment with insulin and drugs and, in theory, this could 
result in secondary depletion of venous plasminogen activator and lesser fibrinolytic 
capacity. However, interpretation of stimulation tests is limited, as their physiological 
significance is not known.
d) The Effects of Improved Diabetic Control on Fibrinolytic Activity
In the newly diagnosed diabetic patients studied by the author, there was a reduction 
of fibrinolytic activity of blood 14 days after introduction of treatment with insulin.
In these patients, the prolonged venous occlusion test (Robertson et al, 1972) was used 
at diagnosis. This may have resulted in depletion of venous plasminogen activator 
stores. Improved blood glucose control in established Type I patients, in whom a lesser 
venous occlusion stimulus was applied and in whom there was a longer interval before 
the second test, allowing full recovery of venous plasminogen activator stores, resulted 
in an apparent increase in basal blood fibrinolytic activity. Post venous occlusion 
fibrinolytic activity was unchanged. The association of basal fibrinolytic activity with 
HbA^C and the increase in basal fibrinolytic activity after a period of improved 
diabetic control in established Type I patients, suggests that better diabetic control 
might be associated with greater blood fibrinolytic activity.
e) The Effects of Insulin on Fibrinolytic Activity
Insulin has also been reported to result in shortening of blood fibrinolytic activity 
(Fearnley et al, 1959). This effect has previously been attributed to concurrent 
hypoglycaemia (Hedlin, 1973). In the author’s study, fibrinolytic activity was increased 
one hour after injection of insulin, despite absence of hypoglycaemia and thus any 
adrenaline mediated effect. However, the post- insulin increase in fibrinolytic activity 
found, could still be unrelated to insulin injection. The post-insulin ECLT 
measurements were made after breakfast and patients were given tea containing 
caffeine. Caffeine is known to increase fibrinolytic activity (Samarrae & Truswell, 
1977). Dietry factors may also have influenced the comparison of normal sujects and 
diabetic patients. For practical reasons, diabetic patients were examined in the 
morning, in the fasting resting state The control subjects, whilst rested before 
venesection, were not fasted. In view of influences of caffeine containing beverages 
and diurnal variations on fibrinolytic activity (Fearnley et al, 1957), ideally normal 
control subjects and diabetic patients should be examined under identical conditions.
f) Factor VIII Activities in Diabetic Patients
Overall, Factor VIII activities were not significantly different from those of normal 
subjects but a strong association of diabetic control as measured by HbA^C and blood
135
glucose and factor VIII:C and vWF:AG levels was noted. Other independent predictors 
of high levels of Factor VIII:C and vWF:Ag activities were long duration of diabetes 
mellitus and the presence of deteriorating retinopathy. Independent predictors of the 
ristocetin cofactor were high diastolic blood pressure and blood glucose levels.
HbA^C, in the assay method used in this thesis, measures changes in erythrocytes 
which respond gradually over the course of days to changes in the average blood 
glucose and gives no indication of hour to hour fluctuation in blood glucose levels.
Von Willebrand factor, as measured by ristocetin cofactor activity was not correlated 
with HbA^^C levels but showed a positive correlation with blood glucose at the time of 
testing, suggesting that functional activity of von Willebrand factor responds more 
immediately to changes in blood glucose. As the main storage site of von Willebrand 
factor is the endothelium, particular interest in the role of von Willebrand Factor as a 
marker of endothelial damage has been generated. Perfusion of endothelium with 
elevated glucose concentrations in vitro, has been shown to result in release of von 
Willebrand factor from human umbilical vein (Mordes et al, 1983), suggesting that 
direct effects of glucose on the vascular endothelium may lead to the release of von 
Willebrand factor.
g) The Effect of Treatment, Insulin versus Oral Agents on Factor VIII Activities
It was noted that factor VIII:C , vWF:Ag and ristocetin cofactor levels were lower in 
patients treated with oral agents than in patients on insulin. In the multilinear 
regression analysis, of the influence of variables on factor VIII, insulin treatment was 
an independent predictor of higher levels of ristocetin cofactor measurements of von 
Willebrand factor. Diabetic control, as measured by HbA-^C, was slightly better in the 
oral therapy group and lower levels of Factor VIII activities may also be partly due to 
better diabetic control. On stepwise multilinear regression analysis, plasma insulin 
levels did not emerge as a significant determinant of haemostatic factor levels and the 
transfer of 3 patients, normally well controlled on oral therapy agents, onto insulin was 
not associated with any dramatic changes in coagulation factors but insulin 
requirements were low. Small and colleagues (1986), in a study of the effects of 
insulin treatment in 20 patients (who had poorly controlled diabetes mellitus on 
maximal treatment with oral agents) similarly did not note any change in Factor VIII:C 
or Factor VIII:AG levels. Whether differences in coagulation factors, in the author’s 
study, between patients on oral antidiabetic drugs and patients on insulin, were due to 
treatment or intrinsic differences in the patients is debatable. Proportionally more of 
the patients treated with insulin had proven diabetic microangiopathy, whose presence 
in many studies has been associated with higher factor VIII levels.
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6-10 3 Fibrinopeptide-A in Diabetes Mellitus
Direct evidence for activation of the haemostatic system as assessed by measurements 
of FPA was lacking in the present studies of diabetes mellitus but the numbers 
involved were small. FPA levels were studied sequentially in 15 established diabetic 
patients and levels fell throughout the course of the studies. During this time, blood 
sampling technique became defter, and the anticoagulant into which the blood sample 
was collected was changed as the first batch was unreliable. Subjects in whom 
venepuncture was difficult had the highest levels of FPA and the usefulness of basal 
FPA measurements is perhaps limited, as any raised level is suspicious of poor 
venesection technique. Unless some objective measurement of excellence of 
venesection technique and speed of blood flow is made, raised levels of FPA levels 
must be interpreted with caution. However, an association of higher blood pressure 
with higher FPA levels was noted in both normal and diabetic patients in this study. 
Others have found marginally higher levels of FPA in diabetic patients but do not 
report on the association with blood pressure (Borsey et al, 1984; Small et al,1987). In 
the latter study, levels of FPA, studied sequentially for 3 months, also fell. During 
Small et al’s study, diabetic control did not improve and the fall in FPA levels was 
attributed to treatment with insulin in patients normally controlled on oral agents.
6-10-4 Effects of Treatment with Biosynthetic Human Insulin
Treatment with biosynthetic human insulin was not associated with any significant 
differences in haemostatic function factors compared with treatment with purified 
porcine insulin. In view of the questionable effect of insulin on haemostatic function 
factors, the negative result of the study of biosynthetic human insulin on haemostatic 
factors is hardly surprising. Given the limited understanding of the haemostatic 
system, empirical studies such as this have a role in the assessment of a new treatment 
with regard to any potentially unexpected beneficial or deleterious effects.
6-10-5 Conclusions
Haemostatic factors have been extensively studied in diabetes mellitus, but, as 
mentioned at the beginning of this chapter, there has been confusion as to the 
importance of metabolic control, treatment, and vascular disease on levels of 
haemostatic variables. This confusion may reflect on a lack of inter-laboratory 
standardization of assays of haemostatic factors in early studies, as well as on the 
marked heterogeneity of diabetic patients.
Descriptive studies of the levels of haemostatic factors in diabetes mellitus (such as this 
author’s), highlight the important predictors of levels of circulating factors. They do 
not increase our fundamental understanding of the in-vivo effects of these changes in
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diabetes mellitus. Simple associations are not proof of a causal relationship with the 
development of vascular damage. Future progress in the study of haemostasis and 
diabetes mellitus, requires knowledge of factors controlling the production of 
haemostatic factors and of the interaction of factors with the vascular endothelium. No 
direct evidence for a hypercoagulable state in association with diabetes has been found 
and the case for the presence of significant hypercoagulability in diabetes mellitus 
remains non-proven.
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TABLE 6 - 5
Normal  C o n t r o l  S u b j e c t  and D i a b e t i c  P a t i e n t  Med i an  H a e m o s t a t i c  
F a c t o r  L e v e l s  and p V a l u e s  o f  Mann W h i t n e y  T e s t  C o m p a r i n g  
D i a b e t i c  P a t i e n t s  w i t h  Nor mal  C o n t r o l s
Normal  
Cont  r o l
A l l
D i a b e t i c s
A l l  
IDD NIDD
E s t . 
IDD
New
IDD
Numb e r 15 3 8 24 12 15 9
ECLT
( m i n u t e s )
101 1 4 0 . 0 130 180 106 185
PV ECLT 
( m i n u t e s )
70 NA NA NA 57 . 5 NA
F i b  r i n o g e n  
( gms / L)
1 . 6 9 .2.39 2 . 3 4 2.  60 2 . 3 2 2 . 7 0
V I I I : C (Z) 1 0 7 . 5 1 00 .  0 1 1 0 . 0 87 1 1 0 . 0 1 1 0 . 0
VWfsAg (%) 1 1 9 . 0 98.  0 113.  0 7 3 . 0 1 1 5 . 0 1 1 1 . 0
R i s t o c e t i n
c o f a c t o r
a c t i v i t y Z
89 . 5 1 0 0 . 0 1 1 8 . 0 7 9 . 0 1 2 6 . 0 1 03 .  5
FPA(pm/ ml ) 1 . 2 NA NA NA 2 . 1 NA
A g e ( y e a r s ) 48 52 49 55.  5 51 44
We i g h t  
I n d e x  (%)
23 2 2 . 5 2 2 . 4 5 23.  25 23 .  4 1 9 . 3
p v a l u e s  o f  Mann W h i t n e y  T e s t
A l l
d i a b e t i c s
A l l
IDD
A l l
NIDD
Es t . 
IDD
New
IDD
ECLT 0 . 2 7 3 0 0 . 4 0 2 0 NS NS NS
( m i n u t e s )
NAPV ECLT NA NA NA NS
( m i n u t e s )
< 0 . 0 2F i b r i n o g e n 0 . 0 0 0 5 0 . 0 0 3 6 <0.  05 < 0 . 0 5
( gms/ L)
NS NSV I I I : C (%) 0 .  82 81 0 . 4 9 7 7 NS
VWf:Ag (Z) 0 .  86 85 0 . 5 4 4 9 NS NS NS
R i s t o c e t i n 0 . 2 1 0 6 0 . 0 3 1 1 NS 0 . 0 5 NS
c o f a c t o r
ac t  i v  i t y%
NAFPA pm/ml NA NA NA NS
A g e ( y e a r s ) 0 . 0  87 4 0 . 2 8 4 3 0 . 0 5 <0.  1 NS
We i g h t  
I n d e x  (Z)
0.  7526 0 . 5 6 2 7 NS NS 0 . 0 6 83
E s t  = e s t a b l i s h e d  d i a b e t i c  p a t i e n t  w i t h  m i c r o v a s c u l a r  c o m p l i c a t i o n s
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TABLE 6 -  9
The R e s u l t s  o f  Improved D i a b e t i c  Control  on Haemostat ic  Funct ion  
T e s t s  in 30 D i a b e t i c  P a t i e n t s ,  Medians and (Ranges) and R e s u l t s  o f  
Wilcoxon Test
B e f o r e A f t e r p v a l u e
HbAiC (%) 12.1  
8.4  -  24 .5
9 . 8  
7 . 6  -  17 .2
<0.0001
FBG (mmol/L) 10. 8 
4 .1  -  7 7 .0
8. 1 
2 .4  -  17.6
<0.05
ECLT (minutes) 130 
37 -  47 9
132 
32 -  695
0 .1 6 8 2
F ibr ino gen  (gm/L) 2 .4  
1 .1 8  -  3 .5
2 .36  
1.46  -  5.07
0 .9 3 9 9
V I I I : C (%) 100 
48 -  300
100 
54 -  200
0 .2187
VWf:Ag (%) 107.5  
52 -  320
94 .5
4 6 - 1 8 6
0 .0 0 6 5
R i s t o c e t i n  
c o f a c t o r  
a c t i v i t y  (%)
103.5  
60 -  23 5
107 
62 -  205
0 . 0 2 6 8
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Table 6 -  10
The Results of a Period of Improved Diabetic Control 
on Haemostatic Function 9 Newly diagnosed 
Insulin Requiring Diabetic Pat ients  
(Medians and Ranges)
Invest igation
V is i t  A 
Day 0
V i s i t  B 
Day 14
V i s i t  C 
Day 40
Fasting Whole Blood 
Glucose (mmol/1)
11.9
(8 .2-77 .5)
5.7**
(4 .0-12 .2)
5.6**
(4 .8 -10 .3)
Haemoglobin AlC (%) 14.5
(11 .2-24 .5)
12.5*
(9 .9-17 .2)
9.8**
(7 .4-11 .1 )
Resting Euglobulin Clot  
Lysis Time (Minutes)
185.0
(80-330)
522.0*
(21-695)
149.0
(60-545)
Fibrinogen (gm/L) 2.73
(1 .86 -3 .5)
2.75
(2 .27-5 .07)
2.9
(2 .13-4 .11)
Factor VIII Coagulant 
Act iv ity  (%)
110.0
(76-300)
107.0
(54-200)
79.0
(53-151)
Von Willebrand Related 
Antigen (%)
111.0
(77-320)
107.0*
(54-200)
76.0*
(42-100)
Factor VIII Ris tocet in  
Co factor {%)
103.0
(84-190)
113.5
(74-205)
102.0
(82-179)
* p 0.05 ** p 0.01 Wilcoxon Test
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TABLE 6 11
Results of a 90 Day Period of Improved Diabetic  Control in 14 
Established Insul in  Treated Pat ients;  medians (ranges) and 
p values of Wilcoxon t e s t .
Before After p value
HbA-jc (?) 10.7 
(8 .4  -  13.8)
10.1' 
(7 .8  - 13.4)
0.0076
FBG (mmol/L) 10
(4.1 - 22.2)
8.7
(2 .4  -  17.6)
0.0640
V II I:C (?) 112 
(57 - 230)
102 
(74 -  180)
0.5091
vWF:Ag (?) 115 
(52 - 204)
96
(55 -  186)
0.1026
R isto ce t in  
cofactor  
a n t iv i t y  (?)
135 
(80 - 255)
98
(80 - 170)
0.1422
Fibrinogen
(gm/L)
2.36  
(1.18 - 3.45)
2.16  
(1.46 -  2 .63)
0.3451
ECLT (minutes) 111
(38 -  479)
85
(32 -  400)
0.0393
PV ECLT (minutes) 93
(49 - 352)
72
(28 - 145)
0.2487
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TABLE 6 -  12
Serial Fibrinopeptide - A(FPA) levels in 
15 established Diabetic Patients 
(pg/ml)
Abnormal
Results
Visit 1 
F.P.A.
Visit 2 
F.P.A.
Visit 3 
F.P.A.
Visit 4 
F.P.A.
Retinopathy
S/D
5.8 N.A. 4.9 2.5 S
21.3 8.5 3.9 8.2 D
4.6 3.4 1.9 0.3 D
5.3 1.5 6.8 1.5 1 S
2.1 1.8 1.5 1.8 s
4.5 . 1.6 1.4 2.1 s
6.5 1.6 2.0 2.4 s
1.2 1.4 1.1 0.3 s
6.0 •; 4.5 60.0 2.4 s
4.4 3.5 1.1 0.3 s
NA 12.2 7.3 1.6 s
16.5 60.0 60.0 60.0 D
2.5 2.1 3.7 22.5 s
1.2 1.2 1.3 2.7 s
1.0 0.3 0.8 0.5 s
9.0 5.0 7.0 3.0
N.A. = Not Assessed
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TABLE 6 - 1 3
Medians and Ranges of Haemostatic Function Factors on Treatment 
with BHI and PPI and Median Changes occurring on Treatment with  
each Insulin,ABHI andAPPI.
BHI PPI p value ABHI APPI p value  1
| ECLT j 
I (minutps) |
108 
(33-3 87)
111
(42-495)
NS - 9 .5 - 1 .0 NS j
| PV ECLT | 
I (minutes) |
39
(8-517)
45
(18-350)
NS 0 -4 .5 NS I
1 1
| PI ECLT | 
I (minutes) |
65
(36-295)
80
(45-480)
NS -14 .0 +11.0 NS 1
I Fibrinogen|  
I (gm/L) j 
1 1
2. 16 
(1 .54-3 .49)
2. 1 
(1 .17-3 .66 )
NS +0.02 -0 .03 NS I
j VIII:C | 
1 (%) 1
110
(64-180)
86
(70-220)
NS +4.0 -1 1 .0 NS 1
I VWF:Ag | 
1 (%) 1
95
(45-171)
103 
(3 8-158)
NS -2 .0 - 9 .0 NS I
I R is tocet in!  
I cofactor  | 
1 (%) 1
97
(72-205)
115
(86-188)
NS 0.0 +7.0 NS 1
1 1
I FPA | 
I (pmol/ml) |
2. 1 
(0.3-60)
2.0
(0 .3-60)
NS +0.15 - 0 . 2 NS 1
152
TABLE 6 - 1 4
The Effects  of Treatment with Insul in  on Haemostatic Function in 
NIDD: a) Results at Entry to Study, b) Results  After  a 90 day 
Run-in Period of Improved Control on Oral Agents, c) Results  
a f t e r  90 days' Treatment with In su l in .
JS GM MD
■ —  —  -■ ■■ ■ 
Mean
Hbic (%) a 9.5 8.4 9.6 9.2
b 7 .8 7 .9 8.6 8.0
c 7.3 9. 8 9.7 8.9
FBG (mmol/L) a 4.2 6.5 NA
b 6.5 7.4 5.7 6.5
c 7.9 8.7 7.7 8.1
VIII:C (%) a 90 80 62 77.3
b 80 170 64 104.6
c 62 115 80 85.7
vWf: Ag (%) a 96 72 74 80.7
b 95 65 46 6 8.7
c 85 101 59 81.7
R istoce t in a 84 88 100 90.6
cofactor b 84 90 100 91.3
a c t i v i t y  (%) c 90 100 105 98.3
Fibrinogen (gms/L) a 2.56 2.63 2.70 2.63
b 2.95 2.36 2.33 2.54
c 2.56 2. 88 2.29 2.57
ECLT (minutes) a 97 108 260 155
b 397 167 232 259
c 195 161 23 8 198
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CHAPTER 7
PERIPHERAL BLOOD FLOW RESULTS
7-1 INTRODUCTION
Blood flow is determined by extrinsic (neural and hormonal) control systems, intrinsic 
autoregulatory capacity and the rheological properties of blood, all of which may be 
altered by diabetes mellitus. It has been postulated that high blood flow rates and loss 
of capillary flow autoregulation might result in "overperfusion" and this may cause 
capillary damage and lead to the development of microangiopathy (Parving et al, 1983 
[b]). Current diabetic practice is based on the premise that the development of 
microangiopathy is in some way related to the duration and degree of hyperglycaemia, 
but there is little evidence that, once diabetic complications have occurred, good 
control of blood glucose levels will prevent further damage. Indeed, in some instances, 
paradoxical deterioration of microvascular diabetic complications has been noted on the 
institution of strict regimes which lower blood glucose levels (Hooymans et al, 1982). 
Alterations in blood flow with changes in glycaemia might contribute to these 
undesirable effects, and it would appear that a more thorough understanding of the 
changes in blood flow regulation, and the relationship of these changes to quality of 
control and treatment of diabetes mellitus is required before a rational treatment policy 
can be formed.
7-2 AIMS OF THE STUDIES OF PERIPHERAL BLOOD FLOW 
These were to establish whether:
i) there was any specific defect of peripheral blood flow associated with the 
presence of diabetes mellitus
ii) there was any influence of age, duration of diabetes mellitus and diabetic 
control on peripheral blood flow
iii) there was any effect of improved blood glucose control on peripheral blood 
flow
iv) treatment with biosynthetic human insulin improved the blood flow in the 
lower limb in diabetes mellitus.
In view of the marked heterogeneity of diabetic patients, blood flow in Type I insulin 
dependent patients was studied, and compared with blood flow in Type II non-insulin 
dependent diabetic patients. Blood flow in newly diagnosed diabetic patients without 
complications was also compared with blood flow in established diabetic patients with
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known microvascular disease. A control group was also studied. The blood flow 
parameters studied were:
i) Resting calf flow (RCF)
ii) Resting foot flow (RFF)
iii) Reactive hyperaemia, following the ischaemic stress induced by a 4 minute 
arterial occlusion with;
a) time taken to attain peak flow values following release of the arterial 
tourniquet (Time Peak Flow; TPF)
b) peak flow value attained during the reactive hyperaemia phase (Peak Post 
Stimulus Flow; PPSF) and also PPSF-RFF
c) time for the peak flow to fall to half its original value following release 
of the arterial tourniquet (T^q)
d) arterial debt: this represents the deficit in blood flow induced by 
artifactual arterial occlusion and is calculated by multiplying resting foot 
flow (RFF) per minute by the time in minutes of arterial occlusion (Art 
Debt).
e) the percentage of the arterial debt paid off during the first 30 seconds of 
blood flow after release of the arterial tourniquet, (0-30%): this is 
calculated by dividing the blood flow in the first 30 seconds of the 
reactive hyperaemia response by the arterial debt and multiplying by 100 
0-30% = (Flow in 0-30 seconds /  art debt) x 100
7-3 METHODS AND STATISTICAL ANALYSIS
Blood flow measurement methods are described in chapter 3. The results were 
analyzed using non-parametric statistical methods because of the small numbers and the 
non-symmetrical distribution of the results. Different groups were compared using the 
Mann Whitney U test, and the effects of treatment with purified porcine and 
biosynthetic human insulins were examined using the Wilcoxon rank signed test, and 
the correlations of flow measurements with age, duration of diabetes, diabetic control 
and insulin levels were examined using Spearman’s test of rank correlation.
7-4 DETAILS OF THE SUBJECTS STUDIED 
7-4-1 Normal Subjects
Details and results of the 16 normal subjects (6 female, 10 male) are shown in Table 7- 
1. Many of these subjects also participated in the studies of haemostatic factors. The 
median age was 47.5 (range 24 - 62 years). There were no smokers in this group and 
all the subjects were in good health and gave no history of vascular disease apart from 
R.A. who had a history of previous myocardial infarction, but was asymptomatic at the
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time of study. Examination of the peripheral pulses was normal. These subjects were 
generally studied during the afternoon and were examined once.
7-4-2 Newly Diagnosed and Established Insulin Treated Diabetic Patients
The diabetic patients studied included 9 newly diagnosed patients with Type 1 diabetes 
mellitus of whom 6 were re-examined after a period of improved diabetic control.
Full medical details of these patients, who had no evidence of diabetic vascular disease 
are given in Chapter 6, Table 6-2. Peripheral blood flow results on these patients are 
shown in Table 7-2. In addition, 28 established diabetic patients with microangiopathy 
were studied. This included 15, Type I, insulin dependent diabetic patients who took 
part in the double blind crossover study of the effects of treatment with purified 
porcine and biosynthetic human insulins, details of whom are given in Chapter 6, Table
6-3. Peripheral blood flow results are given in Table 7-2.
7-4-3 Established Diabetic Patients Treated with Oral Hvppglvcaemic Agents
The remaining 13 established patients were Type II diabetics, treated with oral 
hypoglycaemic agents. Medical details of 12 of these patients who also took part in the 
haemostatic factor studies are shown in Chapter 6, Table 6-4. Peripheral blood flow 
results are given in Table 7-3. The additional Type II patient (D.J.), was a 54 year old 
male with a ten year known duration of diabetes, treated with glibenclamide and 
metformin, who had proliferative retinopathy.
In summary, a total of 37 diabetic patients were studied, median age 52, range 18-68 
years. Ten patients had no evidence of micro vascular disease, 17 had mild retinopathy 
and 10 had required laser photo-coagulation treatment for proliferative disease. Blood 
flow measurements in the diabetic patients were performed in the morning, post 
prandially between 9.30 and 10.45 am. Full details of blood flow measurements are 
given in Chapter 3. Six of the newly diagnosed patients were examined twice, at 
diagnosis and after a period of improved control. The 15 patients who participated in 
the double blind BHI and PPI insulin crossover study were examined four times;
1) at entry to the study
2) after a three month run-in period
3)&4) after treatment with each trial insulin respectively for three months.
The 13 established Type II patients were examined once.
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7-5 RESULTS OF BLOOD FLOW MEASUREMENTS IN NORMAL VOLUNTEER 
SUBJECTS.
Results are shown in Table 7-1 and summarized in Table 7-4. Resting blood flow 
rates in both the calf (RCF), range 1.6 - 7.6 mis per 100 mis of tissue, and foot (RFF), 
range 0.09 - 4.2 mis per 100 mis of tissue, showed wide individual variations and in 3 
subjects RFF was barely recordable and arbitrarily given a value of 0.09 mis per 100 
mis of tissue as the lowest recordable value of flow was 0.1ml/100 mis of tissue. The 
median value of RCF was 3.8 mis per 100 mis of tissue and the median value of RFF 
0.7 mis per 100 mis of tissue. The plethysmograph measures changes of volume 
occurring with arterial inflow and the large non-distensible bony component of the 
forefoot probably accounts for the lower recorded RFF, as compared with the more 
distensible calf (see discussion, 7-8-2). Very low recorded RFF made calculation of 
arterial debt following arterial occlusion impossible, and also affected the accuracy of 
the calculation of peak post stimulus flow rates - resting flow rates (PPSF-RFF) and 
percentage of arterial debt paid back in the first 30 seconds of reactive hyperaemia (0- 
30%). When RFF was very low i.e. 0.09 mis per 100 mis of tissue, 0-30%, was often 
apparently several hundred percent but was given an arbitrary value of 500%. Despite 
attempts to achieve acclimatization by the resting of subjects for 30 minutes in a 
constant temperature room before commencing measurements, foot temperature varied 
greatly between individuals and, as expected, warmer feet exhibited higher resting flow 
values, (p=0.0007), see table 7-5.
After arterial occlusion, Peak Post Stimulus Flow rates (PPSF) were rapidly achieved, 
and Time to Peak Flow (TPF) was always within 9 seconds, indicating that the low 
flow rates in some of the normal control subjects were not due to impaired perfusion 
secondary to undiagnosed atherosclerosis. The range of 0-30% was 29 - 500%, with a 
median value of 67.2%. The 0-30% value of 29% may be an inaccurate estimate as it 
was obtained on a 28 year old female with barely recordable foot flow. TPF was 
normal in this subject. Mean and median values of 0-30%, omitting patients with 
barely recordable RFF (and hence estimated 0-30% values) were also calculated. The 
mean -  SD, (0-30%) was 87%, — 61.6%, n= 13, and the median value 51%. Vascular 
reactivity following ischaemic stimuus, was also highly variable between individuals, as 
witnessed by the wide range of half-life of reactive hyperaemia following arterial 
occlusion (T5q) from 7 to 62 seconds, median 24 seconds.
Whilst metabolic, emotional and environmental factors might all contribute to these 
wide variations in blood flow, so might structural changes in the vessels such as loss of 
elasticity as associated with increasing age. On analysis of the correlation of age with 
the various blood flow measurements the only significant finding was unexpected (see 
Table 7-5). Increasing age was associated with a greater 0-30%, (p =0.0044), the
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reverse of what might be expected with a loss of vessel elasticity due to age. However 
numbers are small, only 2 patients being over 50 years of age, and the inaccuracy in 
recording very low resting foot flow may mean that the association of increased 0-30% 
with increasing age may be a spurious finding. A typical blood flow recording is 
shown in Figure 3.4.
7-6 RESULTS OF PERIPHERAL BLOOD FLOW MEASUREMENTS IN 
DIABETIC PATIENTS
7-6-1 All diabetic patients
Details on individual patients are given in Tables 7-2 and 7-3. Results are summarized 
in Table 7-4. There were large individual variations in blood flow, RCF ranged from 
1.6 - 5.3 mis per 100 mis of tissue and RFF from 0.09 - 2.7 mis per 100 mis of tissue. 
RFF was barely recordable in 4 patients and given an arbitrary value of 0.09. Diabetes 
mellitus is commonly associated with high resting blood flow rates, particularly when 
neuropathy is present (Ward, 1982). However, in this group of 37 diabetic patients, the 
minimum resting flow rates were comparable and maximum resting flow rates in the 
foot and calf were in fact less than those of the normal subjects. The median RCF,
2.5 mis per 100 mis of tissue and RFF, 0.8 mis per 100 mis of tissue were not 
significantly different from normal volunteer resting blood flow (RCF 3.8 and RFF 0.7 
mis per 100 mis of tissue respectively). As with the normal subjects, higher RFF was 
associated with warmer feet, p=0.0214, (see Table 7-6). It was noted that the 
established diabetic patients had cooler feet (median 28.9 °C versus 31.8 °C) than 
normal subjects, although this was not statistically significant. Toe-pad skin 
temperature was not recorded in the newly diagnosed patients. Arterial insufficiency is 
a cause of cool feet, but there was no obvious correlation of temperature and other 
indices of arterial insufficiency such as delay in TPF or low values of 0-30%. Whether 
slight differences in environmental temperature or of adaptation of foot temperature to 
the temperature in the constant temperature room accounts for differences in skin 
temperature between diabetic subjects and normal volunteers is not known.
Temperature is an important determinant of resting skin blood flow.
A striking finding was, that compared with the normal subjects, the corrected median 
peak blood flow value following arterial occlusion of the foot (PPSF-RFF) was 35% 
lower in diabetic patients, (median diabetic 6.2 versus normal 9.5 mis per 100 mis. of 
tissue (p < 0.0001]). The median TPF of 4.8 seconds, was identical in diabetic and 
normal subjects, but TPF was more than 9 seconds in 8 diabetic patients whereas it was 
always less than 9 seconds in the normal volunteers. Reduced peak flow following 
arterial occlusion and delay in TPF could both be interpretated as indicating 
obstructive arterial disease, but it was noted that delayed TPF was found in diabetic
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patients with resting flow rates amongst the highest of those measured. Delay in TPF 
was also noted in 3 out of 9 newly diagnosed diabetic patients. There were no 
significant differences of T^q, median value 21.6 seconds (range 4.6 - 122 seconds) nor 
any evidence of reduced 0-30%, median value 72.6% (range 22.5 - 500%) in the 
diabetic patients. Prolongation of T^q and reduced 0-30% are also features of arterial 
insufficiency due to atherosclerosis. Atherosclerosis of the larger vessels is thus 
unlikely to be the only explanation of reduced PPSF-RFF and delay in TPF in the 
diabetic patients. Overall the results suggest that the distensibility of diabetic vessels 
might be reduced either because of an intrinsic vessel defect or because of alterations 
in the mechanisms controlling vasodilation, whether neural, hormonal or metabolic. 
Furthermore, it would appear that this abnormality occurs early in the history of 
diabetes mellitus. Another possible explanation of delay in TPF and reduced PPSF- 
RFF is that increased blood viscosity in diabetes results in impaired perfusion of 
vessels (see chapter 5).
7-6-2 The Influence of Age. Duration of Diabetes Mellitus and of Diabetic Control on 
Peripheral Blood Flow
It as been suggested that flow rates decline with increasing duration of diabetes 
mellitus due to loss of vessel elasticity and the development of atherosclerosis 
(Christensen, 1969). However, this author did not find any statistical correlation of age 
nor of duration of diabetes with RCF, RFF, TPF, PPSF-RFF, T^q or 0-30% values to 
support the notion of a progressive vascular lesion (see Table 7-6). Duration of 
diabetes is however difficult to assess, particularly in Type II diabetic patients who 
may have a long history of symptoms of diabetes mellitus before presentation and 
diagnosis. There was no significant difference in peripheral blood flow values between 
newly diagnosed and established diabetic patients (see Table 7-4) although it was noted 
that Type II established diabetic patients had the lowest median resting flow values and 
PPSF-RFF. Eight out of 13 (61%) of Type II patients were over the age of 50, but 
only 10 out of 24 (42%) Type I insulin dependent diabetic patients were over 50 years. 
(Only 2 out of the 16 (12%) of normal control subjects were over 50 years). The trend 
towards lower PPSF-RFF in the Type II patients may reflect increasing age and loss of 
vessel elasticity. There was a weak correlation of lower PPSF-RFF with increasing age 
in the Type II diabetic patients, p = 0.0609, but there was no evidence of reduced 
repayment of arterial debt with increasing age. Diabetic control, as assessed by 
HbA^C and blood glucose levels, taken at the time of blood flow recordings, was not 
associated with any significant trend in blood flow measurements although reversible 
high flow rates in the forearm are reported in association with poor diabetic control 
(Gundersen, 1974), see discussion. The interaction of multiple other determinants of 
blood flow may have obscured any relationship, see Table 7-6.
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7-6-3 Insulin and Peripheral Blood Flow
As insulin may be a vasodilator (Tooke et al, 1980), the results were examined to see if 
insulin levels at the time of blood flow measurement had any influence on blood flow. 
Insulin levels were measured in the 15 established Type I diabetic patients and in 4 
other patients treated with oral agents, but there was no association with blood flow 
measurements (see Table 7-10).
7-6-4 Peripheral Nerve Function and Peripheral Blood Flow
Diabetic neuropathy is associated with marked disturbances of blood flow and the 
results were examined to establish whether there was any association of peripheral 
nerve function, as measured by Common Peroneal Nerve sensory and motor conduction 
times, and peripheral blood flow measurements. Peripheral nerve conduction studies 
were performed in 18 established diabetic patients within a week of the peripheral 
blood flow measurements. Detailed studies of autonomic nerve function were not 
performed because of lack of time and equipment. There was no association of higher 
resting blood flow rates and impaired peripheral nerve function as assessed by nerve 
conduction times. However, the Common Peroneal nerve f  latency value showed an 
association with the TPF following arterial occlusion in the foot (p = 0.0484), 
indicating that neural factors may influence peripheral blood flow in diabetes mellitus 
(see Table 7-10). Results of peripheral nerve function are presented fully in chapter 8, 
Table 8-1.
7-6-5 The Effect of Improving Blood Glucose Control on Peripheral Blood Flow in 
Newly Diagnosed Patients
Nine patients were examined and median flow values were similar to those of 
established diabetic patients with the same wide range of blood flow values (see table 
7-4). The effects of improvement of diabetic control on peripheral blood flow was 
examined in 7 patients. Three of them were examined both before treatment at 
diagnosis and 30 days later and the others were examined both after starting insulin 
treatment and 30 days later. Results are shown in Table 7-7. Improvement of diabetic 
control was confirmed by a fall in HbA^C levels in each case (p < 0.05). In those 
patients who were examined before diagnosis and after treatment, the consistent 
changes noted were an increase in the PPSF - RFF following arterial occlusion in the 
foot and a shortening of TPF. These changes could be interpreted as representing an 
increase in vessel distensibility, or perhaps representing changes in the neural control 
of vasodilation. It is known that nerve conduction is abnormal in newly diagnosed 
diabetic patients and returns to normal on treatment with insulin (Ward et al, 1971). A 
relationship between TPF and nerve conduction has been demonstrated by the author 
in established diabetic patients (see above, 7-6 a) providing support that neural control
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mechanisms may affect vasodilation. Alternatively, alterations in blood viscosity may 
have affected flow. In the time period (40 days) over which the new diabetic patients 
were examined, rehydration will have resulted in a fall of haematocrit but it is unlikely 
that any change in fibrinogen, the other main determinant of whole blood viscosity, 
will have occurred. The effect of rehydration on TPF and PPSF have not been 
investigated elsewhere. There were no consistent changes in duration of reactive 
hyperaemia or of resting flow values. In the patients examined after starting treatment 
for diabetes, there were no significant changes during the period of improved control. 
This indicates that changes in the regulation of peripheral blood flow in acute diabetes 
mellitus, of whatever cause, are rapidly reversible with treatment.
7-6-6 The Effects of Treatment with Biosynthetic Human Insulin and Purified
Porcine Insulins on Peripheral Blood Flow in 15 established Type 1 Diabetic 
Patients
Fifteen diabetic patients with microvascular disease took part in a double-blind trial of 
treatment with BHI and PPI. Details of the protocol are given in chapter 2-4.
Peripheral blood flow in these 15 patients was measured on 4 occasions, at entry to the 
study and after a 3 month period of optimized diabetic control on conventional 
multiple subcutaneous insulin regimes and after 3 months treatment with each of the 
trial (BHI and PPI) insulins. Results are shown in Table 7-8. Blood flow in the foot 
and calf were similar to those of newly diagnosed Type I and established Type II 
diabetic patients. A small improvement in diabetic control was achieved during the 
run-in period, median fall in HbA^C% 1.0% (p < 0.05). This improvement of diabetic 
control was associated with an apparent small increase of RFF (p < 0.04), but foot 
temperature at the time of the second recording was also noted to be significantly 
higher, 30 °C versus 28.1 °C (p= 0.0119). Thus environmental factors may have 
influenced flow. Alternatively, higher flow rates might have resulted in warmer feet.
On treatment with BHI and PPI there was no change in the overall control of diabetes 
mellitus as assessed by HbA^C and fasting blood glucose levels. Similarly there were 
no changes in any of the parameters of peripheral blood flow assessed. Treatment with 
BHI had no detectable effects on peripheral blood flow in the calf and foot. Results 
are summarized in Table 7-8.
7-7 RESULTS OF LASER DOPPLER FLOW STUDIES
Towards the end of the studies the opportunity to measure skin blood flow with a 
Laser Doppler Flow Meter became available. Toe pad flow in response to arterial 
occlusion of the foot was examined in 9 of the diabetic subjects (all established 
insulin-requiring) and 4 of the normal volunteers. Full details of methods used are 
given in Chapter 3-5. Measurements were made TPF following arterial occlusion and
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results are shown in Table 7-9. A simultaneous recording of plethysmographic TPF 
was made. Although numbers are small, there was no overlap in the the TPF’s 
measured by the laser doppler meter of diabetic individuals and those of normal 
volunteers, all the former being longer. Plethysmographic TPF’s were similar but in 
normal subjects and diabetic patients TPF’s measured by the Laser Doppler Flow Meter 
are notably longer than TPF values obtained using plethysmographic measurements. In 
normals the median laser doppler TPF was 19.8 seconds, 4 times longer than the 
plethysmographic TPF whilst in diabetic patients the median laser doppler TPF was 
55.2 seconds, some 13 times longer than the plethysmographic TPF. These findings 
suggest that there is a defect in the vasodilation of small blood vessels (arterioles and 
capillaries) in diabetes mellitus in response to an ischaemic stimulus. Abnormalities of 
blood flow in small vessels appear to be greater than flow abnormalities in large vessels 
as measured by plethysmography. These changes could be explained by decreased 
small vessel distensibility, either functional or mechanical, or impaired vessel perfusion 
due to alterations in blood viscosity.
7-8 DISCUSSION 
7-8-1 Factors Influencing Blood Flow Measurements.
Although the main manifestations of diabetic complications are vascular, peripheral 
blood flow has been less extensively studied than many other aspects of diabetes 
mellitus. Special equipment is needed and measurements of peripheral blood flow are 
time-consuming. In addition, there are many practical problems related to the extreme 
lability of blood flow, and the critical influence of such factors as the emotional state 
of the patient, and ambient and body temperatures. Temperature is particularly 
important with regard to the flow in the medium sized vessels measured by the 
plethysmograph (Felder et al, 1954). Achieving identical conditions for follow-up and 
comparison studies presents many difficulties. In the studies presented here, the 
diabetic patients were studied over a 9 month period, during which ambient 
temperatures varied greatly. Patients were in the hospital for approximately one and a 
half hours, of which half an hour was spent in a constant temperature room, before 
blood flow was measured. They were always studied at the same time, and at the same 
interval after an identical breakfast and usual morning medication. Despite these 
attempts at standardization, it was noted that the median foot temperature in diabetics, 
who were predominantly recruited during the winter months and early spring, was 
cooler (though not significantly) than that of the normal controls, who were generally 
studied in autumn. The median diabetic foot temperature was significantly higher at 
the second visit, in those patients participating in the double-blind crossover insulin 
treatment trial. The normal control subjects were studied in the afternoon, on the 
assumption that diurnal variations in flow were unimportant, but the cooler
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temperature of the diabetic feet may also reflect this time difference. Slower 
adaptation of skin temperature to changes in environmental temperature is a feature of 
diabetes (as reviewed in section 1-7-2), and although foot temperatures were not 
significantly different, an even longer period of aclimatization in the constant 
temperature room may have been desirable.
7-8-2 Comparison of Blood Flow in Diabetic and Normal Volunteers
Blood flow in the feet was studied because this is the extremity in which diabetic 
vascular problems occur. Resting flow rates in the all diabetic patients were not 
significantly different from normal. Other plethysmographic studies of blood flow in 
diabetes have generally examined the calf and forearm, predominantly measures of 
muscle blood flow. In poorly-controlled, short-duration diabetes, increased resting 
forearm blood flow rates have been noted (Christensen, 1970; Gundersen, 1974). Less 
information on blood flow in the foot is available. In an early study by Mendolowitz 
and colleagues (1953) decreased diabetic toe flow was found, and was thought to 
represent asymptomatic vascular disease. However in the author’s study, of poorly 
controlled newly diagnosed diabetic subjects who will be free of chronic diabetic 
damage, resting flow values were also generally low and in some cases barely 
recordable. Whilst these results are apparently at odds with the studies of forearm flow 
by Christensen (1970) and Gundersen (1974), plethysmographic recordings of foot 
blood flow may not be equivalent to measures of forearm muscle flow. The foot has a 
larger non-distensible bony component, and the proportion of skin to muscle is greater. 
Foot flow measurements may be less sensitive than both those of the calf and the 
forearm, and the low flow rates may be a spurious finding, reflecting small numbers. 
Another possibility is that the abnormalities of blood flow were largely reversed by the 
time the patients were examined, as only 3 patients were examined before commencing 
treatment for diabetes mellitus. Gundersen (1974) on the other hand, examined 
forearm blood flow in diabetic subjects whose usual diabetic treatment had been 
deliberately stopped some days before.
In the established diabetic patients examined by the author, there was no association 
between resting blood flow values and diabetic control as measured by HbA^C levels 
or blood glucose. Long duration of diabetes mellitus has been previously associated 
with lower resting flow values (as reviewed by Christensen 1972). In the author’s 
studies, the opposing effects of hyperglycaemia and duration of diabetes mellitus may 
have effectively cancelled each other out. A small improvement of diabetic control, 
did not result in any significant change in resting blood flow values. This apparent 
discrepancy from the results of other studies, (Gundersen, 1974), may reflect on the 
small improvement of diabetic control achieved. However, the aim of the author’s
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study was to establish the effects of improved diabetic control, as can be achieved in 
clinical out-patient practice.
The main difference, between normal control and all diabetic subjects, was a marked 
reduction of peak post stimulus flow (PPSF) following arterial occlusion in the feet. 
Reduced PPSF in diabetic patients was also noted in a study by Cunningham et al, 
(1983). Both cooler foot temperature and reduced PPSF could be manifestations of 
vascular disease, but reduced PPSF was also noted in newly diagnosed Type I diabetic 
patients studied by the author. The reduction of PPSF in newly diagnosed diabetic 
patients and subsequent improvement after starting treatment, suggests the presence of 
a reversible abnormality of vasodilation. In addition, poor vasodilation responses in 
diabetes have have been reported on CC>2 challenge with regard to cerebral blood flow 
(Dandona et al, 1978), in toe flow after ganglion blockage (Megibow, 1949 as reviewed 
by Christensen, 1972) and with local heating or needle injection trauma (as reviewed 
by Tooke, 1986). In young patients without neuropathy, it has been noted that 
haemoconcentration in the dependant foot on quiet standing does not occur to the same 
extent as in normal subjects (Rayman et al, 1986). These abnormalities have been 
suggested as evidence of an intrinsic defect of pre-capillary vasoconstriction in 
diabetes.
Other plethysmographic measurements of reactive hyperaemia, the time taken to reach 
peak post stimulus flow values (TPF) and the duration of reactive hyperaemia as 
measured by its half life (T^q) were not abnormal in diabetes mellitus, although a 
shortening of TPF was noted after starting treatment with insulin in 2 of the 3 newly 
diagnosed patients, the other remaining unchanged. The TPF in the toe pad following 
arterial occlusion of the foot was also measured in 9 established diabetic patients and in 
4 normal controls using a Laser Doppler Flow Meter which became available towards 
the end of the studies. The Laser Doppler Flowmeter measures microcirculatory as 
opposed to arterial flow. The thickness of the overlying skin keratin determines the 
site and hence type of skin blood vessel in which flow is measured. In the diabetic 
patients, TPF measured by the Laser Doppler Flowmeter was considerably prolonged 
and this delay was greater than plethysmographic TPF values suggesting that the 
principal abnormality of flow regulation is to be found in the small vessels. Thus there 
is evidence of increased vascular resistance or of decreased distensibility of the vascular 
bed, particularly of the small vessels, in diabetes.
7-8-3 Autoreeulation of Blood Flow in Diabetes mellitus
Anecdotal reports of deterioration in diabetic retinopathy, following dramatic 
improvement in diabetic control on commencing treatment with continuous 
subcutaneous insulin infusion, have raised doubts about the efficacy of quickly
164
lowering blood glucose near normal. The theory is that sudden reversal of the high 
flow rates associated with poor diabetic control may be deleterious to ischaemic retina, 
dependent on high perfusion rates for adequate nutrition.
Whilst the studies presented in this thesis provide no evidence of high perfusion rates 
in diabetes mellitus, nor of dramatic changes in resting flow rates on modest 
improvement of diabetic control, much evidence of overperfusion is available. Parving 
et al (1983 [b]) proposed that the late structural microvascular abnormalities in diabetes 
mellitus are a consequence of early haemodynamic changes that lead to increased 
capillary flow and pressure. It was suggested that high glucose levels might in some 
way interfere with the normal autoregulation of flow. Failure of normal autoregulation 
of capillary blood flow in the face of changing perfusion pressures may then lead to 
high capillary pressure and the development of basement membrane thickening and 
vessel degeneration. In support of this theory, they cited a mass of evidence including; 
reports of the reversible increases in glomerular filtration rates and urinary excretion of 
proteins in newly diagnosed diabetic patients, which they postulated were due to 
increased renal plasma flow and increased glomerular pressure; the protection from 
retinopathy which appears to be afforded by carotid stenosis and hence lower perfusion 
pressure of the retinal vessels (Dandona et al, 1978); and similarly the protection from 
nephropathy by renal artery stenosis (Behrendt & Duane, 1970). Indeed, the increased 
severity of diabetic vascular lesions in the foot (where hydrostatic pressure is greater) 
compared with the arm, would also support this theory of loss of normal flow 
autoregulation in the face of changing perfusion pressures in diabetic patients.
Loss of normal autoregulation, may also result in inappropriately low blood flow.
Studies indicate that nailfold capillary flow velocity in diabetic patients is lower than 
normal (Tooke & Tymms, 1983). It has been suggested that in diabetic patients flow 
through arteriovenous anastomotic shunt pathways is increased at the expense of skin 
blood flow. Studies of the oxygen content of venous blood (Boulton et al, 1982) and of 
Doppler sonographic studies (Edmonds et al, 1981) of diabetic feet provide further 
evidence for the presence of arteriovenous shunting in the diabetic neuropathic foot. 
Whether reversible shunt flow occurs in patients without neuropathy, and is a feature 
of transient autonomic nerve dysfunction associated with poor control, or is a 
physiological response to the raised metabolic rate and need for heat dissipation in 
uncontrolled diabetes, is unknown.
7-8-4 Neural Factors and Blood Flow
Direct measurements of the peripheral autonomic nerve conduction times are not 
possible. The author did not have the facilities and time for detailed testing of 
autonomic nerve function. Measurements of the Peroneal Nerve conduction times were
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used as a guide to the state of the peripheral nerves in the diabetic patients (although it 
cannot be assumed that these measurements accurately reflect autonomic nerve 
function). No associations of Peroneal Nerve conduction times and resting blood flow 
values were found in this author’s studies but only two patients had symptomatic 
diabetic neuropathy. However, there was an association of the TPF with Peroneal *F 
latency times, suggesting that impaired vasodilation may partly related to alterations of 
vessel neural control mechanisms.
7-8-5 The Influence of Insulin. Diabetic Control. Blood Viscosity and Treatment with 
Biosynthetic Human Insulin on Peripheral Blood Flow.
Other factors thought to influence blood flow in diabetes include i) raised glucose 
levels, which in animal experiments have been associated with retinal vessel 
vasodilation and increased blood flow (Atherton et al, 1980), ii) insulin, which appears 
to act as a micro-vasodilator in the skin (Tooke et al, 1985) and iii) duration of 
diabetes mellitus (as reviewed by Christiansen 1972), but in these studies no 
associations of glucose or insulin levels or duration of diabetes mellitus with blood flow 
measurements were found. Blood rheological properties have also attracted attention as 
influencing flow. The relationship of whole blood viscosity with peripheral blood flow 
was examined in Chapter 5. Whilst peak flow values were statistically related to whole 
blood viscosity in normal control subjects, no such relationship was found in diabetes 
mellitus. It seems unlikely that the minor changes in blood viscosity described in these 
studies have influenced blood flow.
Similarly insulin levels were not specifically associated with any abnormality of blood 
flow and it is hardly surprising that the crossover study of the effects of treatment 
with biosynthetic human and purified porcine insulins on peripheral blood flow 
provided no differences. Certainly treatment with biosynthetic human insulin does not 
confer any advantage as regards peripheral blood flow.
7-8-6 Conclusions
The belief that abnormalities of blood flow regulation in the microcirculation might 
contribute to vessel damage is gaining increasing support although the determinants of 
these abnormalities remain speculative. In the studies presented here, evidence of 
impaired vasodilatory responses after ischaemic stress, occurring early in the history of 
diabetes supports the concept of a functional microangiopathy preceding small vessel 
degeneration in diabetic patients. The opposing effects of the many variables 
influencing blood flow make interpretation difficult and examination of the effects of 
specific factors e.g. glucose or insulin levels, would be better achieved by glucose 
clamp type experiments in patients matched for age, sex and duration of disease.
Further studies are required to determine the site of these abnormal flow patterns i.e.
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whether the lesion is an intrinsic vessel malfunction, or due to abnormal neural control 
mechanisms or indeed a physiological response to the altered metabolic milieu of 
diabetes mellitus. The combined use of Plethysmographic and Laser Doppler 
measurements of blood flow may help distinguish between large and small vessel 
damage. However, as the principal defect in diabetes is thought to reside in the small 
vessels, studies of skin blood flow using the Laser Doppler Flowmeter may prove more 
rewarding. Further research into the exact nature of the vessels measured by the Laser 
Doppler Flowmeter at different skin sites are required because of the influence of the 
thickness of the overlying layer of keratin.
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TABLE 7 - 5
Correlations of Age and Foot Temperature 
with Peripheral Blood Flow in 16 Normal 
Control Subjects 
(P Values)
Age Temperature
Resting Calf Flow 0.4117 0.1118
Resting Foot Flow 0.3912 0.0007
Time to Peak Flow 0.8139 0.4028
Peak Post Stimulus 
Flow (Resting Flow) 0.4101 0.6893
T50 0.3519 0.0798
0-30% 0.0044 
(+ ve)
0.3124
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T A B L E  7 - 8
Median Peripheral Blood Flow Results of 
15 Established Insulin Requiring Diabetic Patients
At Entry After Run In Treatment with BHI
Treatment 
with PPI
Haemoglobin A-jC ( % ) 10.5 9.5 10.4 10.1
Blood Glucose (during 
test) (mmol/1) 15.0 14.5 12.6 13.7
Resting Calf Flow 
(ml/100 ml tissue/min) 2.7 3.1 3.5 3.4
Resting Foot Flow 
(ml/100 ml tissue/min)
0.7 1.6 1.5 0.7
Time to Peak Flow 
(Seconds) 3.6 5.1 3.6 3.6
Peak Post Stimulus Flow 
(-Resting Flow)
(ml/100 ml tissue/min)
7.7 6.3 7.2 7.5
T__ (Seconds) bO 21.6 34.2 62.4 25.2
Temperature of Foot 
(°C) 28.1 30.0 29.5 29.3
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TABLE 7 - 9
Results of Laser Doppler Flow Meter and 
Plethysinograph Measurements of T.P.F.
Laser
Doppler
Plethys­
mography
Subject T.P.F.(Seconds)
T.P.F.
(Seconds)
Normals R.C. 15.0 6.0
D.P. 20.4 4.2
D.H. 19.2 6.0
R.A. 21.5 0.0
Median 19.8 5.1
Diabetic Patients D.C. 42.0 3.6
A.E. 55.2 4.8
C.H. 55.2 3.6
R.G. 27.0 4.8
M.W. 178.8 3.6
P.P. 25.2 16.8
W.M. 84.0 3.6
W.H. 66.0 6.0
M.T. 75.6 4.8
D.D. 46.8 3.6
Median 55.2 4.2
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TABLE 7 - 1 0
Correlations of Common Peroneal F Latency 
and Insulin Levels with Peripheral Blood Flow 
(P Values)
Common Peroneal 
F Latency Insulin Level
Resting Calf Flow 0.6273 0.5171
Resting Foot Flow 0.6042 0.9008
Time to Peak Flow 0.0484 0.1763
Peak Post Stimulus 
Flow ( - Resting Flow) 0.6076 0.9252
T50 0.2983 0.3032
0-30% 0.8831 0.3597
Temperature 0.3388 0.7490
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CHAPTER 8
RESULTS OF PERIPHERAL NERVE FUNCTION STUDIES
8-1 INTRODUCTION
Although treatment of established diabetic neuropathy is disappointing, many studies, 
in both experimental and clinical diabetes (Gregerson, 1967; Ward et al, 1971; Fraser et 
al, 1979; Graf et al, 1981; Hreidarsson, 1981; Sidenius & Jakobsen 1982) have 
established that some improvement in nerve conduction velocity is associated with 
improvement of blood glucose levels. In clinical practice, intensive insulin therapy, to 
achieve near normal blood glucose levels is usually the treatment of symptomatic 
neuropathy.
It has been suggested that reversible changes in autonomic nerve function may partly 
account for the changes in blood flow associated with uncontrolled diabetes mellitus.
In the neuropathic foot, blood flow patterns are grossly altered, with evidence of 
arterio-venous shunting (Edmonds et al, 1981; Boulton et al, 1982). Autonomic nerve 
function is more difficult to assess quantitatively than peripheral nervous function, but 
changes in autonomic nerve function, which occur on improvement of diabetic control, 
have been shown to parallel those of peripheral nerve function (Fraser et al, 1979).
8-2 AIMS OF THE STUDIES
The aims of the studies of peripheral nerve function were to establish, (in view of the 
clinical habit of prescribing intensive insulin therapy to achieve near normal blood 
glucose levels in the treatment of diabetic peripheral neuropathy):
1) whether treatment with the then newly available biosynthetic human insulin 
conferred any advantage as regards nerve function
2) whether there was any link in changes of blood flow patterns and nerve 
function tests.
8-3 METHODS AND STATISTICAL ANALYSIS
Protocols used to recruit and manage patients during the studies the double-blind 
crossover study of PPI and BHI are given in chapter 2. The methods used in the 
assessment of electrophysiological function are given in chapter 3. Fourteen patients 
participated in the double-blind study of the effects of treatment with BHI and PPI on 
peripheral nerve function. Clinical and electrophysiological assessments of these 
patients were made on the following 4 occasions:
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(a) at entry to the study
(b) after the 3 month run-in period on actrapid and monotard porcine insulin 
therapy and
(c&d) after each 3 month randomized double blind treatment with (c) BHI or (d) PPI
In addition, four Type II diabetic patients treated with oral agents were studied once. 
This data was only used in the analysis of the relationship between peripheral nerve 
function and peripheral blood flow.
The results are expressed as means and analyzed by the Wilcoxon matched-pairs 
signed-rank test accepting a level of significant difference .of 5%. The changes in 
peripheral nerve function tests occurring on treatment with BHI and PPI in the double­
blind study were also analyzed using the Wilcoxon matched-pairs signed-rank test. 
Spearman’s test of rank correlation was used to assess for correlations of peripheral 
blood flow measurements and peripheral nerve function tests.
8-4 DETAILS OF DIABETIC PATIENTS STUDIED.
The patients in whom peripheral nerve function was studied were 14 of the 15 
established diabetics with microvascular disease, who had agreed to participate in the 
double blind crossover study of biosynthetic human and purified porcine insulins. The 
missing patient, W.H. who participated in the studies of haemostatic function, failed to 
attend for electrophysiological examination. Details of these subjects are given in 
chapter 6, section 6-3, and in table 6-3. In addition, results of electrophysiological 
tests on 4 patients treated with oral hypoglycaemic agents (J.S., G.M., M.W., and M.D. 
details of whom are given in chapter 6, section 6-3, and in tables 5-2 and 6-4) were 
used in the analysis of the relationship of blood flow and peripheral nerve function. 
None of the 18 patients were on any agent known to interfere with peripheral nerve 
function and all reported light to moderate alcohol consumption (Drinking in England 
and Wales, 1980). All 18 subjects had retinopathy (confirmed by fluorescein 
angiography). Thirteen had clinical evidence of neuropathy (diminished soft touch, 
pinprick or vibration sense plus or minus ankle jerks) although only 2 patients, 
(G.B.,R.K.) were symptomatic. All 18 patients had electrophysiological abnormalities 
consistent with neuropathy. Results of peripheral nerve function tests are given in 
Table 8-1.
8-5 RESULTS OF THE DOUBLE-BLIND STUDY WITH BHI AND PPI
Results are given in Tables 8-2 (run-in period) and 8-3 (double-blind period). During 
the run-in period of improved blood glucose control preceding the double blind 
crossover study of BHI and PPI, the mean HbA^C fell significantly (p <0.02). The 
mean motor conduction velocities and F response latencies of the ulnar (p <0.04) and
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common peroneal (p <0.03) nerves also improved during the run-in period but changes 
in sensory conduction velocities were less consistent: SCV of the ulnar nerve was 
unchanged although sural SCV did improve (p <0.03). During the double blind phase 
of the study blood glucose control was marginally worse on treatment with BHI than 
PPI (p = 0.049). All nerve conduction velocities on treatment with PPI and BHI were 
the same, apart from the common peroneal MoCV, which was decreased on BHI 
treatment (p = 0.0157). Throughout the study there was no clinical or symptomatic 
improvement in neuropathy, even in the run-in period.
8-6 RELATIONSHIP OF PERIPHERAL NERVE FUNCTION TESTS AND 
PERIPHERAL BLOOD FLOW
Results of associations of peripheral nerve function tests and peripheral blood flow are 
given in Table 7-10 and discussed in Chapter 7.
8-7 DISCUSSION
Neuropathy is a common cause of disability in diabetic patients. Many diabetic 
patients have electrophysiological changes and an estimated 25% will eventually develop 
symptomatic neuropathy (Clements, 1979). The available evidence in experimental 
diabetes suggests that if hyperglycaemia is completely reversed at an early stage, 
peripheral nerve function returns to normal pre-diabetic levels (Sidenius & Jakobsen 
1982). In clinical diabetes mellitus this reversible "hyperglycaemic" component 
probably coexists with irreversible nerve damage. In this study, of long-standing 
diabetic patients, a small improvement in blood glucose control in the run-in period of 
the study resulted in significant improvement in nerve conduction velocities. However 
there was no improvement in neurological signs or symptoms. During the period of 
improved diabetic control, the F response latencies of the ulnar and peroneal nerves 
proved the most sensitive indicators of change with a 3.8% and 6.2 % improvement 
respectively compared with a 2.6% and 3.9% respective improvement in motor 
conduction velocities. Treatment with BHI was associated with a slight deterioration in 
blood glucose control and a tendency towards slowing of nerve conduction velocities, 
which was only significant with regard to common peroneal motor nerve conduction.
If better diabetic control had been achieved on treatment with BHI, it is likely that 
nerve conduction velocities would also have improved. Treatment with BHI was not 
associated with any advantages with regard to peripheral nerve function.
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T a b l e  8 - 2
Results of Nerve Conduction Tests at entry to the 
study and period of Improved Control in 14 Diabetic Patients
(Mean ± standard error)
Pre Trial Post Run In p Value
HbA, C% 10.9+0.48 10.1+0.56 0.011
Ulnar Motor Conduction 
V elo c i ty  (metres /sec)
49.7+0.92 51.0+0.99 0.033
Ulnar F Latency 
(m i l l isecon ds)
31.9+0.82 30.7+0.72 0 .028
Ulnar Sensory Conduction 
V elo c i ty  (metres/sec)
47.0+1.04 48.1+0.87 0.500
Common Peroneal Motor 
Conduction V eloc i ty  
(metres /sec)
38.3+1.15 39.8+1.18 0.022
Common Peroneal F 
Latency (m i l l iseconds)
58.3+1.80 55.5+1.76 0.005
Sural Sensory Nerve 
Conduction Ve loc i ty  
(metres /sec)
39.2+1.00 37.5+3.27 • 0.002
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CHAPTER 9
ASSESSMENT OF RETINAL STATE
9-1 INTRODUCTION
All established diabetic patients participating in the double- blind crossover study of 
treatment with biosynthetic human and purified porcine insulins on haemostatic 
function, blood rheology and peripheral blood flow were selected on the basis of the 
presence of microangiopathy when screened in the diabetic eye clinic by an 
experienced ophthalmologist. These patients subsequently had plain fundal photographs 
and fluorescein angiography of the retinal vessels at entry to and at the end of the 
studies to assess progression of retinopathy. The fundal photographs and retinal 
fluorescein angiograms were examined and reported by a second ophthalmologist. Full 
details of the photography and fluorescein angiography are given in chapter 3.
9-2 RESULTS
In all, only 9 out of 15 patients who participated in the double- blind crossover study 
had fully assessable retinal angiograms. Plain fundal photographs and fluorescein 
angiograms were not available on 2 patients at entry to the study because of staff 
shortages. Both these patients (C.H. and R.G.) were considered to have simple 
background retinopathy on screening with an ophthalmoscope by the ophthalmologist.
In addition, one patient (W.H.) refused fluorescein retinal angiography and only had 
one set of plain fundal photographs taken because he found the procedure 
uncomfortable. In 2 patients (M.W. and M.T.), the fluorescein angiograms were of 
poor quality at both visits and in one other (W.M.), the angiograms were of poor 
quality at the second visit. Because of these technical problems, elaborate quantitative 
methods of assessment of the fundal photographs and retinal angiograms (as 
recommended by Baudoin et al, 1983) were not considered worthwhile.
Of the 15 patients participating in the double-blind crossover study of biosynthetic 
human and purified porcine insulins, 4 had required photocoagulation treatment before 
entry into the study.
D.C. to both eyes for proliferative retinopathy, first treatment 3 years before entry 
to the study. On screening at entry to the study new vessels were noted and 
she was placed on the waiting list for further photocoagulation treatment.
P.P. to the right eye for treatment of maculopathy one month before entry to the 
study (left eye background changes only).
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W.H. to both eyes for proliferative retinopathy, first treatment 4 years before entry
to the study, last treatment 2 years before study.
D.D. had received multiple treatments for proliferative retinopathy to both eyes, first 
treatment 4 years before study, last treatment within a year before study.
The remaining patients were all considered to have simple background retinopathy at 
entry to the study with the exception of R.K. who had numerous microaneurysms, dot 
haemorraghes, hard exudates and areas of capillary non-perfusion in both eyes.
During the course of the study, 3 patients required laser photocoagulation treatment:
R.K. the changes in the eyes became more florid during the 3 month run-in period 
of the study and he required laser photocoagulation treatment to both eyes.
G.B. developed maculopathy in the left eye and received photocoagulation treatment 
6 months after entry into the study.
D.C. had laser coagulation of new vessels in the right eye 2 months after entering the
study and subsequently suffered a vitreous haemorrhage in the same eye.
There was no deterioration or improvement in any of the eyes of the remaining 
patients who had simple background retinopathy at the time of entry to the study. 
Neither W.H. or D.D., who both had received laser photocoagulation treatments 
remained stable throughout the study period. Details of the assessment of individual 
eyes are given in Table 9-1.
9-3 DISCUSSION
Although initial reports suggested that diabetic retinopathy could be reversed by 
improvement of diabetic control (Irsigler et al, 1979), accumulating recent reports 
provide evidence of deterioration of existing retinopathy particularly in patients in 
whom rapid return to near normoglycaemia is achieved by treatment with continuous 
infusion or multiple subcutaneous injection of insulin (Hooymans et al, 1982; Lauritzen 
et al, 1983; Kroc Collaborative Study Group, 1984; Dahl-Jorgensen et al, 1985). Such 
regimens would appear to result in improved retinal function but morphological 
deterioration (Lauritzen et al, 1983). In this study, gentle improvement of diabetic 
control was achieved during the run-in period of the study on twice daily subcutaneous 
soluble and intermediate acting insulin regimens. The initial improvement of diabetic 
control in the first three months of the study was however not maintained. Of the 15 
patients studied, deterioration of diabetic retinopathy occurred in 3 individuals of 
whom 2, R.K. and G.B., showed deterioration of retinal morphology and in the third 
bleeding occurred from new vessels. The small number of patients involved and lack
187
of a control group means that no significant conclusions can be drawn as to the effects 
of participating in the study on progression of diabetic retinopathy.
Whilst it is generally believed that degree and duration of exposure to hyperglycaemia 
increases the risk of developing retinopathy, the paradoxical risks of improving 
diabetic control are becoming apparent. Amongst the reasons put forward to explain 
deterioration of established background retinopathy with improved diabetic control are 
first, that after a certain critical level of damage has occurred diabetic retinopathy is 
irreversible; secondly that the damaged retinal circulation has become dependent on the 
high flow rates associated with hyperglycaemia to maintain flow through sclerosed 
vessels and that reduction of hyperglycaemia and blood flow results in retinal ischaemia 
and thirdly that the regimens used to obtain good diabetic control may themselves be 
harmful, for instance, by increasing episodes of hypoglycaemia (Dahl-Jorgensen, 1985). 
Thus in the early stages of diabetes, strict control of blood glucose levels would appear 
to protect from the development of retinopathy but once damage has occurred the 
appropriateness and benefits of attempting to achieve normoglycaemia require cautious 
assessment. Despite these reservations, in the absence of any other pharmacological 
option, normoglycaemia remains the treatment of choice for preventing new diabetic 
damage. Identification of areas of ischaemic retina and early treatment may help 
prevent paradoxical deterioration of retinopathy on improving diabetic control.
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CHAPTER 10
CONCLUSIONS AND IMPLICATIONS FOR FUTURE RESEARCH
Vessel changes in both large and small vessels are the most important longterm 
complications of diabetes mellitus. Whilst it is accepted that severity and length of 
duration of exposure to hyperglycaemia are the most important predictors of the 
development of diabetic vascular complications, the pathogenetic mechanisms remain 
unclear and consequently no specific preventative measures have been developed.
Changes in 1) blood rheology, 2) haemostatic function and 3) the regulation of blood 
flow in diabetes mellitus have all been suggested has contributing to the development 
of vascular damage. In this thesis the relationship of these factors to 1) the presence of 
diabetes mellitus, 2) the degree of hyerglycaemia, 3) improving diabetic control and 4) 
treatment with Biosynthetic Human Insulin have been studied.
The studies have shown that many factors, such as whole blood viscosity and levels of 
various haemostatic factors are positively related to the severity of hyperglycaemia and 
that a modest improvement in diabetic control, as can be achieved by closer outpatient 
supervision, may result in small changes of some factors. Treatment with Biosynthetic 
Human Insulin does not confer any advantage as regards blood rheology, haemostatic 
function, peripheral blood flow or peripheral nerve function.
The development of diabetic vessel disease is undoubtedly multifactorial. The concept 
of the diabetic whose blood vessels are stressed by the passage of more rigid 
erythrocytes, whose hyperviscous blood impairs flow in the microcirculation, whose 
blood clots more readily but whose fibrin clots are removed less efficiently because of 
an impaired fibrinolytic capacity, might, in itself, appear to provide an adequate 
explanation for the predisposition of diabetics towards vascular disease. Is it possible 
that these changes alone are the cause of blood flow disturbances and eventual vascular 
damage?
The contention that abnormal blood rheology contributes to impaired perfusion of the 
microcirculation found little support in the studies presented here, as the filtration 
method used to determine erythrocyte deformability was not specific for erythrocytes. 
Previous studies, which have used filtration methods to assess erythrocyte 
deformability, and on which the evidence for reduced erythrocyte deformability in 
diabetes mellitus are largely based, are probably invalid. Only the development and 
application of new methods of measuring erythrocyte deformability will solve this 
issue. In addition, the cell of interest may prove to be the leucocyte, rather than the 
erythrocyte.
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The overall rheological properties of blood were assessed by measuring whole blood 
viscosity. A mild elevation of whole blood viscosity was recorded in diabetic patients, 
but no obvious association of whole blood viscosity and blood flow was found, 
although there was an association in normal controls between whole blood viscosity and 
resting forefoot flow. The plethysmographic method used to assess peripheral blood 
flow was not as sensitive as the Laser Doppler Flowmeter to changes in 
microcirculatory blood flow. It might be interesting to study the relationship between 
skin microcirculation (with the Laser Doppler Flowmeter) and whole blood viscosity in 
normals, diabetics and non-diabetic patients with hyperviscosity syndromes. Recent 
theoretical analysis (Rampling & Challoner, 1983) suggests that raised fibrinogen 
(which largely accounts for the increased viscosity of diabetes not accountable for by 
haematocrit) is not an important determinant of flow under normal physiological 
conditions. Perhaps in diseased vessels, where flow rates are low, this increase in 
whole blood viscosity may have more noticeable effects, and may further hinder flow.
It seems unlikely that the small increase in whole blood viscosity, described in diabetes, 
plays more than an aggravating role in the development of microvascular damage. In 
one of the few available investigations of in-vivo rheology, Branemark et al (1971) did 
not find any impairment of erythrocyte deformability and blood flow, except in 
diabetic ketoacidosis, where erythrocyte entry into capillaries was sluggish. Further in- 
vivo studies of blood flow in relation to alterations of blood rheology are required.
No indisputable evidence of a hypercoagulable state in diabetes mellitus was found, 
although elevation of certain haemostatic factors was noted. Whether these changes 
contribute towards vessel damage in diabetic patients is still a subject of conjecture. It 
seems unlikely that the coagulation changes described in this thesis, namely of raised 
levels of fibrinogen and factor VIII, von Willebrand factor, could cause vessel 
thrombosis under normal conditions. But on interaction with damaged endothelium, 
these changes may favour clot formation. Impaired fibrin clearing mechanisms might 
tip the balance towards vessel occlusion. Fibrin deposition has been shown to stimulate 
smooth muscle proliferation, and is a possible factor in the development of 
atheromatous lesions (Kadish et al, 1979; Ishida & Tamaka, 1982). It has also been 
noted, that large amounts of fibrin are found in the atheromatous lesions of arteries 
(Haust et al, 1965) and diabetic patients are more prone to the development of 
atheroma which is generally of a more extensive nature than in non-diabetic patients 
(Kramer & Perilstein, 1958). In small vessels, histological studies have revealed the 
presence of intravascular coagulation, in both neural (Timperley et al, 1976) and in 
cerebral small vessels (as reviewed by West, 1982). Fresh fibrin deposits are seen in 
the vasa nervorum following diabetic ketosis, and whilst this is not necessarily the 
cause of nerve damage, obstructed vessels are also found in established diabetic 
neuropathy. It might prove interesting to study the relationships between haemostatic
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factors, vessel wall state and clot weight, size and clearance following artifical arterial 
damage in diabetic and non-diabetic animals.
As it seems unlikely that changes in blood rheology and haemostatic factors described 
initiate the development of diabetic microangiopathy, attention must turn to the blood 
vessels themselves. Is it possible that there is a primary, initially reversible, 
degeneration of small blood vessels in diabetes, and that the changes in blood rheology 
and haemostatic factors described are secondary? The presence of raised levels of von 
Willebrand Factor may be a marker for the presence of vascular damage - its main site 
of storage is the endothelium (as reviewed by Porta et al, 1987) and fibrinogen (which 
largely accounts for the raised blood viscosity found in diabetes mellitus) is an acute 
phase reactant protein. Thus changes in blood rheology and haemostatic factors, 
described in this thesis, could be entirely explained as markers for the presence of 
vascular disease. The presence of deteriorating retinopathy was an independent 
predictor for higher levels of both factors and other independent predictors such as 
high HbA2C, high blood pressure and long duration of diabetes mellitus are also 
known risk factors for the development of vascular disease. Abnormalities of 
vasodilation were found on both plethysmographic and Laser Doppler Flowmeter 
studies of foot blood flow and may represent a defect of the microvessels, although 
alterations in other factors influencing blood flow such as autonomic nerve function, 
and hormonal and metabolic factors may have affected regulation of blood flow. 
Further studies to elucidate the nature of the flow defect in diabetes mellitus and to 
establish the importance of the interaction in-vivo of alterations in blood rheology and 
coagulation factors are required.
The presence of an abnormal test or raised level of a particular factor is not evidence 
of a role in the development of late diabetic complications. It has been argued that the 
correlation of a factor with the presence of hyperglycaemia is more in favour of the 
factor being a simple marker of hyperglycaemia rather than signifying any importance 
in the genesis of vessel damage. Greater confidence could be attributed to a causative 
relationship if the abnormality of the suspect factor were more marked at a given level 
of diabetic control, in those patients who subsequently develop vessel complications. In 
this respect, very large, longterm prospective studies of suspected pathogenic factors 
and the development of diabetic vascular damage may be considered a better guide of 
pathogenic factors, than the relatively small, shorterm studies presented in this thesis. 
However causative relationships are best established by longterm intervention studies 
using agents which selectively affect factors under study. Examples of such specific 
intervention studies include the treatment of blood pressure and the progression of 
diabetic nephropathy (Parving et al,1983 [a]); this study supports the hypothesis, that 
there is a failure of autoregulation of capillary perfusion (under changing pressure 
heads) and subsequent capillary hypertension and damage in diabetes, since lowering
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blood pressure slows the progression of nephropathy. Another intervention study is the 
successful treatment of diabetic neuropathy with aldolase reductase inhibitors 
(Judzewitsch et al, 1983) a finding which suggest a role for abnormal metabolites in the 
causation of neural damage.
Unfortunately, there are few acceptable agents with which to perform such studies on 
the effects of altering levels of blood haemostatic factors, blood viscosity or peripheral 
blood flow in diabetes mellitus.
(
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